Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis.
Acidosis
Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy.
Acidosis
Lipopolysaccharide directly inhibits bicarbonate absorption by the renal outer medullary collecting duct.
Acidosis
Phosphoinositide 3-kinase accelerates calpain-dependent proteolysis of fodrin during hypoxic cell death.
Acidosis
Phosphoinositide 3-kinase accelerates necrotic cell death during hypoxia.
Acidosis
The Metabolic Mechanisms of Breast Cancer Metastasis.
Acquired Immunodeficiency Syndrome
'How can I halt thee?' The puzzles involved in autophagic inhibition.
Acquired Immunodeficiency Syndrome
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
Acute Coronary Syndrome
Endothelial Microparticles From Acute Coronary Syndrome Patients Induce Premature Coronary Artery Endothelial Cell Aging and Thrombogenicity: Role of the Ang II/AT1 Receptor/NADPH Oxidase-Mediated Activation of MAPKs and PI3-Kinase Pathways.
Acute Kidney Injury
Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1.
Acute Kidney Injury
Telluric Acid Ameliorates Endotoxemic Kidney Injury in Mice: Involvement of TLR4, Nrf2, and PI3K/Akt Signaling Pathways.
Acute Lung Injury
Lack of phosphoinositide 3-kinase-gamma attenuates ventilator-induced lung injury.
Acute Lung Injury
Preventive and therapeutic effects of phosphoinositide 3-kinase inhibitors on acute lung injury.
Adenocarcinoma
Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components.
Adenocarcinoma
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
Adenocarcinoma
Amplification of CCND1, EMS1, PIK3CA, and ERBB oncogenes in ethmoid sinus adenocarcinomas.
Adenocarcinoma
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
Adenocarcinoma
ARID1A gene mutation in ovarian and endometrial cancers (Review).
Adenocarcinoma
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Adenocarcinoma
Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component.
Adenocarcinoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Adenocarcinoma
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Adenocarcinoma
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Adenocarcinoma
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Adenocarcinoma
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Adenocarcinoma
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes.
Adenocarcinoma
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Adenocarcinoma
Distinctive Patterns of CTNNB1 (?-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Adenocarcinoma
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Adenocarcinoma
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Adenocarcinoma
EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy.
Adenocarcinoma
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Adenocarcinoma
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.
Adenocarcinoma
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Adenocarcinoma
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
Adenocarcinoma
GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Adenocarcinoma
Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.
Adenocarcinoma
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Adenocarcinoma
Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020.
Adenocarcinoma
Hepatoid adenocarcinoma of the stomach with PIK3Ca mutation during pregnancy: A case report with molecular profile.
Adenocarcinoma
Hot spot mutations in Finnish non-small cell lung cancers.
Adenocarcinoma
Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes.
Adenocarcinoma
Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment.
Adenocarcinoma
Immunohistochemistry features and molecular pathology of appendiceal neoplasms.
Adenocarcinoma
Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort.
Adenocarcinoma
Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma.
Adenocarcinoma
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Adenocarcinoma
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Adenocarcinoma
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Adenocarcinoma
Integration of gene profile to explore the hub genes of lung adenocarcinoma: A quasi-experimental study.
Adenocarcinoma
Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus).
Adenocarcinoma
Involvement of ERK1/2, p38 MAPK, and PI3K/Akt signaling pathways in the regulation of cell cycle progression by PTHrP in colon adenocarcinoma cells.
Adenocarcinoma
KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.
Adenocarcinoma
KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Adenocarcinoma
Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Adenocarcinoma
MicroRNAs associated with initiation and progression of colonic polyp: A feasibility study.
Adenocarcinoma
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Adenocarcinoma
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Adenocarcinoma
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Adenocarcinoma
Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study.
Adenocarcinoma
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Adenocarcinoma
Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Adenocarcinoma
Mutations of PIK3CA in gastric adenocarcinoma.
Adenocarcinoma
N-terminal domains of the class ia phosphoinositide 3-kinase regulatory subunit play a role in cytoskeletal but not mitogenic signaling.
Adenocarcinoma
Next-Generation Sequencing in Salivary Gland Basal Cell Adenocarcinoma and Basal Cell Adenoma.
Adenocarcinoma
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Adenocarcinoma
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.
Adenocarcinoma
Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Adenocarcinoma
p85? is a microRNA target and affects chemosensitivity in pancreatic cancer.
Adenocarcinoma
Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110?.
Adenocarcinoma
Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.
Adenocarcinoma
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
Adenocarcinoma
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Adenocarcinoma
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Adenocarcinoma
PIK3CA mutation status in Japanese lung cancer patients.
Adenocarcinoma
PIK3CA mutations and copy number gains in human lung cancers.
Adenocarcinoma
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Adenocarcinoma
PIK3CA mutations in small bowel adenocarcinoma.
Adenocarcinoma
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Adenocarcinoma
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Adenocarcinoma
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Adenocarcinoma
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Adenocarcinoma
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Adenocarcinoma
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Adenocarcinoma
Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.
Adenocarcinoma
Retinoic acid signaling through PI 3-kinase induces differentiation of human endometrial adenocarcinoma cells.
Adenocarcinoma
Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer.
Adenocarcinoma
Sodium butyrate-mediated differentiation of colorectal cancer cells: regulation of PKCbetaII by PI 3-kinase.
Adenocarcinoma
Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.
Adenocarcinoma
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Adenocarcinoma
Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Adenocarcinoma
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Adenocarcinoma
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Adenocarcinoma
The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.
Adenocarcinoma
The Landscape of PIK3CA Mutations in Colorectal Cancer.
Adenocarcinoma
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Adenocarcinoma
The PI 3-kinase-Rac-p38 MAP kinase pathway is involved in the formation of signet-ring cell carcinoma.
Adenocarcinoma
The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Adenocarcinoma
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Adenocarcinoma
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Adenocarcinoma
Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
Adenocarcinoma
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Adenocarcinoma
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Adenocarcinoma
[Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]
Adenocarcinoma
[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Adenocarcinoma
[New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].
Adenocarcinoma of Lung
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Adenocarcinoma of Lung
AKT1 and AKT2 mutations in lung cancer in a Japanese population.
Adenocarcinoma of Lung
Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma.
Adenocarcinoma of Lung
Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex.
Adenocarcinoma of Lung
Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
Adenocarcinoma of Lung
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Adenocarcinoma of Lung
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Adenocarcinoma of Lung
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Adenocarcinoma of Lung
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Adenocarcinoma of Lung
Concealed driver in lung adenocarcinoma with single PIK3CA mutation: a case report and single-center genotyping review.
Adenocarcinoma of Lung
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Adenocarcinoma of Lung
Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.
Adenocarcinoma of Lung
Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma.
Adenocarcinoma of Lung
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.
Adenocarcinoma of Lung
Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas.
Adenocarcinoma of Lung
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population.
Adenocarcinoma of Lung
Integration of gene profile to explore the hub genes of lung adenocarcinoma: A quasi-experimental study.
Adenocarcinoma of Lung
Lung Adenocarcinoma Biomarker Incidence in Hispanic Versus Non-Hispanic White Patients.
Adenocarcinoma of Lung
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Adenocarcinoma of Lung
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Adenocarcinoma of Lung
Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.
Adenocarcinoma of Lung
Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas.
Adenocarcinoma of Lung
Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Adenocarcinoma of Lung
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
Adenocarcinoma of Lung
Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo.
Adenocarcinoma of Lung
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
Adenocarcinoma of Lung
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Adenocarcinoma of Lung
PTEN is a Potent Suppressor of Small Cell Lung Cancer.
Adenocarcinoma of Lung
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Adenocarcinoma of Lung
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Adenocarcinoma of Lung
Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Adenocarcinoma of Lung
Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma.
Adenocarcinoma of Lung
The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition.
Adenocarcinoma of Lung
Tyrosine kinase-dependent, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase-independent signaling pathways prevent lung adenocarcinoma cells from anoikis.
Adenocarcinoma of Lung
Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients.
Adenocarcinoma of Lung
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Adenocarcinoma of Lung
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Adenocarcinoma, Clear Cell
ARID1A gene mutation in ovarian and endometrial cancers (Review).
Adenocarcinoma, Clear Cell
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Adenocarcinoma, Clear Cell
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Adenocarcinoma, Clear Cell
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Adenocarcinoma, Follicular
FOXO3a: a novel player in thyroid carcinogenesis?
Adenocarcinoma, Mucinous
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Adenocarcinoma, Mucinous
Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component.
Adenocarcinoma, Mucinous
Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Adenocarcinoma, Mucinous
Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
Adenocarcinoma, Mucinous
Genotype-phenotype associations in breast pathology: Achievements of the past quarter century.
Adenocarcinoma, Mucinous
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Adenocarcinoma, Mucinous
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Adenocarcinoma, Mucinous
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
Adenocarcinoma, Mucinous
P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma.
Adenocarcinoma, Mucinous
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Adenocarcinoma, Mucinous
[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Adenofibroma
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Adenoma
Activity and PI3-kinase dependent trafficking of the intestinal anion exchanger downregulated in adenoma depend on its PDZ interaction and on lipid rafts.
Adenoma
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
Adenoma
Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers.
Adenoma
Frequent PIK3CA activating mutations in nipple adenomas.
Adenoma
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Adenoma
MicroRNAs associated with initiation and progression of colonic polyp: A feasibility study.
Adenoma
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Adenoma
Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.
Adenoma
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Adenoma
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Adenoma
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Adenoma
PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation.
Adenoma
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Adenoma, Pleomorphic
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Adenoma, Pleomorphic
Malignant transformation of salivary gland pleomorphic adenoma: proof of principle.
Adenoma, Pleomorphic
PIK3CA mutations and PTEN loss in salivary duct carcinomas.
Adenomatous Polyposis Coli
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
Adenomatous Polyposis Coli
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Adenomatous Polyposis Coli
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Adenomatous Polyposis Coli
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Adenomatous Polyposis Coli
H-Ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of beta-catenin in epidermal keratinocytes.
Adenomatous Polyposis Coli
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Adenomatous Polyposis Coli
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Adenomatous Polyposis Coli
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Adenomatous Polyps
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Adenomyoepithelioma
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Adenomyoepithelioma
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.
Adenomyosis
MiR-10b Directly Targets ZEB1 and PIK3CA to Curb Adenomyotic Epithelial Cell Invasiveness via Upregulation of E-Cadherin and Inhibition of Akt Phosphorylation.
Adenoviridae Infections
Corneal cell survival in adenovirus type 19 infection requires phosphoinositide 3-kinase/Akt activation.
Agammaglobulinemia
A novel monoallelic gain of function mutation in p110? causing atypical activated phosphoinositide 3-kinase ? syndrome (APDS-1).
Agammaglobulinemia
Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1.
Agammaglobulinemia
Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis.
Agammaglobulinemia
De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly.
Agammaglobulinemia
Gain-of-function mutation in PIK3R1 in a patient with a narrow clinical phenotype of respiratory infections.
Albinism, Oculocutaneous
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Alzheimer Disease
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Alzheimer Disease
A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway.
Alzheimer Disease
Caffeic acid phenethyl ester rescued streptozotocin-induced memory loss through PI3-kinase dependent pathway.
Alzheimer Disease
Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's disease: Involvement of PI3-kinase, eNOS and NF?B.
Alzheimer Disease
p110? PI 3-kinase inhibition perturbs APP and TNF? trafficking, reduces plaque burden, dampens neuroinflammation and prevents cognitive decline in an Alzheimer's disease mouse model.
Alzheimer Disease
Phosphatidylinositol 3-kinase: increased activity and protein level in amyotrophic lateral sclerosis.
Alzheimer Disease
Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.
Alzheimer Disease
Rho-associated kinases contribute to the regulation of tau phosphorylation and amyloid metabolism during neuronal plasticity.
Alzheimer Disease
Targeting disease through novel pathways of apoptosis and autophagy.
Alzheimer Disease
Weighted burden analysis of exome-sequenced late-onset Alzheimer's cases and controls provides further evidence for a role for PSEN1 and suggests involvement of the PI3K/Akt/GSK-3? and WNT signalling pathways.
Amyotrophic Lateral Sclerosis
Survival activity of troglitazone in rat motoneurones.
Amyotrophic Lateral Sclerosis
VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3-K pathway and inhibition of p38MAPK.
Anaphylaxis
Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function.
Anemia
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Anemia
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Aneurysm
Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.
Angiolipoma
Frequent activating PIK3CA mutations in sporadic angiolipoma.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report.
Anus Neoplasms
Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.
Anus Neoplasms
EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.
Anus Neoplasms
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Anus Neoplasms
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.
Arrhythmias, Cardiac
Ouabain attenuates cardiotoxicity induced by other cardiac steroids.
Arrhythmias, Cardiac
Phosphoinositide 3-kinase ? protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases.
Arrhythmias, Cardiac
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arteriovenous Malformations
Functional assessment of two variants of unknown significance in TEK by endothelium-specific expression in zebrafish embryos.
Arthritis
Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function.
Arthritis
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
Arthritis
Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils.
Arthritis, Experimental
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Arthritis, Experimental
Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice.
Arthritis, Experimental
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
Arthritis, Rheumatoid
Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Arthritis, Rheumatoid
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
Arthritis, Rheumatoid
Discovery of novel PI3-kinase ? specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
Arthritis, Rheumatoid
Discovery of Orally Efficacious Phosphoinositide 3-Kinase ? Inhibitors with Improved Metabolic Stability.
Arthritis, Rheumatoid
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
Arthritis, Rheumatoid
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Arthritis, Rheumatoid
Novel phosphoinositide 3-kinase ?,? inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
Arthritis, Rheumatoid
PBT-6, a Novel PI3KC2? Inhibitor in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Phosphoinositide 3-kinase ? regulates migration and invasion of synoviocytes in rheumatoid arthritis.
Arthritis, Rheumatoid
Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis.
Arthritis, Rheumatoid
Targeting phosphoinositide 3-kinase: moving towards therapy.
Arthritis, Rheumatoid
[Therapeutic potential of phosphoinositide 3-kinase inhibitors in rheumatoid arthritis]
Arthus Reaction
Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.
Asthma
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Asthma
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Asthma
Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice.
Asthma
An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model.
Asthma
Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway.
Asthma
Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT.
Asthma
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Asthma
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Asthma
Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management.
Asthma
Distinct phosphoinositide 3-kinases mediate mast cell degranulation in response to G-protein-coupled versus FcepsilonRI receptors.
Asthma
Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma.
Asthma
Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation.
Asthma
FIZZ1 promotes airway remodeling through the PI3K/Akt signaling pathway in asthma.
Asthma
Histone deacetylase-2 and airway disease.
Asthma
Increased expression of PI-3K in asthmatic rat T lymphocytes.
Asthma
Inhibition of phosphoinositide 3-kinase {delta} attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model.
Asthma
Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
Asthma
Interleukin 13 increases contractility of murine tracheal smooth muscle by a phosphoinositide 3-kinase p110delta-dependent mechanism.
Asthma
Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
Asthma
Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.
Asthma
Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.
Asthma
Phosphoinositide 3-kinase {delta} inhibitor suppresses IL-17 expression in a murine asthma model.
Asthma
PI 3-kinase inhibition: a therapeutic target for respiratory disease.
Asthma
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
Asthma
PI3K and Notch signal pathways coordinately regulate the activation and proliferation of T lymphocytes in asthma.
Asthma
PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling.
Asthma
PI3K inhibition in inflammation: Toward tailored therapies for specific diseases.
Asthma
PI3K? contributes to ER stress-associated asthma through ER-redox disturbances: the involvement of the RIDD-RIG-I-NF-?B axis.
Asthma
Signalling through Class I PI3Ks in mammalian cells.
Asthma
Tangeretin has anti-asthmatic effects via regulating PI3K and Notch signaling and modulating Th1/Th2/Th17 cytokine balance in neonatal asthmatic mice.
Asthma
Targeting phosphoinositide 3-kinase ? for allergic asthma.
Astrocytoma
A Screen for Novel Phosphoinositide 3-kinase Effector Proteins.
Astrocytoma
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Astrocytoma
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
Astrocytoma
Cross-talk between phospholipase C and phosphoinositide 3-kinase signalling pathways.
Astrocytoma
Differential effects of GH and GH-releasing peptide-6 on astrocytes.
Astrocytoma
Differential in vitro neurotoxicity of the flame retardant PBDE-99 and of the PCB Aroclor 1254 in human astrocytoma cells.
Astrocytoma
Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.
Astrocytoma
Malignant astrocytoma cell attachment and migration to various matrix proteins is differentially sensitive to phosphoinositide 3-OH kinase inhibitors.
Astrocytoma
MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.
Astrocytoma
Muscarinic receptor-mediated activation of p70 S6 kinase 1 (S6K1) in 1321N1 astrocytoma cells: permissive role of phosphoinositide 3-kinase.
Astrocytoma
Muscarinic receptors mediate phospholipase C-dependent activation of protein kinase B via Ca2+, ErbB3, and phosphoinositide 3-kinase in 1321N1 astrocytoma cells.
Astrocytoma
Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
Astrocytoma
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Astrocytoma
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Astrocytoma
Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.
Astrocytoma
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Astrocytoma
Synchronous rosette-forming glioneuronal tumor and diffuse astrocytoma with molecular characterization: a case report.
Ataxia
Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.
Ataxia Telangiectasia
A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation.
Ataxia Telangiectasia
ATM activation accompanies histone H2AX phosphorylation in A549 cells upon exposure to tobacco smoke.
Ataxia Telangiectasia
DNA-dependent protein kinase and related proteins.
Ataxia Telangiectasia
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Ataxia Telangiectasia
Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC.
Ataxia Telangiectasia
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Ataxia Telangiectasia
Human UPF1 interacts with TPP1 and telomerase and sustains telomere leading-strand replication.
Ataxia Telangiectasia
Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase.
Ataxia Telangiectasia
SMG1 heterozygosity exacerbates haematopoietic cancer development in Atm null mice by increasing persistent DNA damage and oxidative stress.
Atherosclerosis
Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis.
Atherosclerosis
Early growth response gene-1 expression in vascular smooth muscle cells effects of insulin and oxidant stress.
Atherosclerosis
Fluid-Phase Pinocytosis of LDL by Macrophages: A Novel Target to Reduce Macrophage Cholesterol Accumulation in Atherosclerotic Lesions.
Atherosclerosis
Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.
Atherosclerosis
Glucosamine enhances platelet-derived growth factor-induced DNA synthesis via phosphatidylinositol 3-kinase pathway in rat aortic smooth muscle cells.
Atherosclerosis
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
Atherosclerosis
Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.
Atherosclerosis
p110Delta Inhibits Monocyte Infiltration by Thioglycollate-Induced Periotoneal Inflammation but Not HCD-Induced Inflammation and Atherosclerosis in APOE KO Mice.
Atherosclerosis
The interleukin-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages requires MAP kinase, phosphoinositide 3-kinase and nuclear factor-?B signaling pathways.
Atherosclerosis
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Atrial Fibrillation
Cardiotoxicity of Novel Targeted Hematological Therapies.
Atrial Fibrillation
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Autoimmune Diseases
Attenuation of phosphoinositide 3-kinase ? signaling restrains autoimmune disease.
Autoimmune Diseases
Auto-immune disorders in a child with PIK3CD variant and 22q13 deletion.
Autoimmune Diseases
Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists.
Autoimmune Diseases
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
Autoimmune Diseases
Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice.
Autoimmune Diseases
Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
Autoimmune Diseases
Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Autoimmune Diseases
Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
Autoimmune Diseases
Phosphoinositide 3-kinase p110delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.
Autoimmune Diseases
PI3K? drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation.
Autoimmune Diseases
Role of phosphoinositide 3-kinase signaling in autoimmunity.
Autoimmune Diseases
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
Autoimmune Diseases
The PI3K? inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sj?gren's syndrome.
Autoimmune Diseases
WITHDRAWN: Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Autoimmune Lymphoproliferative Syndrome
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
Autoimmune Lymphoproliferative Syndrome
Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.
Bacterial Infections
Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection.
Bacterial Infections
Phosphoinositide 3-kinase family in channel catfish and their regulated expression after bacterial infection.
Barrett Esophagus
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Biliary Tract Neoplasms
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
Blister
Bleb-driven chemotaxis of Dictyostelium cells.
Blister
CIB1 synergizes with EphrinA2 to regulate Kaposi's sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells.
Blister
ESCRT-I Protein Tsg101 Plays a Role in the Post-macropinocytic Trafficking and Infection of Endothelial Cells by Kaposi's Sarcoma-Associated Herpesvirus.
Blister
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Blister
Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection.
Bone Resorption
c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase.
Bone Resorption
Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through Akt-mediated vesicle transport.
Bone Resorption
Effects of wortmannin analogs on bone in vitro and in vivo.
Bone Resorption
Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength.
Bone Resorption
Important roles of PI3Kgamma in osteoclastogenesis and bone homeostasis.
Bone Resorption
Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice.
Bone Resorption
Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton, and its involvement in osteoclast attachment and spreading.
Brain Diseases
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Brain Diseases
Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.
Brain Edema
Inhibition of FOXO3a/BIM signaling pathway contributes to the protective effect of salvianolic acid A against cerebral ischemia/reperfusion injury.
Brain Injuries
BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway.
Brain Injuries
Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain.
Brain Ischemia
Insulin blocks cytochrome c release in the reperfused brain through PI3-K signaling and by promoting Bax/Bcl-XL binding.
Brain Ischemia
Phosphoinositide 3-Kinase ? Restrains Neurotoxic Effects of Microglia After Focal Brain Ischemia.
Brain Ischemia
Phosphoinositide 3-kinase-gamma expression is upregulated in brain microglia and contributes to ischemia-induced microglial activation in acute experimental stroke.
Brain Ischemia
Role of phosphoinositide 3-kinase in ischemic postconditioning-induced attenuation of cerebral ischemia-evoked behavioral deficits in mice.
Brain Neoplasms
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Brain Neoplasms
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Brain Neoplasms
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.
Brain Neoplasms
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Brain Neoplasms
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Brain Neoplasms
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Brain Neoplasms
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Brain Neoplasms
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
Brain Neoplasms
Impact of somatic mutations on patterns of metastasis in colorectal cancer.
Brain Neoplasms
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Brain Neoplasms
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Brain Neoplasms
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Brain Neoplasms
The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
Brain Neoplasms
The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors.
Brain Neoplasms
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Brain Neoplasms
Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors.
Brain Neoplasms
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting a treatment outcomes of non-small cell lung cancer.
Breast Carcinoma In Situ
Lobular breast cancer: Clinical, molecular and morphological characteristics.
Breast Carcinoma In Situ
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Breast Neoplasms
3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.
Breast Neoplasms
A butterfly effect in cancer.
Breast Neoplasms
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
Breast Neoplasms
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.
Breast Neoplasms
A comparative survey of functional footprints of EGFR pathway mutations in human cancers.
Breast Neoplasms
A Comparison Between Full-COLD PCR/HRM and PCR Sequencing for Detection of Mutations in Exon 9 of PIK3CA in Breast Cancer Patients.
Breast Neoplasms
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Breast Neoplasms
A microscopic landscape of the invasive breast cancer genome.
Breast Neoplasms
A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Breast Neoplasms
A novel carcinogenic PI3K? mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
Breast Neoplasms
A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation.
Breast Neoplasms
A novel Phosphatidylinositol 3-Kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes.
Breast Neoplasms
A Novel PIK3CA Hotspot Mutation in Isfahanian Breast Cancer Patients.
Breast Neoplasms
A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM(high) and EpCAM(low/negative) CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer.
Breast Neoplasms
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.
Breast Neoplasms
A Phase Ib Study of Alpelisib (BYL719), a PI3K?-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer.
Breast Neoplasms
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Breast Neoplasms
A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.
Breast Neoplasms
A PI3K p110?-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
Breast Neoplasms
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
Breast Neoplasms
A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
Breast Neoplasms
A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer.
Breast Neoplasms
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Breast Neoplasms
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Breast Neoplasms
Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer.
Breast Neoplasms
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.
Breast Neoplasms
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Breast Neoplasms
Activation of HIF-1? by ?-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells.
Breast Neoplasms
Activation of IGF1R/p110?/AKT/mTOR confers resistance to ?-specific PI3K inhibition.
Breast Neoplasms
Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells.
Breast Neoplasms
Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells.
Breast Neoplasms
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Breast Neoplasms
Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-? signaling axes.
Breast Neoplasms
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating ?-Catenin Signaling.
Breast Neoplasms
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.
Breast Neoplasms
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Breast Neoplasms
Alpelisib to treat breast cancer.
Breast Neoplasms
Alpelisib-Induced Diabetic Ketoacidosis.
Breast Neoplasms
Alpelisib: First Global Approval.
Breast Neoplasms
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Breast Neoplasms
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
Breast Neoplasms
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Breast Neoplasms
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Breast Neoplasms
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.
Breast Neoplasms
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Breast Neoplasms
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Breast Neoplasms
Analysis of PIK3CA mutations in breast cancer subtypes.
Breast Neoplasms
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
Breast Neoplasms
Antagonists of the serotonin receptor 5A target human breast tumor initiating cells.
Breast Neoplasms
Anthricin Isolated from Anthriscus sylvestris (L.) Hoffm. Inhibits the Growth of Breast Cancer Cells by Inhibiting Akt/mTOR Signaling, and Its Apoptotic Effects Are Enhanced by Autophagy Inhibition.
Breast Neoplasms
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Breast Neoplasms
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Breast Neoplasms
Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
Breast Neoplasms
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.
Breast Neoplasms
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
Breast Neoplasms
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
Breast Neoplasms
Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk.
Breast Neoplasms
Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Breast Neoplasms
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Breast Neoplasms
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Breast Neoplasms
Available and emerging molecular markers in the clinical management of breast cancer.
Breast Neoplasms
BAG-1/SODD, HSP70 and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
Breast Neoplasms
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110? and p110? activities in tumor cell lines and xenograft models.
Breast Neoplasms
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Breast Neoplasms
Benefits versus risk profile of buparlisib for the treatment of breast cancer.
Breast Neoplasms
Beta-Tocotrienol Exhibits More Cytotoxic Effects than Gamma-Tocotrienol on Breast Cancer Cells by Promoting Apoptosis via a P53-Independent PI3-Kinase Dependent Pathway.
Breast Neoplasms
Bilateral Breast Radiation Associated Angiosarcoma After Radiotherapy for Bilateral Invasive Ductal Adenocarcinoma.
Breast Neoplasms
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.
Breast Neoplasms
Biomarkers in Her2- Positive Disease.
Breast Neoplasms
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
Breast Neoplasms
Biphasic papillary and lobular breast carcinoma with PIK3CA and IDH1 mutations.
Breast Neoplasms
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
Breast Neoplasms
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.
Breast Neoplasms
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
Breast Neoplasms
Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.
Breast Neoplasms
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Breast Neoplasms
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Breast Neoplasms
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Breast Neoplasms
CD44/HA signaling mediates acquired resistance to a PI3K? inhibitor.
Breast Neoplasms
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Breast Neoplasms
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Breast Neoplasms
cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12.
Breast Neoplasms
Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation.
Breast Neoplasms
Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.
Breast Neoplasms
Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI 3-Kinase and Akt.
Breast Neoplasms
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Breast Neoplasms
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Breast Neoplasms
Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.
Breast Neoplasms
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Breast Neoplasms
Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer.
Breast Neoplasms
Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer.
Breast Neoplasms
Classifying cancer genome aberrations by their mutually exclusive effects on transcription.
Breast Neoplasms
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Breast Neoplasms
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Breast Neoplasms
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Breast Neoplasms
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Breast Neoplasms
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Breast Neoplasms
Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer.
Breast Neoplasms
Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Breast Neoplasms
Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population.
Breast Neoplasms
Clinicopathological Characteristics of PIK3CA Mutation and Amplification in Korean Patients with Breast Cancers.
Breast Neoplasms
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Breast Neoplasms
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Breast Neoplasms
Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
Breast Neoplasms
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Breast Neoplasms
Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation.
Breast Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Breast Neoplasms
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
Breast Neoplasms
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer.
Breast Neoplasms
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
Breast Neoplasms
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
Breast Neoplasms
Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
Breast Neoplasms
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.
Breast Neoplasms
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Breast Neoplasms
Comprehensive Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients.
Breast Neoplasms
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Breast Neoplasms
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Breast Neoplasms
Convergent loss of PTEN leads to clinical resistance to a PI(3)K? inhibitor.
Breast Neoplasms
Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation.
Breast Neoplasms
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.
Breast Neoplasms
Cooperative oncogenic effect and cell signaling crosstalk of co?occurring HER2 and mutant PIK3CA in mammary epithelial cells.
Breast Neoplasms
Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer.
Breast Neoplasms
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Breast Neoplasms
Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Breast Neoplasms
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.
Breast Neoplasms
Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Breast Neoplasms
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Breast Neoplasms
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2.
Breast Neoplasms
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Breast Neoplasms
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
Breast Neoplasms
Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.
Breast Neoplasms
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Breast Neoplasms
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Breast Neoplasms
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Breast Neoplasms
Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth.
Breast Neoplasms
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Breast Neoplasms
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.
Breast Neoplasms
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Breast Neoplasms
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.
Breast Neoplasms
Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Breast Neoplasms
Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood.
Breast Neoplasms
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Breast Neoplasms
Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Breast Neoplasms
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Breast Neoplasms
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas.
Breast Neoplasms
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Breast Neoplasms
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Breast Neoplasms
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110?/PIK3CA but not by HER2 or mutant AKT1.
Breast Neoplasms
Distinct epithelial-to-mesenchymal transitions induced by PIK3CA H1047R and PIK3CB.
Breast Neoplasms
Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells.
Breast Neoplasms
Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In vitro and In vivo.
Breast Neoplasms
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations.
Breast Neoplasms
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K? inhibitors.
Breast Neoplasms
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Breast Neoplasms
Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer.
Breast Neoplasms
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Breast Neoplasms
Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer.
Breast Neoplasms
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Breast Neoplasms
Efficacy of buparlisib in treating breast cancer.
Breast Neoplasms
Efficacy of PI3K inhibitors in advanced breast cancer.
Breast Neoplasms
EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy.
Breast Neoplasms
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Breast Neoplasms
Enhanced PI3K p110? signaling confers acquired lapatinib resistance that can be effectively reversed by a p110?-selective PI3K inhibitor.
Breast Neoplasms
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Breast Neoplasms
EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Breast Neoplasms
Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism.
Breast Neoplasms
Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product.
Breast Neoplasms
ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Breast Neoplasms
ErbB2-positive mammary tumors can escape PI3K-p110? loss through downregulation of the Pten tumor suppressor.
Breast Neoplasms
ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Breast Neoplasms
Estrogen receptor ? induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.
Breast Neoplasms
Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Breast Neoplasms
Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Breast Neoplasms
Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001).
Breast Neoplasms
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Breast Neoplasms
Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Breast Neoplasms
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Breast Neoplasms
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.
Breast Neoplasms
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
Breast Neoplasms
Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.
Breast Neoplasms
Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Breast Neoplasms
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Breast Neoplasms
Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation.
Breast Neoplasms
Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Breast Neoplasms
FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach.
Breast Neoplasms
Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
Breast Neoplasms
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Breast Neoplasms
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Breast Neoplasms
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Breast Neoplasms
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Breast Neoplasms
Frequent PIK3CA mutations in radial scars.
Breast Neoplasms
Function of MiR-152 As a Tumor Suppressor in Human Breast Cancer By Targeting PIK3CA.
Breast Neoplasms
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.
Breast Neoplasms
Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells.
Breast Neoplasms
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Breast Neoplasms
Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer.
Breast Neoplasms
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Breast Neoplasms
Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients.
Breast Neoplasms
Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours.
Breast Neoplasms
Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
Breast Neoplasms
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Breast Neoplasms
Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.
Breast Neoplasms
Genetically engineered ER? positive breast cancer mouse models.
Breast Neoplasms
Genomic profile of advanced breast cancer in circulating tumour DNA.
Breast Neoplasms
Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.
Breast Neoplasms
Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein.
Breast Neoplasms
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Breast Neoplasms
Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.
Breast Neoplasms
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Breast Neoplasms
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Breast Neoplasms
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Breast Neoplasms
High-resolution genomic and expression analyses of copy number alterations in breast tumors.
Breast Neoplasms
High-Resolution Melting Analysis as a Sensitive Prescreening Diagnostic Tool to Detect KRAS , BRAF , PIK3CA , and AKT1 Mutations in Formalin-Fixed, Paraffin-Embedded Tissues.
Breast Neoplasms
High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Breast Neoplasms
Highlights from the 38th SABCS annual meeting, 8th - 12th December 2015, San Antonio, USA.
Breast Neoplasms
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Breast Neoplasms
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Breast Neoplasms
Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
Breast Neoplasms
Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas.
Breast Neoplasms
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Breast Neoplasms
Identification of effective natural PIK3CA H1047R inhibitors by computational study.
Breast Neoplasms
Identification of frequent somatic mutations in inflammatory breast cancer.
Breast Neoplasms
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
Breast Neoplasms
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
Breast Neoplasms
Identification of upregulated phosphoinositide 3-kinase ? as a target to suppress breast cancer cell migration and invasion.
Breast Neoplasms
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.
Breast Neoplasms
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Breast Neoplasms
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
Breast Neoplasms
Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients.
Breast Neoplasms
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.
Breast Neoplasms
Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations.
Breast Neoplasms
In silico investigation of heparanase-correlated genes in breast cancer subtypes.
Breast Neoplasms
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Breast Neoplasms
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Breast Neoplasms
Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis.
Breast Neoplasms
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Breast Neoplasms
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K? inhibition through the transcriptional regulation of ER?.
Breast Neoplasms
Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
Breast Neoplasms
Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
Breast Neoplasms
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Breast Neoplasms
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Breast Neoplasms
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
Breast Neoplasms
Initiating breast cancer by PIK3CA mutation.
Breast Neoplasms
Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.
Breast Neoplasms
Insulin-dependent leptin expression in breast cancer cells.
Breast Neoplasms
Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells.
Breast Neoplasms
Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway.
Breast Neoplasms
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Breast Neoplasms
Integrating mutation and gene expression cross-sectional data to infer cancer progression.
Breast Neoplasms
Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.
Breast Neoplasms
Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.
Breast Neoplasms
Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk.
Breast Neoplasms
Intermittent high dose scheduling of AZD8835, a novel selective inhibitor of PI3K? and PI3K?, demonstrates treatment strategies for PIK3CA-dependent breast cancers.
Breast Neoplasms
Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
Breast Neoplasms
Investigation of somatic PIK3CA gene mutations in breast cancer patients.
Breast Neoplasms
Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells.
Breast Neoplasms
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Breast Neoplasms
Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells.
Breast Neoplasms
Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
Breast Neoplasms
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Breast Neoplasms
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Breast Neoplasms
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
Breast Neoplasms
Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.
Breast Neoplasms
LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Breast Neoplasms
Liquid Biopsy in Breast Cancer: A Focused Review.
Breast Neoplasms
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Breast Neoplasms
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Breast Neoplasms
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Breast Neoplasms
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast Neoplasms
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Breast Neoplasms
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Breast Neoplasms
Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis.
Breast Neoplasms
Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.
Breast Neoplasms
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Breast Neoplasms
Management of toxicity to isoform ?-specific PI3K inhibitors.
Breast Neoplasms
Mango polyphenolics suppressed tumor growth in breast cancer xenografts in mice: role of the PI3K/AKT pathway and associated microRNAs.
Breast Neoplasms
Manic episode occurring during investigational treatment with pan-class I phosphoinositide 3-kinase inhibitor in a patient with breast cancer.
Breast Neoplasms
Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Breast Neoplasms
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model.
Breast Neoplasms
Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Breast Neoplasms
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Breast Neoplasms
Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome.
Breast Neoplasms
Metabolic Imaging Detects Resistance to PI3K? Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer.
Breast Neoplasms
Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line.
Breast Neoplasms
MEX3A promotes development and progression of breast cancer through regulation of PIK3CA.
Breast Neoplasms
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Breast Neoplasms
MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
Breast Neoplasms
miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.
Breast Neoplasms
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Breast Neoplasms
Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Breast Neoplasms
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Breast Neoplasms
Molecular Characterization of Apocrine Salivary Duct Carcinoma.
Breast Neoplasms
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.
Breast Neoplasms
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Breast Neoplasms
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Breast Neoplasms
Molecular Testing in Breast Cancer.
Breast Neoplasms
Molecular Testing in Breast Cancer: Current Status and Future Directions.
Breast Neoplasms
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Breast Neoplasms
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
Breast Neoplasms
mTORC1 inhibition is required for sensitivity to PI3K p110? inhibitors in PIK3CA-mutant breast cancer.
Breast Neoplasms
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Breast Neoplasms
Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells.
Breast Neoplasms
Multiplex detection of DNA mutations by the fluorescence fingerprint spectrum technique.
Breast Neoplasms
Multiplexed assays for detection of mutations in PIK3CA.
Breast Neoplasms
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Breast Neoplasms
Mutant PIK3CA Induces EMT in a Cell Type Specific Manner.
Breast Neoplasms
Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Breast Neoplasms
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
Breast Neoplasms
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Breast Neoplasms
Mutation of the PIK3CA gene in ovarian and breast cancer.
Breast Neoplasms
Mutation of the PTCH1 gene predicts recurrence of breast cancer.
Breast Neoplasms
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Breast Neoplasms
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Breast Neoplasms
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Breast Neoplasms
Mutational Hotspot in Exon 20 of PIK3CA in Breast Cancer Among Singapore Chinese.
Breast Neoplasms
Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics.
Breast Neoplasms
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Breast Neoplasms
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Breast Neoplasms
Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin.
Breast Neoplasms
N-substituted hydroxynaphthalene imino-oxindole derivatives as new class of PI3-kinase inhibitor and breast cancer drug: Molecular validation and structure-activity relationship studies.
Breast Neoplasms
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.
Breast Neoplasms
Nanopore Identification of Single Nucleotide Mutations in Circulating Tumor DNA by Multiplexed Ligation.
Breast Neoplasms
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Breast Neoplasms
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Breast Neoplasms
Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.
Breast Neoplasms
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Breast Neoplasms
Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Breast Neoplasms
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Breast Neoplasms
Novel Method for PIK3CA Mutation Analysis: Locked Nucleic Acid-PCR Sequencing.
Breast Neoplasms
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Breast Neoplasms
Novel Mutations in Neuroendocrine Carcinoma of the Breast: Possible Therapeutic Targets.
Breast Neoplasms
Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
Breast Neoplasms
NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Breast Neoplasms
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects.
Breast Neoplasms
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Breast Neoplasms
Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells.
Breast Neoplasms
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
Breast Neoplasms
OPENchip: an on-chip in situ molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells.
Breast Neoplasms
Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer.
Breast Neoplasms
Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Breast Neoplasms
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
Breast Neoplasms
Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Breast Neoplasms
Overexpression of PIK3CA impacts global survival of patients with HER2 subtype breast carcinoma.
Breast Neoplasms
p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells.
Breast Neoplasms
p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.
Breast Neoplasms
pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.
Breast Neoplasms
Particular molecular and ultrastructural aspects in invasive mammary carcinoma.
Breast Neoplasms
Pathway-driven discovery of rare mutational impact on cancer.
Breast Neoplasms
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
Breast Neoplasms
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
Breast Neoplasms
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K? Inhibition.
Breast Neoplasms
Pharmacological explorations of eco-friendly amide substituted (Z)-?-enaminones as anti-breast cancer drugs.
Breast Neoplasms
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Breast Neoplasms
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
Breast Neoplasms
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Breast Neoplasms
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Breast Neoplasms
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.
Breast Neoplasms
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Breast Neoplasms
PHLPP2 gene L1016S (rs61733127) and PIK3R1 gene Met326Ile (rs3730089) polymorphisms are associated with the risk of colon and breast cancers.
Breast Neoplasms
Phospatidylinositol 3-kinase expression in human breast cancer.
Breast Neoplasms
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Breast Neoplasms
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Breast Neoplasms
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Breast Neoplasms
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Breast Neoplasms
Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
Breast Neoplasms
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Breast Neoplasms
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.
Breast Neoplasms
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth.
Breast Neoplasms
Phosphoinositide 3-kinase and INPP4B in human breast cancer.
Breast Neoplasms
Phosphoinositide 3-kinase assay in breast cancer cell extracts.
Breast Neoplasms
Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer.
Breast Neoplasms
Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation.
Breast Neoplasms
Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
Breast Neoplasms
Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Breast Neoplasms
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Breast Neoplasms
Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Breast Neoplasms
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
Breast Neoplasms
Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells.
Breast Neoplasms
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ER?-positive tumors.
Breast Neoplasms
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer.
Breast Neoplasms
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Breast Neoplasms
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
Breast Neoplasms
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Breast Neoplasms
PI3K inhibition to overcome endocrine resistance in breast cancer.
Breast Neoplasms
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Breast Neoplasms
PI3K mutations in breast cancer: prognostic and therapeutic implications.
Breast Neoplasms
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Breast Neoplasms
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Breast Neoplasms
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
Breast Neoplasms
PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85?.
Breast Neoplasms
PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.
Breast Neoplasms
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
Breast Neoplasms
PI3K? links integrin activation and PI(3,4)P2 production during invadopodial maturation.
Breast Neoplasms
PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer.
Breast Neoplasms
PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System.
Breast Neoplasms
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Breast Neoplasms
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
Breast Neoplasms
PIK3CA and PTEN Genes Expressions in Breast Cancer.
Breast Neoplasms
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.
Breast Neoplasms
PIK3CA cancer mutations display gender and tissue specificity patterns.
Breast Neoplasms
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
Breast Neoplasms
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
Breast Neoplasms
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Breast Neoplasms
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
Breast Neoplasms
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Breast Neoplasms
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
Breast Neoplasms
PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies.
Breast Neoplasms
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Breast Neoplasms
PIK3CA Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Breast Neoplasms
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Breast Neoplasms
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Breast Neoplasms
PIK3CA in Breast Carcinoma: A Mutational Analysis of Sporadic and Hereditary Cases.
Breast Neoplasms
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Breast Neoplasms
PIK3CA mutation associates with improved outcome in breast cancer.
Breast Neoplasms
PIK3CA mutation detected by liquid biopsy in patients with metastatic breast cancer.
Breast Neoplasms
PIK3CA mutation enrichment and quantitation from blood and tissue.
Breast Neoplasms
PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups.
Breast Neoplasms
PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.
Breast Neoplasms
PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come.
Breast Neoplasms
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Breast Neoplasms
PIK3CA mutation predicts resistance to breast cancer therapy.
Breast Neoplasms
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
Breast Neoplasms
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Breast Neoplasms
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Breast Neoplasms
PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ER? serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.
Breast Neoplasms
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Breast Neoplasms
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
Breast Neoplasms
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
Breast Neoplasms
PIK3CA mutations and downstream effector p-mTOR expression: implication for prognostic factors and therapeutic targets in triple negative breast cancer.
Breast Neoplasms
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.
Breast Neoplasms
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
Breast Neoplasms
PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Breast Neoplasms
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.
Breast Neoplasms
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Breast Neoplasms
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Breast Neoplasms
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Breast Neoplasms
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Breast Neoplasms
PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.
Breast Neoplasms
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Breast Neoplasms
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.
Breast Neoplasms
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Breast Neoplasms
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
Breast Neoplasms
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Breast Neoplasms
PIK3CA mutations in breast cancer are associated with poor outcome.
Breast Neoplasms
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.
Breast Neoplasms
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Breast Neoplasms
PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients
Breast Neoplasms
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.
Breast Neoplasms
PIK3CA mutations in in situ and invasive breast carcinomas.
Breast Neoplasms
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Breast Neoplasms
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in Breast Cancer.
Breast Neoplasms
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
Breast Neoplasms
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Breast Neoplasms
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2 and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Breast Neoplasms
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.
Breast Neoplasms
PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer.
Breast Neoplasms
PIK3CA rs7640662 (C/G) single nucleotide polymorphism lacks association with breast cancer cases in Persians.
Breast Neoplasms
PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
Breast Neoplasms
PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.
Breast Neoplasms
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Breast Neoplasms
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Breast Neoplasms
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
Breast Neoplasms
PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Breast Neoplasms
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Breast Neoplasms
PIKing the right patient.
Breast Neoplasms
Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.
Breast Neoplasms
Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition.
Breast Neoplasms
Potential Anticancer Effect of Calcium-mediated Src Degradation on Hormone-dependent Breast Cancer.
Breast Neoplasms
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
Breast Neoplasms
Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics.
Breast Neoplasms
Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.
Breast Neoplasms
Precision medicine for metastatic breast cancer--limitations and solutions.
Breast Neoplasms
Precision medicine for metastatic breast cancer.
Breast Neoplasms
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Breast Neoplasms
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Breast Neoplasms
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
Breast Neoplasms
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Breast Neoplasms
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Breast Neoplasms
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Breast Neoplasms
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Breast Neoplasms
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Breast Neoplasms
Prognosis of women with early breast cancer and PIK3CA mutations.
Breast Neoplasms
Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer.
Breast Neoplasms
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Breast Neoplasms
Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.
Breast Neoplasms
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Breast Neoplasms
Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Breast Neoplasms
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Breast Neoplasms
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Breast Neoplasms
Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting.
Breast Neoplasms
Proximity ligation assay to detect and localize the interactions of ER? with PI3-K and Src in breast cancer cells and tumor samples.
Breast Neoplasms
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the ?-catenin signaling pathway.
Breast Neoplasms
PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Breast Neoplasms
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Breast Neoplasms
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.
Breast Neoplasms
Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
Breast Neoplasms
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Breast Neoplasms
Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring.
Breast Neoplasms
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Breast Neoplasms
Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c.
Breast Neoplasms
Regulation of macrophage inhibitory factor (MIF) by epidermal growth factor receptor (EGFR) in the MCF10AT model of breast cancer progression.
Breast Neoplasms
Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2.
Breast Neoplasms
Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer.
Breast Neoplasms
Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.
Breast Neoplasms
Relationship Between PIK3CA Amplification and P110? and CD34 Tissue Expression as Angiogenesis Markers in Iranian Women with Sporadic Breast Cancer.
Breast Neoplasms
Relationship of PIK3CA mutation and pathway activity with anti-proliferative response to aromatase inhibition.
Breast Neoplasms
Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB.
Breast Neoplasms
Rlip Depletion Suppresses Growth of Breast Cancer.
Breast Neoplasms
RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells.
Breast Neoplasms
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Breast Neoplasms
Role of E542 and E545 missense mutations of PIK3CA in breast cancer: A comparative Computational approach.
Breast Neoplasms
Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells.
Breast Neoplasms
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Breast Neoplasms
Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Breast Neoplasms
Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells.
Breast Neoplasms
S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
Breast Neoplasms
Science Signaling Podcast for 21 February 2017: Pentraxin-3 in basal-like breast cancer.
Breast Neoplasms
Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors.
Breast Neoplasms
Secretion of Mutant DNA and mRNA by the Exosomes of Breast Cancer Cells.
Breast Neoplasms
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Breast Neoplasms
Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Breast Neoplasms
Sensitization of breast cancer cells to radiation by trastuzumab.
Breast Neoplasms
Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase.
Breast Neoplasms
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Breast Neoplasms
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Breast Neoplasms
Signaling-dependent nuclear export of estradiol receptor controls cell cycle progression in breast cancer cells.
Breast Neoplasms
Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing.
Breast Neoplasms
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Breast Neoplasms
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Breast Neoplasms
Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer.
Breast Neoplasms
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Breast Neoplasms
Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms.
Breast Neoplasms
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Breast Neoplasms
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Breast Neoplasms
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Breast Neoplasms
Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.
Breast Neoplasms
Somatic mutations in the notch, NF-KB, PIK3CA, and hedgehog pathways in human breast cancers.
Breast Neoplasms
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.
Breast Neoplasms
Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells.
Breast Neoplasms
Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients.
Breast Neoplasms
Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients.
Breast Neoplasms
Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.
Breast Neoplasms
Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Breast Neoplasms
Suppression of epidermal growth factor receptor-mediated ?-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Breast Neoplasms
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Breast Neoplasms
Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Breast Neoplasms
Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease.
Breast Neoplasms
Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Breast Neoplasms
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Breast Neoplasms
Synergistic interactions with PI3K inhibition that induce apoptosis.
Breast Neoplasms
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Breast Neoplasms
Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types.
Breast Neoplasms
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.
Breast Neoplasms
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Breast Neoplasms
Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples.
Breast Neoplasms
Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.
Breast Neoplasms
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Breast Neoplasms
Targeting HER2 heterogeneity in early-stage breast cancer.
Breast Neoplasms
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Breast Neoplasms
Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Breast Neoplasms
Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?
Breast Neoplasms
Targeting the Phosphatidyl Inositol 3-Kinase Signaling Pathway in Breast Cancer.
Breast Neoplasms
Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.
Breast Neoplasms
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
Breast Neoplasms
Telocinobufagin inhibits the epithelial-mesenchymal transition of breast cancer cells through the phosphoinositide 3-kinase/protein kinase B/extracellular signal-regulated kinase/Snail signaling pathway.
Breast Neoplasms
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Breast Neoplasms
The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway.
Breast Neoplasms
The cancer genetics and pathology of male breast cancer.
Breast Neoplasms
The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.
Breast Neoplasms
The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer-A Preliminary Study.
Breast Neoplasms
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Breast Neoplasms
The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China.
Breast Neoplasms
The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
Breast Neoplasms
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
Breast Neoplasms
The Gene Mutation Spectrum of Breast Cancer Analyzed by Semiconductor Sequencing Platform.
Breast Neoplasms
The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
Breast Neoplasms
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Breast Neoplasms
The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.
Breast Neoplasms
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Breast Neoplasms
The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.
Breast Neoplasms
The interaction of p130Cas with PKN3 promotes malignant growth.
Breast Neoplasms
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Breast Neoplasms
The molecular contribution of TNF-? in the link between obesity and breast cancer.
Breast Neoplasms
The Occurrence of Genetic Alterations during the Progression of Breast Carcinoma.
Breast Neoplasms
The paradox of cancer genes in non-malignant conditions: implications for precision medicine.
Breast Neoplasms
The PIK3CA gene is mutated with high frequency in human breast cancers.
Breast Neoplasms
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
Breast Neoplasms
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
Breast Neoplasms
The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis.
Breast Neoplasms
The promise of combining inhibition of PI3K and PARP as cancer therapy.
Breast Neoplasms
The role of adapter protein Shc in estrogen non-genomic action.
Breast Neoplasms
The role of insulin receptor substrate-1 in transformation by v-src.
Breast Neoplasms
The role of phosphoinositide 3-kinase in breast cancer: an overview.
Breast Neoplasms
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors.
Breast Neoplasms
The sensitivity and efficacy method of PIK3CA exon 9 E545A as a high diagnostic accuracy in breast cancer.
Breast Neoplasms
The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
Breast Neoplasms
Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Breast Neoplasms
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
Breast Neoplasms
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Breast Neoplasms
Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.
Breast Neoplasms
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Breast Neoplasms
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Breast Neoplasms
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Breast Neoplasms
Understanding the histogenesis of a HRAS-PIK3R1 co-driven metastatic metaplastic breast carcinoma associated with squamous metaplasia of lactiferous ducts.
Breast Neoplasms
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Breast Neoplasms
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Breast Neoplasms
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients.
Breast Neoplasms
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
Breast Neoplasms
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Breast Neoplasms
USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor ?.
Breast Neoplasms
VEGF-A165 Induces Human Aortic Smooth Muscle Cell Migration by Activating Neuropilin-1-VEGFR1-PI3K Axis.
Breast Neoplasms
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.
Breast Neoplasms
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Breast Neoplasms
XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
Breast Neoplasms
[Activation of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways.]
Breast Neoplasms
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
Breast Neoplasms
[Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
Breast Neoplasms
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Breast Neoplasms
[PI3K/AKT pathway activation and therapeutic consequences in breast cancer].
Breast Neoplasms
[PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Breast Neoplasms
[What's new liquid biopsy-PIK3CA testing in breast cancer].
Breast Neoplasms, Male
PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
Bronchiectasis
Activated phosphoinositide 3-kinase ? syndrome in a patient with a former diagnosis of common variable immune deficiency, bronchiectasis, and lymphoproliferative disease.
Bronchiectasis
Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis.
Brucellosis
RNAi screen of endoplasmic reticulum-associated host factors reveals a role for IRE1alpha in supporting Brucella replication.
Burkitt Lymphoma
Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways.
Burkitt Lymphoma
Hydrogen peroxide in the Burkitt's lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway.
Burkitt Lymphoma
Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
Burkitt Lymphoma
Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.
Carcinogenesis
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Carcinogenesis
A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis.
Carcinogenesis
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Carcinogenesis
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Carcinogenesis
Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
Carcinogenesis
Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Carcinogenesis
Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.
Carcinogenesis
Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif.
Carcinogenesis
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Carcinogenesis
Activation of WNT/?-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Carcinogenesis
Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin.
Carcinogenesis
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Carcinogenesis
Algorithm-Based Meta-Analysis Reveals the Mechanistic Interaction of the Tumor Suppressor LIMD1 With Non-Small-Cell Lung Carcinoma.
Carcinogenesis
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Carcinogenesis
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Carcinogenesis
An insulin-like growth factor-mediated, phosphatidylinositol 3' kinase-independent survival signaling pathway in beta tumor cells.
Carcinogenesis
An integrated strategy for revealing the pharmacological changes based on metabolites profiling and network pharmacology: Arctiin as an example.
Carcinogenesis
APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Carcinogenesis
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Carcinogenesis
Atypical Endometrial Hyperplasia, Low-grade: "Much ADO About Nothing".
Carcinogenesis
B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Carcinogenesis
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
Carcinogenesis
Biological functions of cytokeratin 18 in cancer.
Carcinogenesis
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy.
Carcinogenesis
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Carcinogenesis
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Carcinogenesis
Cancer Genetic Network Inference Using Gaussian Graphical Models.
Carcinogenesis
Carcinogenesis of PIK3CA.
Carcinogenesis
Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines.
Carcinogenesis
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Carcinogenesis
Chemopreventive Effects of Licorice and Its Components.
Carcinogenesis
Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Carcinogenesis
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Carcinogenesis
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Carcinogenesis
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Carcinogenesis
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.
Carcinogenesis
Commentary on Essential roles of PI(3)K-p110beta in cell growth, metabolism, and tumorigenesis Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Carcinogenesis
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
Carcinogenesis
Copper Promotes Tumorigenesis by Activating the PDK1-AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner.
Carcinogenesis
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Carcinogenesis
Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation.
Carcinogenesis
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Carcinogenesis
Detection of PIK3R1 (L449S) Mutation in a Patient with Ovarian Cancer: A Case Report.
Carcinogenesis
Differences in Somatic Mutation Profiles between Korean Gastric Cancer and Gastric Adenoma Patients.
Carcinogenesis
Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.
Carcinogenesis
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Carcinogenesis
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation.
Carcinogenesis
Endometrial cancer cells exhibit high expression of p110? and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Carcinogenesis
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Carcinogenesis
Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
Carcinogenesis
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling.
Carcinogenesis
Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Carcinogenesis
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Carcinogenesis
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Carcinogenesis
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Carcinogenesis
Gene expression profiling analysis contributes to understanding the association between non-syndromic cleft lip and palate, and cancer.
Carcinogenesis
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Carcinogenesis
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Carcinogenesis
Genetic and pharmacologic dissection of ras effector utilization in oncogenesis.
Carcinogenesis
Genetic factors in ovarian carcinoma.
Carcinogenesis
Genetics of hepatobiliary carcinogenesis.
Carcinogenesis
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Carcinogenesis
HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
Carcinogenesis
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Carcinogenesis
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Carcinogenesis
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit.
Carcinogenesis
Initiating breast cancer by PIK3CA mutation.
Carcinogenesis
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Carcinogenesis
Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.
Carcinogenesis
Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma.
Carcinogenesis
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer.
Carcinogenesis
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
Carcinogenesis
LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA.
Carcinogenesis
Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction.
Carcinogenesis
Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Carcinogenesis
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases.
Carcinogenesis
Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype-dependent fashion.
Carcinogenesis
MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27(Kip1.).
Carcinogenesis
MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.
Carcinogenesis
MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
Carcinogenesis
MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer.
Carcinogenesis
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Carcinogenesis
Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Carcinogenesis
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Carcinogenesis
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation.
Carcinogenesis
Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities.
Carcinogenesis
Molecular profiles of benign and (pre)malignant endometrial lesions.
Carcinogenesis
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Carcinogenesis
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.
Carcinogenesis
Mutant PIK3CA Induces EMT in a Cell Type Specific Manner.
Carcinogenesis
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Carcinogenesis
Mutation of the PIK3CA oncogene in human cancers.
Carcinogenesis
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Carcinogenesis
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Carcinogenesis
Mutational Hotspot in Exon 20 of PIK3CA in Breast Cancer Among Singapore Chinese.
Carcinogenesis
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Carcinogenesis
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Carcinogenesis
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Carcinogenesis
Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis.
Carcinogenesis
Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic.
Carcinogenesis
Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease - Report of six rare and unique cases.
Carcinogenesis
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Carcinogenesis
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Carcinogenesis
Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Carcinogenesis
Nuclear PTEN deficiency causes microcephaly with decreased neuronal soma size and increased seizure susceptibility.
Carcinogenesis
Nuclear upregulation of class I phosphoinositide 3-kinase p110? correlates with high 47S rRNA levels in cancer cells.
Carcinogenesis
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Carcinogenesis
Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands.
Carcinogenesis
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Carcinogenesis
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Carcinogenesis
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Carcinogenesis
OncomiRs: the discovery and progress of microRNAs in cancers.
Carcinogenesis
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Carcinogenesis
PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy.
Carcinogenesis
Phosphatidylinositol-3-kinase ? catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.
Carcinogenesis
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Carcinogenesis
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Carcinogenesis
Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Carcinogenesis
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ER?-positive tumors.
Carcinogenesis
PI3K enters beta-testing.
Carcinogenesis
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
Carcinogenesis
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
Carcinogenesis
PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation.
Carcinogenesis
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.
Carcinogenesis
PIK3CA as an oncogene in cervical cancer.
Carcinogenesis
PIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9.
Carcinogenesis
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
Carcinogenesis
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.
Carcinogenesis
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Carcinogenesis
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
Carcinogenesis
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
Carcinogenesis
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis.
Carcinogenesis
PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.
Carcinogenesis
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
Carcinogenesis
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
Carcinogenesis
PIK3CA mutation and amplification in human lung cancer.
Carcinogenesis
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Carcinogenesis
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
Carcinogenesis
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Carcinogenesis
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Carcinogenesis
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Carcinogenesis
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Carcinogenesis
PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations.
Carcinogenesis
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Carcinogenesis
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Carcinogenesis
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Carcinogenesis
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Carcinogenesis
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
Carcinogenesis
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
Carcinogenesis
PIK3CA somatic mutation in sinonasal teratocarcinosarcoma.
Carcinogenesis
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Carcinogenesis
PKCiota promotes ovarian tumor progression through deregulation of cyclin E.
Carcinogenesis
Prevalence and architecture of posttranscriptionally impaired synonymous mutations in 8,320 genomes across 22 cancer types.
Carcinogenesis
Preventive Effects of Calcitriol on the Development of Capsular Invasive Carcinomas in a Rat Two-Stage Thyroid Carcinogenesis Model.
Carcinogenesis
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Carcinogenesis
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Carcinogenesis
Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer.
Carcinogenesis
PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression.
Carcinogenesis
PTEN loss and activation of K-RAS and ?-catenin cooperate to accelerate prostate tumourigenesis.
Carcinogenesis
PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3? signaling pathway in DMH induced early colon carcinogenesis in rat.
Carcinogenesis
Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis.
Carcinogenesis
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Carcinogenesis
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Carcinogenesis
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation.
Carcinogenesis
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.
Carcinogenesis
Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma.
Carcinogenesis
Role of RAS in the Regulation of PI 3-Kinase.
Carcinogenesis
Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
Carcinogenesis
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Carcinogenesis
Should individual PI3 kinase isoforms be targeted in cancer?
Carcinogenesis
Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic ?-Catenin, PIK3CA and MET.
Carcinogenesis
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
Carcinogenesis
SOX2 recruits KLF4 to regulate nasopharyngeal carcinoma proliferation via PI3K/AKT signaling.
Carcinogenesis
Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.
Carcinogenesis
Stopping ras in its tracks.
Carcinogenesis
SUMOylation modulates the stability and function of PI3K-p110?.
Carcinogenesis
Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Carcinogenesis
Targetable "driver" mutations in non small cell lung cancer.
Carcinogenesis
Targeting molecules to medicine with mTOR, autophagy, and neurodegenerative disorders.
Carcinogenesis
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Carcinogenesis
The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway.
Carcinogenesis
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Carcinogenesis
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Carcinogenesis
The phosphoinositide 3-kinase pathway and cancer.
Carcinogenesis
The phosphoinositide 3-kinase pathway and therapy resistance in cancer.
Carcinogenesis
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
Carcinogenesis
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.
Carcinogenesis
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Carcinogenesis
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
Carcinogenesis
The PIK3CA gene is mutated with high frequency in human breast cancers.
Carcinogenesis
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors.
Carcinogenesis
The target therapy of ovarian clear cell carcinoma.
Carcinogenesis
The Wnt/?-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.
Carcinogenesis
Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Carcinogenesis
TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
Carcinogenesis
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Carcinogenesis
Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.
Carcinogenesis
Transgenic mouse models of breast cancer.
Carcinogenesis
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
Carcinogenesis
[Advanced research of mTOR and lung carcinoid tumors].
Carcinogenesis
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Carcinogenesis
[Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol]
Carcinogenesis
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
Carcinoid Tumor
Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy.
Carcinoid Tumor
Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.
Carcinoid Tumor
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Carcinoid Tumor
PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours.
Carcinoma
3q26 Amplifications in Cervical Squamous Carcinomas.
Carcinoma
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
Carcinoma
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Carcinoma
A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing.
Carcinoma
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
Carcinoma
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
Carcinoma
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Carcinoma
A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.
Carcinoma
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Carcinoma
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Carcinoma
A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.
Carcinoma
Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population.
Carcinoma
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Carcinoma
Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta.
Carcinoma
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Carcinoma
AIB1 Promotes DNA Replication by JNK Repression and AKT Activation during Cellular Stress.
Carcinoma
Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells.
Carcinoma
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Carcinoma
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Carcinoma
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Carcinoma
Amplicon profiles in ovarian serous carcinomas.
Carcinoma
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
Carcinoma
Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.
Carcinoma
Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas.
Carcinoma
Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
Carcinoma
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Carcinoma
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Carcinoma
Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical and molecular single institution study.
Carcinoma
Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3? signaling pathway.
Carcinoma
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.
Carcinoma
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Carcinoma
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Carcinoma
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Carcinoma
BER gene polymorphisms associated with key molecular events in bladder cancer.
Carcinoma
Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Carcinoma
Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
Carcinoma
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Carcinoma
Cancer Implications for Patients with Endometriosis.
Carcinoma
Capn4 regulates migration and invasion of ovarian carcinoma cells via targeting osteopontin-mediated PI3K/AKT signaling pathway.
Carcinoma
CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
Carcinoma
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Carcinoma
cDNA expression library screening revealed novel functional genes involved in clear cell carcinogenesis of the ovary in vitro.
Carcinoma
Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation.
Carcinoma
Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia.
Carcinoma
Cerebellar Metastasis From Ovarian Carcinoma Harboring PIK3CA-Activating Mutation: A "Clear" Explanation for an Unexpected "Vertigo".
Carcinoma
Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Carcinoma
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma
Class I PI3K in oncogenic cellular transformation.
Carcinoma
Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Carcinoma
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Carcinoma
Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy.
Carcinoma
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Carcinoma
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Carcinoma
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Carcinoma
Clinicopathologic Significance of HNF-1?, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Carcinoma
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Carcinoma
Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Carcinoma
Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.
Carcinoma
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Carcinoma
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Carcinoma
Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
Carcinoma
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
Carcinoma
Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma.
Carcinoma
Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
Carcinoma
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Carcinoma
Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Carcinoma
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Carcinoma
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Carcinoma
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Carcinoma
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Carcinoma
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
Carcinoma
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Carcinoma
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Carcinoma
Copy number loss of variation_91720 in PIK3CA predicts risk of esophageal squamous cell carcinoma.
Carcinoma
Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells.
Carcinoma
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Carcinoma
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Carcinoma
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Carcinoma
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Carcinoma
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Carcinoma
Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.
Carcinoma
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Carcinoma
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Carcinoma
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.
Carcinoma
Discovering functional evolutionary dependencies in human cancers.
Carcinoma
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Carcinoma
Distinct ?-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
Carcinoma
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Carcinoma
Distinguishing the progression of an endometrioma: Benign or malignant?
Carcinoma
Divergent molecular profile of PIK3CA gene in arsenic-associated bladder carcinoma.
Carcinoma
Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.
Carcinoma
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Carcinoma
Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo.
Carcinoma
Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma.
Carcinoma
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.
Carcinoma
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma.
Carcinoma
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Carcinoma
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Carcinoma
Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions.
Carcinoma
Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance.
Carcinoma
EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.
Carcinoma
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
Carcinoma
ERBB2 kinase domain mutation in a gastric cancer metastasis.
Carcinoma
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Carcinoma
Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Carcinoma
Establishment and genomic characterization of gingivobuccal carcinoma cell lines with smokeless tobacco associated genetic alterations and oncogenic PIK3CA mutation.
Carcinoma
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Carcinoma
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Carcinoma
Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma.
Carcinoma
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Carcinoma
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Carcinoma
Expression of Phosphoinositide 3-Kinase p110? and p110? Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma.
Carcinoma
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Carcinoma
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Carcinoma
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Carcinoma
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Carcinoma
Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Carcinoma
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Carcinoma
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Carcinoma
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Carcinoma
Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
Carcinoma
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Carcinoma
Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
Carcinoma
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Carcinoma
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Carcinoma
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.
Carcinoma
Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma.
Carcinoma
Genome wide analysis of pathogenic SH2 domain mutations.
Carcinoma
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Carcinoma
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Carcinoma
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Carcinoma
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Carcinoma
Genotype-phenotype associations in breast pathology: Achievements of the past quarter century.
Carcinoma
Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction.
Carcinoma
Global gene expression profiling of a mouse model of ovarian clear cell carcinoma caused by ARID1A and PIK3CA mutations implicates a role for inflammatory cytokine signaling.
Carcinoma
Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
Carcinoma
GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Carcinoma
Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
Carcinoma
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
Carcinoma
High frequency of PIK3CA and TERT promoter mutations in fibromatosis-like spindle cell carcinomas.
Carcinoma
High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients.
Carcinoma
Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis.
Carcinoma
Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
Carcinoma
Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
Carcinoma
Hot spot mutations in Finnish non-small cell lung cancers.
Carcinoma
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Carcinoma
Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.
Carcinoma
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Carcinoma
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Carcinoma
Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells.
Carcinoma
Hypoxia-induced epithelial-mesenchymal transition is regulated by phosphorylation of GSK3-? via PI3 K/Akt signaling in oral squamous cell carcinoma.
Carcinoma
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Carcinoma
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses.
Carcinoma
Identification of protein kinase C as an intermediate in Na,K-ATPase Beta-subunit mediated lamellipodia formation and suppression of cell motility in carcinoma cells.
Carcinoma
Identification of somatic gene mutations in penile squamous cell carcinoma.
Carcinoma
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Carcinoma
Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Carcinoma
Immunohistochemistry features and molecular pathology of appendiceal neoplasms.
Carcinoma
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Carcinoma
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Carcinoma
Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.
Carcinoma
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Carcinoma
INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.
Carcinoma
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Carcinoma
Integrated Molecular Characterization of Uterine Carcinosarcoma.
Carcinoma
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Carcinoma
Invasive ductal carcinoma arising in borderline phyllode tumor: A potential role of PIK3CA mutation.
Carcinoma
Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.
Carcinoma
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Carcinoma
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
Carcinoma
KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers.
Carcinoma
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
Carcinoma
Landscape of genomic alterations in cervical carcinomas.
Carcinoma
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Carcinoma
Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells.
Carcinoma
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Carcinoma
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Carcinoma
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Carcinoma
Loss of HDAC-Mediated Repression and Gain of NF-?B Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Carcinoma
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Carcinoma
Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing.
Carcinoma
Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
Carcinoma
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Carcinoma
Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas.
Carcinoma
Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases.
Carcinoma
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Carcinoma
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
Carcinoma
MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma.
Carcinoma
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
Carcinoma
Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features.
Carcinoma
Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression.
Carcinoma
Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Carcinoma
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
Carcinoma
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Carcinoma
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Carcinoma
Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation.
Carcinoma
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Carcinoma
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.
Carcinoma
Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.
Carcinoma
Molecular heterogeneity of pancreatic intraductal papillary mucinous neoplasms and implications for novel endoscopic tissue sampling strategies.
Carcinoma
Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Carcinoma
Molecular Pathology of Endometrial Carcinoma: Practical aspects from the diagnostic and therapeutical view points.
Carcinoma
Molecular profiles of benign and (pre)malignant endometrial lesions.
Carcinoma
Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.
Carcinoma
Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma.
Carcinoma
MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress.
Carcinoma
Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.
Carcinoma
Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
Carcinoma
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Carcinoma
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Carcinoma
Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.
Carcinoma
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
Carcinoma
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Carcinoma
Mutation of the PIK3CA gene in ovarian and breast cancer.
Carcinoma
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Carcinoma
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Carcinoma
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Carcinoma
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Carcinoma
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Carcinoma
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance.
Carcinoma
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Carcinoma
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Carcinoma
New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
Carcinoma
New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Carcinoma
Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease - Report of six rare and unique cases.
Carcinoma
Next generation sequencing of cervical high grade dysplasia and invasive squamous cell carcinoma: A case study.
Carcinoma
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Carcinoma
No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.
Carcinoma
Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder.
Carcinoma
Novel insights on the malignant transformation of endometriosis into ovarian carcinoma.
Carcinoma
Novel Method for PIK3CA Mutation Analysis: Locked Nucleic Acid-PCR Sequencing.
Carcinoma
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Carcinoma
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Carcinoma
Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA.
Carcinoma
Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Carcinoma
Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization.
Carcinoma
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Carcinoma
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Carcinoma
Oncogenic mutations in gastric cancer with microsatellite instability.
Carcinoma
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Carcinoma
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Carcinoma
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Carcinoma
One-Step Synthesis of Tunable Zinc-Based Nanohybrids as an Ultrasensitive DNA Signal Amplification Platform.
Carcinoma
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Carcinoma
Ovarian clear cell carcinoma with an immature teratoma component showing ARID1A deficiency and an identical PIK3CA mutation.
Carcinoma
Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?
Carcinoma
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Carcinoma
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
Carcinoma
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
Carcinoma
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Carcinoma
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).
Carcinoma
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Carcinoma
Phosphatidylinositol 3'-kinase, mTOR, and Glycogen synthase kinase-3 beta mediated regulation of p21 in human urothelial carcinoma cells.
Carcinoma
Phosphatidylinositol 3-kinase activity is required for hepatocyte growth factor-induced mitogenic signals in epithelial cells.
Carcinoma
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Carcinoma
Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
Carcinoma
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
Carcinoma
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Carcinoma
PI3K/AKT pathway activation in bladder carcinogenesis.
Carcinoma
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Carcinoma
PI3K/PTEN/AKT Genetic Mouse Models of Endometrial Carcinoma.
Carcinoma
PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Carcinoma
PI3KCA Mutations in Uterine Cervix Carcinoma.
Carcinoma
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
Carcinoma
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Carcinoma
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Carcinoma
PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma.
Carcinoma
PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium.
Carcinoma
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
Carcinoma
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
Carcinoma
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
Carcinoma
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
Carcinoma
PIK3CA as an oncogene in cervical cancer.
Carcinoma
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Carcinoma
PIK3CA gene amplification in Japanese non-small cell lung cancer.
Carcinoma
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Carcinoma
PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
Carcinoma
PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
Carcinoma
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma.
Carcinoma
PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Carcinoma
PIK3CA in ovarian clear cell carcinoma.
Carcinoma
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
Carcinoma
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.
Carcinoma
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
Carcinoma
PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.
Carcinoma
PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation.
Carcinoma
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Carcinoma
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Carcinoma
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Carcinoma
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Carcinoma
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Carcinoma
PIK3CA mutation status in Japanese lung cancer patients.
Carcinoma
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
Carcinoma
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Carcinoma
PIK3CA mutations and copy number gains in human lung cancers.
Carcinoma
PIK3CA mutations and PTEN loss in salivary duct carcinomas.
Carcinoma
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
Carcinoma
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Carcinoma
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
Carcinoma
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Carcinoma
PIK3CA mutations in advanced ovarian carcinomas.
Carcinoma
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Carcinoma
PIK3CA mutations in in situ and invasive breast carcinomas.
Carcinoma
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Carcinoma
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
Carcinoma
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Carcinoma
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Carcinoma
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
Carcinoma
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer.
Carcinoma
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
Carcinoma
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Carcinoma
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Carcinoma
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Carcinoma
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Carcinoma
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Carcinoma
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils.
Carcinoma
Preventive Effects of Calcitriol on the Development of Capsular Invasive Carcinomas in a Rat Two-Stage Thyroid Carcinogenesis Model.
Carcinoma
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Carcinoma
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Carcinoma
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Carcinoma
Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma.
Carcinoma
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Carcinoma
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Carcinoma
Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review.
Carcinoma
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
Carcinoma
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.
Carcinoma
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas.
Carcinoma
PTEN deficiency contributes to the development and progression of head and neck cancer.
Carcinoma
Pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report.
Carcinoma
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Carcinoma
Re: PIK3CA Mutation Spectrum in Urothelial Carcinoma Reflects Cell Context-Dependent Signaling and Phenotypic Outputs.
Carcinoma
Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland.
Carcinoma
Regulation of squamous cell carcinoma antigen production by E-cadherin mediated cell-cell adhesion in squamous cell carcinoma cell line.
Carcinoma
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Carcinoma
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Carcinoma
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Carcinoma
RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo.
Carcinoma
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Carcinoma
Screening for PIK3CA mutations among Saudi women with ovarian cancer.
Carcinoma
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Carcinoma
Sequence Mutations and Amplification of PIK3CA and AKT2 Genes in Purified Ovarian Serous Neoplasms.
Carcinoma
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Carcinoma
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Carcinoma
Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma.
Carcinoma
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Carcinoma
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
Carcinoma
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Carcinoma
Somatic mutations of the ERBB4 kinase domain in human cancers.
Carcinoma
Stage IV Epstein-Barr Virus-Associated Early Gastric Cancer and Comparative Analysis of Genetic Alterations in Primary and Metastatic Tumors.
Carcinoma
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Carcinoma
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
Carcinoma
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
Carcinoma
Tall cell carcinoma of the breast with reversed polarity (TCCRP) with mutations in the IDH2 and PIK3CA genes: a case report.
Carcinoma
Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.
Carcinoma
Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Carcinoma
Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.
Carcinoma
Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Carcinoma
Targeted sequencing of burn scar-related squamous cell carcinomas identified PIK3CA amplification.
Carcinoma
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Carcinoma
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Carcinoma
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Carcinoma
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Carcinoma
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Carcinoma
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
Carcinoma
The C-terminal flanking peptide (CTFP) of progastrin inhibits apoptosis via a PI3-kinase-dependent pathway.
Carcinoma
The conundrum of the Epstein-Barr virus-associated gastric carcinoma in the Americas.
Carcinoma
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Carcinoma
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
Carcinoma
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
Carcinoma
The EDA-containing cellular fibronectin induces epithelial-mesenchymal transition in lung cancer cells through integrin ?9?1-mediated activation of PI3-K/AKT and Erk1/2.
Carcinoma
The evolving genomic landscape of urothelial carcinoma.
Carcinoma
The fibronectin EDA splicing variant induces epithelial-mesenchymal transition in lung cancer cells through integrin {alpha}9{beta}1-mediated activation of PI3-K and Erk.
Carcinoma
The frequent co-expression of the oncogenes PIK3CA and PAK1 in oral carcinomas.
Carcinoma
The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma.
Carcinoma
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Carcinoma
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
Carcinoma
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Carcinoma
The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
Carcinoma
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Carcinoma
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
Carcinoma
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
Carcinoma
The prevalence of PIK3CA mutations in gastric and colon cancer.
Carcinoma
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
Carcinoma
The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Carcinoma
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Carcinoma
The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase.
Carcinoma
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Carcinoma
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
Carcinoma
There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
Carcinoma
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Carcinoma
Translational Genomics and Recent Advances in Oral Squamous Cell Carcinoma.
Carcinoma
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Carcinoma
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Carcinoma
Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
Carcinoma
Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations.
Carcinoma
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Carcinoma
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
Carcinoma
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Carcinoma
Vascular Endothelial Growth Factor Induces CXCL1 Chemokine Release via JNK and PI-3K-Dependent Pathways in Human Lung Carcinoma Epithelial Cells.
Carcinoma
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Carcinoma
[Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
Carcinoma
[Endometriosis-related ovarian tumors].
Carcinoma
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Carcinoma
[Inhibitory Effect of N-Terminal 24 Amino Acids of the p55 Gamma, a Regulatory Subunit of Phosphoinositide 3-Kinase, on Proliferation of Colon Carcinoma Cell Line HT29.]
Carcinoma
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Carcinoma
[PI 3-kinase activity is necessary for F9 mouse embryonic carcinoma cell proliferation]
Carcinoma
[The expression of PIK3CA in nasopharyngeal carcinoma].
Carcinoma in Situ
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Carcinoma in Situ
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses.
Carcinoma in Situ
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Carcinoma in Situ
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
Carcinoma in Situ
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Carcinoma, Adenoid Cystic
Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.
Carcinoma, Adenoid Cystic
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Carcinoma, Adenoid Cystic
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
Carcinoma, Adenoid Cystic
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
Carcinoma, Adenosquamous
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Carcinoma, Adenosquamous
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Carcinoma, Adenosquamous
High rate of PIK3CA mutations but no TP53 mutation in low-grade adenosquamous carcinoma of the breast.
Carcinoma, Adenosquamous
Next generation sequencing of the nidus of early (adenosquamous proliferation rich) radial sclerosing lesions of the breast reveals evidence for a neoplastic precursor lesion.
Carcinoma, Adenosquamous
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Carcinoma, Adenosquamous
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Carcinoma, Basal Cell
Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.
Carcinoma, Ductal
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Carcinoma, Ductal
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Carcinoma, Ductal
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Carcinoma, Ductal
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Carcinoma, Ductal
Invasive ductal carcinoma arising in borderline phyllode tumor: A potential role of PIK3CA mutation.
Carcinoma, Ductal
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Carcinoma, Ductal
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Carcinoma, Ductal
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Carcinoma, Ductal
Molecular Testing in Breast Cancer: Current Status and Future Directions.
Carcinoma, Ductal
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Carcinoma, Ductal
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
Carcinoma, Ductal
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Carcinoma, Ductal
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
Carcinoma, Ductal
PIK3CA in Breast Carcinoma: A Mutational Analysis of Sporadic and Hereditary Cases.
Carcinoma, Ductal
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
Carcinoma, Ductal
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Carcinoma, Ductal
PIK3CA mutations in in situ and invasive breast carcinomas.
Carcinoma, Ductal
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
Carcinoma, Ductal
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Carcinoma, Ductal
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Carcinoma, Ductal
The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Carcinoma, Ductal, Breast
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Carcinoma, Embryonal
Early stage-specific inhibitions of cardiomyocyte differentiation and expression of Csx/Nkx-2.5 and GATA-4 by phosphatidylinositol 3-kinase inhibitor LY294002.
Carcinoma, Endometrioid
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Carcinoma, Endometrioid
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Carcinoma, Endometrioid
Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
Carcinoma, Endometrioid
Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
Carcinoma, Endometrioid
Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Carcinoma, Endometrioid
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Carcinoma, Endometrioid
Current and future strategies for treatment of ovarian clear cell carcinoma.
Carcinoma, Endometrioid
Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Carcinoma, Endometrioid
Genetic analysis and phosphoinositide 3-kinase/protein kinase B signaling pathway status in ovarian endometrioid borderline tumor samples.
Carcinoma, Endometrioid
Molecular Pathology of Endometrial Carcinoma: Practical aspects from the diagnostic and therapeutical view points.
Carcinoma, Endometrioid
Molecular profiles of benign and (pre)malignant endometrial lesions.
Carcinoma, Endometrioid
Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Carcinoma, Endometrioid
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
Carcinoma, Endometrioid
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
Carcinoma, Endometrioid
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.
Carcinoma, Endometrioid
PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
Carcinoma, Endometrioid
Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients.
Carcinoma, Hepatocellular
A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.
Carcinoma, Hepatocellular
Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
Carcinoma, Hepatocellular
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade.
Carcinoma, Hepatocellular
Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis.
Carcinoma, Hepatocellular
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
ARID2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
Carcinoma, Hepatocellular
AT-rich interactive domain 2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
Carcinoma, Hepatocellular
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy.
Carcinoma, Hepatocellular
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Carcinoma, Hepatocellular
Cross-Species Suppression of Hepatoma Cell Growth and Migration by a Schistosoma japonicum MicroRNA.
Carcinoma, Hepatocellular
Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: regulation of the PI3K activity.
Carcinoma, Hepatocellular
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Carcinoma, Hepatocellular
Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Carcinoma, Hepatocellular
Effect of sidt2 Gene on Cell Insulin Resistance and Its Molecular Mechanism.
Carcinoma, Hepatocellular
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
Carcinoma, Hepatocellular
FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients.
Carcinoma, Hepatocellular
Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway.
Carcinoma, Hepatocellular
Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis.
Carcinoma, Hepatocellular
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
Carcinoma, Hepatocellular
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Carcinoma, Hepatocellular
Insulin-induced activation of phosphoinositide 3-kinase in Fao cells.
Carcinoma, Hepatocellular
Involvement of phosphoinositide 3-kinase in regulation of adhesive activity of highly metastatic hepatoma cells.
Carcinoma, Hepatocellular
Jianpijiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase.
Carcinoma, Hepatocellular
Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.
Carcinoma, Hepatocellular
MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
Carcinoma, Hepatocellular
MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
Carcinoma, Hepatocellular
miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients.
Carcinoma, Hepatocellular
MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/?-catenin signaling pathways.
Carcinoma, Hepatocellular
miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma.
Carcinoma, Hepatocellular
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Carcinoma, Hepatocellular
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression.
Carcinoma, Hepatocellular
Participation of a MEK-independent pathway in MAP kinase activation and modulation of cell growth in mouse hepatoma cell lines.
Carcinoma, Hepatocellular
Phosphatidylinositol 3-kinase is required for the regulation of hepatitis B surface antigen production and mitogen-activated protein kinase activation by insulin but not by TPA.
Carcinoma, Hepatocellular
Phosphatidylinositol 3-kinase modulates IL-18-induced nuclear factor-kappa B activation.
Carcinoma, Hepatocellular
PI3-kinase inhibition synergistically promoted the anti-tumor effect of lupeol in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells.
Carcinoma, Hepatocellular
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Carcinoma, Hepatocellular
PIK3CA mutations in hepatocellular carcinoma in Korea.
Carcinoma, Hepatocellular
PIK3CA polymorphisms associated with susceptibility to hepatocellular carcinoma.
Carcinoma, Hepatocellular
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Carcinoma, Hepatocellular
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Carcinoma, Hepatocellular
Role of hepatitis B virus X protein in regulating LIM and SH3 protein 1 (LASP-1) expression to mediate proliferation and migration of hepatoma cells.
Carcinoma, Hepatocellular
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Carcinoma, Hepatocellular
Stephtetrandrine A-D, bisbenzylisoquinoline alkaloids from Stephania tetrandra.
Carcinoma, Hepatocellular
Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Carcinoma, Hepatocellular
Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway.
Carcinoma, Hepatocellular
The phosphoinositide 3-kinase pathway and glycogen synthase kinase-3 positively regulate the activity of metal-responsive transcription factor-1 in response to zinc ions.
Carcinoma, Hepatocellular
[Expression and mutations of PIK3CA gene in hepatocellular carcinomas]
Carcinoma, Intraductal, Noninfiltrating
APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer.
Carcinoma, Intraductal, Noninfiltrating
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Carcinoma, Intraductal, Noninfiltrating
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
Carcinoma, Intraductal, Noninfiltrating
Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Genomic landscape of ductal carcinoma in situ and association with progression.
Carcinoma, Intraductal, Noninfiltrating
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Carcinoma, Intraductal, Noninfiltrating
High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model.
Carcinoma, Intraductal, Noninfiltrating
Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing.
Carcinoma, Intraductal, Noninfiltrating
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Carcinoma, Intraductal, Noninfiltrating
Molecular Testing in Breast Cancer: Current Status and Future Directions.
Carcinoma, Intraductal, Noninfiltrating
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Carcinoma, Intraductal, Noninfiltrating
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
Carcinoma, Intraductal, Noninfiltrating
PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture.
Carcinoma, Intraductal, Noninfiltrating
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Carcinoma, Intraductal, Noninfiltrating
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
PIK3CA mutations in in situ and invasive breast carcinomas.
Carcinoma, Intraductal, Noninfiltrating
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Carcinoma, Intraductal, Noninfiltrating
Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.
Carcinoma, Large Cell
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Carcinoma, Lewis Lung
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.
Carcinoma, Lobular
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.
Carcinoma, Lobular
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Carcinoma, Lobular
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas.
Carcinoma, Lobular
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Carcinoma, Lobular
Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
Carcinoma, Lobular
Lobular breast cancer: Clinical, molecular and morphological characteristics.
Carcinoma, Lobular
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Carcinoma, Lobular
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
Carcinoma, Lobular
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Carcinoma, Lobular
Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing.
Carcinoma, Lobular
Whole exome sequencing of rare aggressive breast cancer histologies.
Carcinoma, Mucoepidermoid
Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations.
Carcinoma, Neuroendocrine
Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
Carcinoma, Neuroendocrine
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Carcinoma, Non-Small-Cell Lung
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Carcinoma, Non-Small-Cell Lung
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
Carcinoma, Non-Small-Cell Lung
Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Carcinoma, Non-Small-Cell Lung
BYL719, a selective inhibitor of phosphoinositide 3-Kinase ?, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Carcinoma, Non-Small-Cell Lung
Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Carcinoma, Non-Small-Cell Lung
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI 3-kinase in KRAS mutant lung cancer.
Carcinoma, Non-Small-Cell Lung
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Carcinoma, Non-Small-Cell Lung
EMT twists the road to PI3K.
Carcinoma, Non-Small-Cell Lung
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation.
Carcinoma, Non-Small-Cell Lung
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.
Carcinoma, Non-Small-Cell Lung
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Carcinoma, Non-Small-Cell Lung
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.
Carcinoma, Non-Small-Cell Lung
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.
Carcinoma, Non-Small-Cell Lung
MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
MiR-486-5p Serves as a Good Biomarker in Nonsmall Cell Lung Cancer and Suppresses Cell Growth With the Involvement of a Target PIK3R1.
Carcinoma, Non-Small-Cell Lung
Molecular profiling of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Carcinoma, Non-Small-Cell Lung
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Carcinoma, Non-Small-Cell Lung
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Carcinoma, Non-Small-Cell Lung
PI3K expression predicts overall survival in lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
PIK3CA gene amplification in Japanese non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Carcinoma, Non-Small-Cell Lung
PIK3CA mutations and copy number gains in human lung cancers.
Carcinoma, Non-Small-Cell Lung
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Carcinoma, Non-Small-Cell Lung
PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Carcinoma, Non-Small-Cell Lung
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Carcinoma, Non-Small-Cell Lung
Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.
Carcinoma, Non-Small-Cell Lung
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of phosphoinositide 3-kinase p110? and p110? isoforms in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Carcinoma, Non-Small-Cell Lung
Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Carcinoma, Non-Small-Cell Lung
Targeted therapies in development for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA.
Carcinoma, Non-Small-Cell Lung
The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Carcinoma, Non-Small-Cell Lung
The Proto-oncogene PKC? regulates the alternative splicing of Bcl-x pre-mRNA.
Carcinoma, Non-Small-Cell Lung
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
Carcinoma, Non-Small-Cell Lung
Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Carcinoma, Non-Small-Cell Lung
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Carcinoma, Non-Small-Cell Lung
[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
Carcinoma, Non-Small-Cell Lung
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
Carcinoma, Ovarian Epithelial
Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling.
Carcinoma, Ovarian Epithelial
Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Carcinoma, Ovarian Epithelial
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Carcinoma, Ovarian Epithelial
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
Carcinoma, Ovarian Epithelial
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models.
Carcinoma, Ovarian Epithelial
The effects of common genetic variants in oncogenes on ovarian cancer survival.
Carcinoma, Ovarian Epithelial
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Carcinoma, Papillary
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Carcinoma, Papillary
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Carcinoma, Papillary
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Carcinoma, Papillary
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Carcinoma, Papillary
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
Carcinoma, Papillary
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Carcinoma, Renal Cell
A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.
Carcinoma, Renal Cell
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
Carcinoma, Renal Cell
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Carcinoma, Renal Cell
Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
Carcinoma, Renal Cell
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Renal Cell
Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.
Carcinoma, Renal Cell
Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma.
Carcinoma, Renal Cell
Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma.
Carcinoma, Renal Cell
GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Carcinoma, Renal Cell
Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
Carcinoma, Renal Cell
MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma.
Carcinoma, Renal Cell
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
Carcinoma, Renal Cell
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Carcinoma, Renal Cell
Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations.
Carcinoma, Signet Ring Cell
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Carcinoma, Small Cell
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Carcinoma, Squamous Cell
3q26 Amplifications in Cervical Squamous Carcinomas.
Carcinoma, Squamous Cell
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
Carcinoma, Squamous Cell
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
Carcinoma, Squamous Cell
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
Carcinoma, Squamous Cell
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Carcinoma, Squamous Cell
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Carcinoma, Squamous Cell
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Carcinoma, Squamous Cell
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Carcinoma, Squamous Cell
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Carcinoma, Squamous Cell
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy.
Carcinoma, Squamous Cell
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Carcinoma, Squamous Cell
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Carcinoma, Squamous Cell
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Carcinoma, Squamous Cell
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Carcinoma, Squamous Cell
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Carcinoma, Squamous Cell
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Carcinoma, Squamous Cell
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Carcinoma, Squamous Cell
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.
Carcinoma, Squamous Cell
Discovering functional evolutionary dependencies in human cancers.
Carcinoma, Squamous Cell
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Carcinoma, Squamous Cell
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Carcinoma, Squamous Cell
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Carcinoma, Squamous Cell
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Carcinoma, Squamous Cell
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Carcinoma, Squamous Cell
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Carcinoma, Squamous Cell
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Carcinoma, Squamous Cell
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Carcinoma, Squamous Cell
Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
Carcinoma, Squamous Cell
Hot spot mutations in Finnish non-small cell lung cancers.
Carcinoma, Squamous Cell
Identification of somatic gene mutations in penile squamous cell carcinoma.
Carcinoma, Squamous Cell
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Carcinoma, Squamous Cell
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Carcinoma, Squamous Cell
Involvement of phosphoinositide 3-kinase in insulin- or IGF-1-induced membrane ruffling.
Carcinoma, Squamous Cell
Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation.
Carcinoma, Squamous Cell
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Carcinoma, Squamous Cell
Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.
Carcinoma, Squamous Cell
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Carcinoma, Squamous Cell
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Carcinoma, Squamous Cell
New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
Carcinoma, Squamous Cell
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Carcinoma, Squamous Cell
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Carcinoma, Squamous Cell
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA.
Carcinoma, Squamous Cell
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Carcinoma, Squamous Cell
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Carcinoma, Squamous Cell
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Carcinoma, Squamous Cell
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
Carcinoma, Squamous Cell
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Phosphoinositide 3-kinase as an upstream regulator of the small GTP-binding protein Rac in the insulin signaling of membrane ruffling.
Carcinoma, Squamous Cell
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
Carcinoma, Squamous Cell
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Carcinoma, Squamous Cell
PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Carcinoma, Squamous Cell
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
Carcinoma, Squamous Cell
PIK3CA gene amplification in Japanese non-small cell lung cancer.
Carcinoma, Squamous Cell
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
Carcinoma, Squamous Cell
PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.
Carcinoma, Squamous Cell
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Carcinoma, Squamous Cell
PIK3CA mutation status in Japanese lung cancer patients.
Carcinoma, Squamous Cell
PIK3CA mutations and copy number gains in human lung cancers.
Carcinoma, Squamous Cell
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
Carcinoma, Squamous Cell
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Carcinoma, Squamous Cell
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
Carcinoma, Squamous Cell
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Carcinoma, Squamous Cell
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Carcinoma, Squamous Cell
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils.
Carcinoma, Squamous Cell
Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3.
Carcinoma, Squamous Cell
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Carcinoma, Squamous Cell
Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma.
Carcinoma, Squamous Cell
PTEN deficiency contributes to the development and progression of head and neck cancer.
Carcinoma, Squamous Cell
Regulation of squamous cell carcinoma antigen production by E-cadherin mediated cell-cell adhesion in squamous cell carcinoma cell line.
Carcinoma, Squamous Cell
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Carcinoma, Squamous Cell
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Carcinoma, Squamous Cell
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Carcinoma, Squamous Cell
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Carcinoma, Squamous Cell
Targeted sequencing of burn scar-related squamous cell carcinomas identified PIK3CA amplification.
Carcinoma, Squamous Cell
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Carcinoma, Squamous Cell
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Carcinoma, Squamous Cell
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
Carcinoma, Squamous Cell
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Carcinoma, Squamous Cell
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
Carcinoma, Squamous Cell
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Carcinoma, Squamous Cell
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
Carcinoma, Squamous Cell
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Carcinoma, Squamous Cell
There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
Carcinoma, Squamous Cell
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Carcinoma, Squamous Cell
Translational Genomics and Recent Advances in Oral Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
Carcinoma, Squamous Cell
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Carcinoma, Squamous Cell
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Carcinoma, Transitional Cell
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).
Carcinosarcoma
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma.
Carcinosarcoma
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Carcinosarcoma
Molecular characterization of carcinosarcomas arising in the uterus and ovaries.
Carcinosarcoma
Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Carcinosarcoma
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Carcinosarcoma
Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Carcinosarcoma
Use of mutation profiles to refine the classification of endometrial carcinomas.
Cardiomegaly
Basal and IGF-I-dependent regulation of potassium channels by MAP kinases and PI3-kinase during eccentric cardiac hypertrophy.
Cardiomegaly
Cardiotoxicity of Novel Targeted Hematological Therapies.
Cardiomegaly
Chronic blockade of class I PI3-kinase attenuates Ang II-induced cardiac hypertrophy and autophagic alteration.
Cardiomegaly
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.
Cardiomegaly
Cross-talk between MAPKs and PI-3K pathways alters the functional density of I(K) channels in hypertrophied hearts.
Cardiomegaly
Decreased p110alpha catalytic activity accompanies increased myocyte apoptosis and cardiac hypertrophy in leptin deficient ob/ob mice.
Cardiomegaly
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
Cardiomegaly
Dual role of cyclic GMP in cardiac cell survival.
Cardiomegaly
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
Cardiomegaly
H11 has dose-dependent and dual hypertrophic and proapoptotic functions in cardiac myocytes.
Cardiomegaly
Local angiotensin II aggravates cardiac remodeling in hypertension.
Cardiomegaly
Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase ? in mouse.
Cardiomegaly
Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.
Cardiomegaly
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Cardiomegaly
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure.
Cardiomegaly
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
Cardiomegaly
Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy.
Cardiomegaly
Role of PI3-Kinase in Angiotensin II-Induced Cardiac Hypertrophy: Class I Versus Class III.
Cardiomegaly
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.
Cardiomegaly
The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection.
Cardiomegaly
The role of leptin in the ventricular remodeling process and its mechanism.
Cardiomegaly
[The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats].
Cardiomyopathies
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice.
Cardiomyopathies
Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells.
Cardiomyopathies
H3K9ac modification was involved in doxorubicin induced apoptosis by regulating Pik3ca transcription in H9C2 cells.
Cardiomyopathies
Phosphoinositide 3-kinase (p110?) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
Cardiomyopathies
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Cardiomyopathies
Temporally controlled overexpression of cardiac-specific PI3K{alpha} induces enhanced myocardial contractility--a new transgenic model.
Cardiomyopathy, Dilated
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
Cardiotoxicity
Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
Cardiovascular Diseases
Phosphoinositide 3-kinase: friend and foe in cardiovascular disease.
Cardiovascular Diseases
Role of PI3 kinase gamma in excitation-contraction coupling and heart disease.
Cardiovascular Diseases
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Cataract
Alterations in lens protein tyrosine phosphorylation and phosphatidylinositol 3-kinase signaling during selenite cataract formation.
Cerebral Infarction
Inhibition of FOXO3a/BIM signaling pathway contributes to the protective effect of salvianolic acid A against cerebral ischemia/reperfusion injury.
Cerebrovascular Disorders
The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets.
Cervical Intraepithelial Neoplasia
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Cholangiocarcinoma
A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing.
Cholangiocarcinoma
Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation.
Cholangiocarcinoma
High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
Cholangiocarcinoma
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
Cholangiocarcinoma
Kras-driven heterotopic tumor development from hepatobiliary organoids.
Cholangiocarcinoma
Molecular characteristics of biliary tract cancer.
Cholangiocarcinoma
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
Cholangiocarcinoma
Neurotensin promotes cholangiocarcinoma metastasis via the EGFR/AKT pathway.
Cholangiocarcinoma
Polypoid Undifferentiated Carcinoma With Osteoclast-like Giant Cells Arising in the Distal Common Bile Duct: A Rare Case Report.
Cholangiocarcinoma
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Cholangiocarcinoma
Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.
Cholecystitis
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Cholera
Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma.
Cholera
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Cholera
Suppression of insulin-stimulated phosphatidylinositol 3-kinase activity by the beta3-adrenoceptor agonist CL316243 in rat adipocytes.
Cholestasis
Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17?-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C.
Chondroma
Carcinogenesis of PIK3CA.
Chondrosarcoma
By activating matrix metalloproteinase-7, shear stress promotes chondrosarcoma cell motility, invasion and lung colonization.
Chondrosarcoma
Fluid shear promotes chondrosarcoma cell invasion by activating matrix metalloproteinase 12 via IGF-2 and VEGF signaling pathways.
Chondrosarcoma
Interleukin-1? and cyclic AMP mediate the invasion of sheared chondrosarcoma cells via a matrix metalloproteinase-1-dependent mechanism.
Chordoma
Chordoma-Current Understanding and Modern Treatment Paradigms.
Chordoma
Development of a Novel Orthotopic Primary Human Chordoma Xenograft Model: A Relevant Support for Future Research on Chordoma.
Chordoma
Prognostic and Therapeutic Markers in Chordomas: A Study of 287 Tumors.
Ciliopathies
Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/Akt-dependent mTORC1 signaling.
Coinfection
Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia.
Colitis
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85? subunit of PI3K.
Colitis
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110?.
Colitis
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
Colitis
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
Colitis
Loss of Phosphoinositide 3-Kinase p110? is Protective in the Acute Phase but Detrimental in the Resolution Phase of Hapten-Induced Colitis.
Colitis
Phosphoinositide 3-Kinase P110?-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation.
Colitis
Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.
Colitis
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis
The absence of functional PI3Kgamma prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice.
Colitis
The Drosophila larva as a tool to study gut-associated macrophages: PI3K regulates a discrete hemocyte population at the proventriculus.
Colitis, Ulcerative
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
Colitis, Ulcerative
How autophagy controls the intestinal epithelial barrier.
Colitis, Ulcerative
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Colitis, Ulcerative
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Colitis, Ulcerative
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis-Associated Neoplasms
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Colonic Neoplasms
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Colonic Neoplasms
Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
Colonic Neoplasms
Activation of NF-kappaB binding in HT-29 colon cancer cells by inhibition of phosphatidylinositol 3-kinase.
Colonic Neoplasms
Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
Colonic Neoplasms
Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Colonic Neoplasms
Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations.
Colonic Neoplasms
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.
Colonic Neoplasms
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
Colonic Neoplasms
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Colonic Neoplasms
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.
Colonic Neoplasms
Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.
Colonic Neoplasms
Brush border phosphatidylinositol 3-kinase mediates epidermal growth factor stimulation of intestinal NaCl absorption and Na+/H+ exchange.
Colonic Neoplasms
Calcium intake and colon cancer risk subtypes by tumor molecular characteristics.
Colonic Neoplasms
Cancer immunology-analysis of host and tumor factors for personalized medicine.
Colonic Neoplasms
Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).
Colonic Neoplasms
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Colonic Neoplasms
Clinicopathological and molecular differences in colorectal cancer according to location.
Colonic Neoplasms
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Colonic Neoplasms
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Colonic Neoplasms
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Colonic Neoplasms
Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.
Colonic Neoplasms
Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.
Colonic Neoplasms
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Colonic Neoplasms
DNA testing and molecular screening for colon cancer.
Colonic Neoplasms
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation.
Colonic Neoplasms
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Colonic Neoplasms
Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.
Colonic Neoplasms
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Colonic Neoplasms
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
Colonic Neoplasms
ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.
Colonic Neoplasms
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Colonic Neoplasms
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.
Colonic Neoplasms
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Colonic Neoplasms
IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Colonic Neoplasms
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Colonic Neoplasms
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Colonic Neoplasms
Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma.
Colonic Neoplasms
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
Colonic Neoplasms
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
Colonic Neoplasms
Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells.
Colonic Neoplasms
Mechanical force modulates global gene expression and beta-catenin signaling in colon cancer cells.
Colonic Neoplasms
Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily.
Colonic Neoplasms
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
Colonic Neoplasms
Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Colonic Neoplasms
Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis.
Colonic Neoplasms
miRNA-29a inhibits colon cancer growth by regulation of the PTEN/Akt/GSK3? and Wnt/?-catenin signaling pathways.
Colonic Neoplasms
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
Colonic Neoplasms
Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Colonic Neoplasms
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
Colonic Neoplasms
Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
Colonic Neoplasms
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Colonic Neoplasms
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Colonic Neoplasms
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Colonic Neoplasms
PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac.
Colonic Neoplasms
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Colonic Neoplasms
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Colonic Neoplasms
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.
Colonic Neoplasms
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
Colonic Neoplasms
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Colonic Neoplasms
PIK3CA mutations predict local recurrences in rectal cancer patients.
Colonic Neoplasms
PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
Colonic Neoplasms
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Colonic Neoplasms
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Colonic Neoplasms
Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Colonic Neoplasms
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Colonic Neoplasms
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.
Colonic Neoplasms
PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.
Colonic Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Colonic Neoplasms
Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells.
Colonic Neoplasms
Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
Colonic Neoplasms
Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
Colonic Neoplasms
Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population.
Colonic Neoplasms
Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer.
Colonic Neoplasms
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Colonic Neoplasms
Targeting ?-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
Colonic Neoplasms
The double life of p85.
Colonic Neoplasms
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.
Colonic Neoplasms
The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
Colonic Neoplasms
The influence of the CHIEF pathway on colorectal cancer-specific mortality.
Colonic Neoplasms
The interplay between GRP78 expression and Akt activation in human colon cancer cells under celecoxib treatment.
Colonic Neoplasms
The prevalence of PIK3CA mutations in gastric and colon cancer.
Colonic Neoplasms
The prognostic value of Microsatellite Instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients.
Colonic Neoplasms
The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion.
Colonic Neoplasms
The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.
Colonic Neoplasms
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
Colonic Neoplasms
[Effects of K-ras gene mutation on colon cancer cell line Caco-2 metastasis by regulating E-cadherin/beta-catenin/p120 protein complex formation and RhoA protein activity]
Colonic Neoplasms
[Molecular analysis of sporadic colon cancer].
Colorectal Neoplasms
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
Colorectal Neoplasms
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Colorectal Neoplasms
A functional variant at miR-520a binding site in PIK3CA alters susceptibility to colorectal cancer in a Chinese Han population.
Colorectal Neoplasms
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
Colorectal Neoplasms
A PIK3CA pyrosequencing-based assay that excludes pseudogene interference.
Colorectal Neoplasms
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Colorectal Neoplasms
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Colorectal Neoplasms
Activation of WNT/?-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Colorectal Neoplasms
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
Colorectal Neoplasms
AKT1 E17K in Colorectal Carcinoma is Associated with BRAF V600E but not MSI-H status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Colorectal Neoplasms
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
Colorectal Neoplasms
An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
Colorectal Neoplasms
An oncogenic gene, SNRPA1, regulates PIK3R1, VEGFC, MKI67, CDK1 and other genes in colorectal cancer.
Colorectal Neoplasms
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Colorectal Neoplasms
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Colorectal Neoplasms
Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.
Colorectal Neoplasms
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Colorectal Neoplasms
Aspirin and colorectal cancer: back to the future.
Colorectal Neoplasms
Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?
Colorectal Neoplasms
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Colorectal Neoplasms
Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!
Colorectal Neoplasms
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
Colorectal Neoplasms
Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
Colorectal Neoplasms
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.
Colorectal Neoplasms
Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Colorectal Neoplasms
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.
Colorectal Neoplasms
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Colorectal Neoplasms
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Colorectal Neoplasms
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
Colorectal Neoplasms
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
Colorectal Neoplasms
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
Colorectal Neoplasms
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
Colorectal Neoplasms
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Colorectal Neoplasms
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Colorectal Neoplasms
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Colorectal Neoplasms
Calcium intake and colon cancer risk subtypes by tumor molecular characteristics.
Colorectal Neoplasms
Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
Colorectal Neoplasms
Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Colorectal Neoplasms
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer.
Colorectal Neoplasms
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Colorectal Neoplasms
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Colorectal Neoplasms
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Colorectal Neoplasms
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Colorectal Neoplasms
Colorectal cancer in Chinese patients: current and emerging treatment options.
Colorectal Neoplasms
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Colorectal Neoplasms
Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.
Colorectal Neoplasms
Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
Colorectal Neoplasms
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Colorectal Neoplasms
Combination of TNF-? and graphene oxide-loaded BEZ235 to enhance apoptosis of PIK3CA mutant colorectal cancer cells.
Colorectal Neoplasms
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Colorectal Neoplasms
Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
Colorectal Neoplasms
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Colorectal Neoplasms
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.
Colorectal Neoplasms
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Colorectal Neoplasms
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Colorectal Neoplasms
Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.
Colorectal Neoplasms
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Colorectal Neoplasms
Consecutive and automatic detection of multi-gene mutations from colorectal cancer samples by coupling droplet array-based capillary electrophoresis and PCR-RFLP.
Colorectal Neoplasms
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Colorectal Neoplasms
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Colorectal Neoplasms
Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.
Colorectal Neoplasms
Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition.
Colorectal Neoplasms
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Colorectal Neoplasms
Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
Colorectal Neoplasms
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Colorectal Neoplasms
Differences in gene mutations according to gender among patients with colorectal cancer.
Colorectal Neoplasms
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Colorectal Neoplasms
Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers.
Colorectal Neoplasms
Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
Colorectal Neoplasms
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Colorectal Neoplasms
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Colorectal Neoplasms
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Colorectal Neoplasms
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
Colorectal Neoplasms
ENKUR Is Involved in the Regulation of Cellular Biology in Colorectal Cancer Cells via PI3K/Akt Signaling Pathway.
Colorectal Neoplasms
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Colorectal Neoplasms
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.
Colorectal Neoplasms
Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer.
Colorectal Neoplasms
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Colorectal Neoplasms
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.
Colorectal Neoplasms
Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer.
Colorectal Neoplasms
Expression profile and biological function of miR-455-5p in colorectal carcinoma.
Colorectal Neoplasms
Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
Colorectal Neoplasms
Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
Colorectal Neoplasms
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Colorectal Neoplasms
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Colorectal Neoplasms
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Colorectal Neoplasms
Gene heterogeneity in metastasis of colorectal cancer to the lung.
Colorectal Neoplasms
Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers.
Colorectal Neoplasms
Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II.
Colorectal Neoplasms
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Colorectal Neoplasms
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
Colorectal Neoplasms
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
Colorectal Neoplasms
Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
Colorectal Neoplasms
How autophagy controls the intestinal epithelial barrier.
Colorectal Neoplasms
IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells.
Colorectal Neoplasms
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ? 2 line cetuximab-based therapy of colorectal cancer patients.
Colorectal Neoplasms
Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Colorectal Neoplasms
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.
Colorectal Neoplasms
In silico approach to target PI3K/Akt/mTOR axis by selected Olea europaea phenols in PIK3CA mutant colorectal cancer.
Colorectal Neoplasms
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Colorectal Neoplasms
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Colorectal Neoplasms
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Colorectal Neoplasms
Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2.
Colorectal Neoplasms
Insulin induction instigates cell proliferation and metastasis in human colorectal cancer cells.
Colorectal Neoplasms
Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.
Colorectal Neoplasms
Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors
Colorectal Neoplasms
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
Colorectal Neoplasms
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
Colorectal Neoplasms
KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report.
Colorectal Neoplasms
KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.
Colorectal Neoplasms
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer.
Colorectal Neoplasms
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer.
Colorectal Neoplasms
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
Colorectal Neoplasms
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer.
Colorectal Neoplasms
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
Colorectal Neoplasms
KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
Colorectal Neoplasms
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Colorectal Neoplasms
Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer.
Colorectal Neoplasms
Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
Colorectal Neoplasms
Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation.
Colorectal Neoplasms
MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
Colorectal Neoplasms
miR-486-5p regulates the migration and invasion of colorectal cancer cells through targeting PIK3R1.
Colorectal Neoplasms
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Colorectal Neoplasms
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Colorectal Neoplasms
Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Colorectal Neoplasms
Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.
Colorectal Neoplasms
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Colorectal Neoplasms
Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Colorectal Neoplasms
Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications.
Colorectal Neoplasms
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
Colorectal Neoplasms
Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations.
Colorectal Neoplasms
Multiplexed assays for detection of mutations in PIK3CA.
Colorectal Neoplasms
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Colorectal Neoplasms
Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer.
Colorectal Neoplasms
Mutation of the PIK3CA gene in ovarian and breast cancer.
Colorectal Neoplasms
Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
Colorectal Neoplasms
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Colorectal Neoplasms
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Colorectal Neoplasms
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Colorectal Neoplasms
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Colorectal Neoplasms
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
Colorectal Neoplasms
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
Colorectal Neoplasms
Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
Colorectal Neoplasms
NRAS mutations are rare in colorectal cancer.
Colorectal Neoplasms
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
Colorectal Neoplasms
Nuclear accumulation of ?-catenin and forkhead box O3a in colon cancer: Dangerous liaison.
Colorectal Neoplasms
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
Colorectal Neoplasms
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Colorectal Neoplasms
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Colorectal Neoplasms
Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity.
Colorectal Neoplasms
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
Colorectal Neoplasms
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Colorectal Neoplasms
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Colorectal Neoplasms
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Colorectal Neoplasms
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Colorectal Neoplasms
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Colorectal Neoplasms
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Colorectal Neoplasms
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.
Colorectal Neoplasms
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
Colorectal Neoplasms
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
Colorectal Neoplasms
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
Colorectal Neoplasms
PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.
Colorectal Neoplasms
PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Colorectal Neoplasms
PIK3CA cancer mutations display gender and tissue specificity patterns.
Colorectal Neoplasms
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Colorectal Neoplasms
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
Colorectal Neoplasms
PIK3CA in Colorectal Cancer.
Colorectal Neoplasms
PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis.
Colorectal Neoplasms
PIK3CA mutation and colorectal cancer precision medicine.
Colorectal Neoplasms
PIK3CA mutation and methylation influences the outcome of colorectal cancer.
Colorectal Neoplasms
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
Colorectal Neoplasms
PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.
Colorectal Neoplasms
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
Colorectal Neoplasms
PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
Colorectal Neoplasms
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Colorectal Neoplasms
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
Colorectal Neoplasms
PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Colorectal Neoplasms
PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.
Colorectal Neoplasms
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
Colorectal Neoplasms
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
Colorectal Neoplasms
PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.
Colorectal Neoplasms
Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.
Colorectal Neoplasms
Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer.
Colorectal Neoplasms
Portrait of the PI3K/AKT pathway in colorectal cancer.
Colorectal Neoplasms
Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.
Colorectal Neoplasms
Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules.
Colorectal Neoplasms
Potential biomarker for aspirin use in colorectal cancer therapy.
Colorectal Neoplasms
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Colorectal Neoplasms
Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.
Colorectal Neoplasms
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Colorectal Neoplasms
Predictors of Lymph Node Count in Colorectal Cancer Resections: Data From US Nationwide Prospective Cohort Studies.
Colorectal Neoplasms
Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer.
Colorectal Neoplasms
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Colorectal Neoplasms
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Colorectal Neoplasms
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Colorectal Neoplasms
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.
Colorectal Neoplasms
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Colorectal Neoplasms
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Colorectal Neoplasms
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Colorectal Neoplasms
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
Colorectal Neoplasms
Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer.
Colorectal Neoplasms
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
Colorectal Neoplasms
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.
Colorectal Neoplasms
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.
Colorectal Neoplasms
PTEN-deficient cancers depend on PIK3CB.
Colorectal Neoplasms
Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Colorectal Neoplasms
Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue.
Colorectal Neoplasms
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Colorectal Neoplasms
Recent therapeutic advances in the treatment of colorectal cancer.
Colorectal Neoplasms
Relationship between mismatch repair protein, RAS, BRAF, PIK3CA gene expression and clinicopathological characteristics in elderly colorectal cancer patients.
Colorectal Neoplasms
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Colorectal Neoplasms
Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution.
Colorectal Neoplasms
Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737.
Colorectal Neoplasms
Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation.
Colorectal Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Colorectal Neoplasms
Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.
Colorectal Neoplasms
Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
Colorectal Neoplasms
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Colorectal Neoplasms
Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction.
Colorectal Neoplasms
Sodium butyrate-mediated differentiation of colorectal cancer cells: regulation of PKCbetaII by PI 3-kinase.
Colorectal Neoplasms
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Colorectal Neoplasms
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Colorectal Neoplasms
Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer.
Colorectal Neoplasms
Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients.
Colorectal Neoplasms
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
Colorectal Neoplasms
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
Colorectal Neoplasms
Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
Colorectal Neoplasms
Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue.
Colorectal Neoplasms
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Colorectal Neoplasms
Targeting glutamine metabolism in PIK3CA mutant colorectal cancers.
Colorectal Neoplasms
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
Colorectal Neoplasms
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.
Colorectal Neoplasms
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer.
Colorectal Neoplasms
The Landscape of PIK3CA Mutations in Colorectal Cancer.
Colorectal Neoplasms
The Molecular Landscape of Synchronous Colorectal Cancer Reveals Genetic Heterogeneity.
Colorectal Neoplasms
The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells.
Colorectal Neoplasms
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Colorectal Neoplasms
The prevalence of PIK3CA mutations in gastric and colon cancer.
Colorectal Neoplasms
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.
Colorectal Neoplasms
The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer.
Colorectal Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Colorectal Neoplasms
The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.
Colorectal Neoplasms
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Colorectal Neoplasms
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
Colorectal Neoplasms
Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.
Colorectal Neoplasms
Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
Colorectal Neoplasms
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
Colorectal Neoplasms
[A study of the relationship between the mutation of PIK3CA, PTEN and the occurrence of liver metastasis of colorectal cancer: survival analysis].
Colorectal Neoplasms
[Aspirin and colorectal cancer].
Colorectal Neoplasms
[Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients].
Colorectal Neoplasms
[Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
Colorectal Neoplasms
[Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Colorectal Neoplasms
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Colorectal Neoplasms
[Predictive biomarkers for anti-EGFR antibodies].
Colorectal Neoplasms, Hereditary Nonpolyposis
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Colorectal Neoplasms, Hereditary Nonpolyposis
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Common Variable Immunodeficiency
Activated phosphoinositide 3-kinase ? syndrome in a patient with a former diagnosis of common variable immune deficiency, bronchiectasis, and lymphoproliferative disease.
Common Variable Immunodeficiency
Advances and highlights in primary immunodeficiencies in 2017.
Common Variable Immunodeficiency
Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis.
Common Variable Immunodeficiency
Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Common Variable Immunodeficiency
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
Corneal Injuries
Corneal epithelial wound healing increases the expression but not long lasting activation of the p85alpha subunit of phosphatidylinositol-3 kinase.
Corneal Neovascularization
The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization.
Coronary Disease
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Coronary Occlusion
Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning.
COVID-19
Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
COVID-19
Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase.
Craniopharyngioma
Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.
Craniopharyngioma
Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.
Crohn Disease
How autophagy controls the intestinal epithelial barrier.
Crohn Disease
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Crohn Disease
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Cystadenofibroma
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Cystadenoma
High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients.
Cystadenoma, Mucinous
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
Cystadenoma, Mucinous
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Cystic Fibrosis
How autophagy controls the intestinal epithelial barrier.
Cystitis
Endogenous PI3K/Akt and NMDAR act independently in the regulation of CREB activity in lumbosacral spinal cord in cystitis.
Cystitis
In vivo regulation of brain-derived neurotrophic factor in dorsal root ganglia is mediated by nerve growth factor-triggered Akt activation during cystitis.
Cystitis
Suppression of the PI3K pathway in vivo reduces cystitis-induced bladder hypertrophy and restores bladder capacity examined by magnetic resonance imaging.
Cysts
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Cysts
A Review of the Diagnosis and Management of Premalignant Pancreatic Cystic Lesions.
Cysts
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Cysts
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Cysts
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Dementia
Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.
Dengue
Use of a tandem affinity purification assay to detect interactions between West Nile and dengue viral proteins and proteins of the mosquito vector.
Dent Disease
The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease.
deoxycytidine kinase deficiency
The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma.
Dermatitis, Exfoliative
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Diabetes Complications
Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control.
Diabetes Mellitus
Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85alpha) with Type 2 diabetes mellitus and hypertension in the Chinese Han population.
Diabetes Mellitus
Association of PI3K/AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese.
Diabetes Mellitus
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Diabetes Mellitus
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus
Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior.
Diabetes Mellitus
Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with Type II diabetes mellitus.
Diabetes Mellitus
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
Diabetes Mellitus
Insulin Resistance: Pathophysiology and Rationale for Treatment.
Diabetes Mellitus
Role and mechanism of PI3K/AKT/FoxO1/PDX-1 signaling pathway in functional changes of pancreatic islets in rats after severe burns.
Diabetes Mellitus
The expression of the p85alpha subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor gamma in human adipocytes.
Diabetes Mellitus
The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells.
Diabetes Mellitus
Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA.
Diabetes Mellitus
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 1
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Diabetes Mellitus, Type 1
Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.
Diabetes Mellitus, Type 1
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 2
Alterations in insulin-induced postreceptor signaling in adipocytes of the Otsuka Long-Evans Tokushima fatty rat strain.
Diabetes Mellitus, Type 2
Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85alpha) with Type 2 diabetes mellitus and hypertension in the Chinese Han population.
Diabetes Mellitus, Type 2
Association of PI3K/AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese.
Diabetes Mellitus, Type 2
Association of the polymorphisms in the 5'-untranslated region of PTEN gene with type 2 diabetes in a Japanese population.
Diabetes Mellitus, Type 2
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Diabetes Mellitus, Type 2
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus, Type 2
Dysfunction of human subcutaneous FAT arterioles in obesity associated or not with Type 2 diabetes.
Diabetes Mellitus, Type 2
Epidermal growth factor and transforming growth factor alpha mimic the effects of insulin in human fat cells and augment downstream signaling in insulin resistance.
Diabetes Mellitus, Type 2
Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM.
Diabetes Mellitus, Type 2
Gene encoding the catalytic subunit p110beta of human phosphatidylinositol 3-kinase: cloning, genomic structure, and screening for variants in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway.
Diabetes Mellitus, Type 2
Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.
Diabetes Mellitus, Type 2
Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue?
Diabetes Mellitus, Type 2
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
Diabetes Mellitus, Type 2
In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity.
Diabetes Mellitus, Type 2
Insulin action in skeletal muscle from patients with NIDDM.
Diabetes Mellitus, Type 2
Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation.
Diabetes Mellitus, Type 2
Insulin Resistance: Pathophysiology and Rationale for Treatment.
Diabetes Mellitus, Type 2
Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients [corrected].
Diabetes Mellitus, Type 2
Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes.
Diabetes Mellitus, Type 2
Lipid phosphatases as drug discovery targets for type 2 diabetes.
Diabetes Mellitus, Type 2
Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats.
Diabetes Mellitus, Type 2
Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes.
Diabetes Mellitus, Type 2
Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.
Diabetes Mellitus, Type 2
PIK3R1 gene polymorphisms are associated with type 2 diabetes and related features in the Turkish population.
Diabetes Mellitus, Type 2
Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in finnish subjects.
Diabetes Mellitus, Type 2
Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.
Diabetes Mellitus, Type 2
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
Diabetes Mellitus, Type 2
[Insulin resistance - its causes and therapy possibilities].
Diabetes, Gestational
Expression of PI3-K, PKB and GSK-3 ? in the skeletal muscle tissue of gestational diabetes mellitus.
Diabetes, Gestational
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
Diabetes, Gestational
The association of leukocyte phosphatidylinositol 3-kinase delta overexpression with gestational diabetes mellitus (GDM).
Diabetic Cardiomyopathies
Phosphoinositide 3-Kinase Therapy in Diabetic Cardiomyopathy: Unravelling an Enigma.
Diabetic Cardiomyopathies
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
Diabetic Cardiomyopathies
Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110?) signaling.
Diabetic Cardiomyopathies
Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA.
Diabetic Nephropathies
Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K/Akt/mTOR pathway.
Diabetic Nephropathies
Thyroid Hormone Ameliorates Diabetic Nephropathy in a Mouse Model of Type II Diabetes.
Diabetic Nephropathies
Zinc Attenuates Tubulointerstitial Fibrosis in Diabetic Nephropathy Via Inhibition of HIF Through PI-3K Signaling.
Diabetic Neuropathies
Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease?
Diphtheria
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I.
Drug-Related Side Effects and Adverse Reactions
For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.
Dyslipidemias
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.
Dyslipidemias
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Dyspnea
Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes.
Encephalitis
PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis.
Encephalomyelitis
Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis, Autoimmune, Experimental
Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice.
Endodermal Sinus Tumor
The genetic landscape of 87 ovarian germ cell tumors.
Endometrial Hyperplasia
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Endometrial Hyperplasia
Autophagy in the physiological endometrium and cancer.
Endometrial Hyperplasia
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Endometrial Neoplasms
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Endometrial Neoplasms
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
Endometrial Neoplasms
A Unique Spectrum of Somatic PIK3CA (p110{alpha}) Mutations Within Primary Endometrial Carcinomas.
Endometrial Neoplasms
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Endometrial Neoplasms
Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1.
Endometrial Neoplasms
Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
Endometrial Neoplasms
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
Endometrial Neoplasms
Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
Endometrial Neoplasms
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Endometrial Neoplasms
Autophagy in the physiological endometrium and cancer.
Endometrial Neoplasms
Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium.
Endometrial Neoplasms
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Endometrial Neoplasms
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Endometrial Neoplasms
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
Endometrial Neoplasms
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Endometrial Neoplasms
Correction: High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
Endometrial Neoplasms
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
Endometrial Neoplasms
Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Endometrial Neoplasms
Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo.
Endometrial Neoplasms
Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.
Endometrial Neoplasms
Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Endometrial Neoplasms
Expression of metabolically targeted biomarkers in endometrial carcinoma.
Endometrial Neoplasms
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Endometrial Neoplasms
FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features.
Endometrial Neoplasms
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Endometrial Neoplasms
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Endometrial Neoplasms
Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays.
Endometrial Neoplasms
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
Endometrial Neoplasms
Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.
Endometrial Neoplasms
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Endometrial Neoplasms
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Endometrial Neoplasms
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
Endometrial Neoplasms
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Endometrial Neoplasms
High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
Endometrial Neoplasms
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.
Endometrial Neoplasms
Identification of a Gene Panel for Endometrioid Endometrial Cancer: a Possible Prognostic Value?
Endometrial Neoplasms
Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
Endometrial Neoplasms
Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas.
Endometrial Neoplasms
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Endometrial Neoplasms
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
Endometrial Neoplasms
Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas.
Endometrial Neoplasms
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Endometrial Neoplasms
Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome.
Endometrial Neoplasms
Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Endometrial Neoplasms
Molecular profiling of endometrial malignancies.
Endometrial Neoplasms
Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study.
Endometrial Neoplasms
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Endometrial Neoplasms
New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes.
Endometrial Neoplasms
Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
Endometrial Neoplasms
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Endometrial Neoplasms
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Endometrial Neoplasms
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Endometrial Neoplasms
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Endometrial Neoplasms
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Endometrial Neoplasms
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Endometrial Neoplasms
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Endometrial Neoplasms
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations.
Endometrial Neoplasms
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-?/VEGF pathway in endometrial cancer.
Endometrial Neoplasms
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Endometrial Neoplasms
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Endometrial Neoplasms
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Endometrial Neoplasms
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
Endometrial Neoplasms
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Endometrial Neoplasms
PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
Endometrial Neoplasms
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Endometrial Neoplasms
PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Endometrial Neoplasms
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Endometrial Neoplasms
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
Endometrial Neoplasms
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.
Endometrial Neoplasms
Progestin-associated shift of meningioma mutational landscape.
Endometrial Neoplasms
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives.
Endometrial Neoplasms
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Endometrial Neoplasms
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Endometrial Neoplasms
Rare Mutations in the PIK3CA Gene Contribute to Aggressive Endometrial Cancer.
Endometrial Neoplasms
Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer.
Endometrial Neoplasms
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.
Endometrial Neoplasms
The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2.
Endometrial Neoplasms
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.
Endometrial Neoplasms
Use of mutation profiles to refine the classification of endometrial carcinomas.
Endometrial Neoplasms
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Endometrial Neoplasms
Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Endometrial Neoplasms
[Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Endometriosis
(Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
Endometriosis
17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway.
Endometriosis
A case report of bladder and intestinal endometriosis, and the relationship between sex hormone receptor expression and PIK3CA mutation analysis.
Endometriosis
A mouse model of endometriosis mimicking the natural spread of invasive endometrium.
Endometriosis
Cancer Implications for Patients with Endometriosis.
Endometriosis
Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
Endometriosis
Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Endometriosis
Distinguishing the progression of an endometrioma: Benign or malignant?
Endometriosis
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer.
Endometriosis
Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic KRAS and PIK3CA Mutations for Understanding the Underlying Biology and Molecular Pathogenesis.
Endometriosis
Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
Endometriosis
Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation.
Endometriosis
Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
Endometriosis
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
Endometriosis
Ovarian cancer in endometriosis: an update on the clinical and molecular aspects.
Endometriosis
Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?
Endometriosis
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Endometriosis
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Endometriosis
Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.
Endometriosis
The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis.
Endotoxemia
Disassociation of muscle insulin signaling and insulin-stimulated glucose uptake during endotoxemia.
Endotoxemia
L-selectin: an emerging player in chemokine function.
Endotoxemia
PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice.
Enterocolitis
Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase ?.
Eosinophilia
The effect of pharmacological PI3K? inhibitor on eotaxin-induced human eosinophil functions.
Ependymoma
Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy.
Ependymoma
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Ependymoma
Pediatric Ependymoma: A Proteomics Perspective.
Ependymoma
Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.
Epilepsies, Partial
Precise detection of low-level somatic mutation in resected epilepsy brain tissue.
Epilepsy
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Epilepsy
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Epilepsy
Effect of PIK3CA variants on glioma-related epilepsy and response to treatment.
Epilepsy
Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3? signaling pathway.
Epilepsy
Interaction Between Akt1-Positive Neurons and Age at Surgery Is Associated With Surgical Outcome in Children With Isolated Focal Cortical Dysplasia.
Epilepsy
mTOR mutations in Smith-Kingsmore syndrome: four additional patients and a review.
Epilepsy
Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.
Epilepsy
Precise detection of low-level somatic mutation in resected epilepsy brain tissue.
Epstein-Barr Virus Infections
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Epstein-Barr Virus Infections
Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Erdheim-Chester Disease
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.
Esophageal Achalasia
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Esophageal Neoplasms
Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.
Esophageal Neoplasms
Genetic analysis of rapidly progressing esophageal squamous cell carcinoma: A case report.
Esophageal Neoplasms
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Esophageal Neoplasms
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Esophageal Neoplasms
PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.
Esophageal Neoplasms
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Esophageal Neoplasms
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Esophageal Neoplasms
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Esophageal Neoplasms
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Esophageal Neoplasms
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Esophageal Neoplasms
TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
Esophageal Squamous Cell Carcinoma
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Copy number loss of variation_91720 in PIK3CA predicts risk of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction.
Esophageal Squamous Cell Carcinoma
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
Esophageal Squamous Cell Carcinoma
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Esophageal Squamous Cell Carcinoma
No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.
Esophageal Squamous Cell Carcinoma
Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Esophageal Squamous Cell Carcinoma
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Esophageal Squamous Cell Carcinoma
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Exanthema
High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.
Exanthema
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ? 2 line cetuximab-based therapy of colorectal cancer patients.
Exanthema
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Familial Mediterranean Fever
MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase ? pathway.
Fanconi Anemia
FANCM-FAAP24 and HCLK2: roles in ATR signalling and the Fanconi anemia pathway.
Fasciculation
The small GTPase Rac is involved in clustering of hippocampal neurons and fasciculation of their neurites.
Fatty Liver
Ablation of PI3K p110-{alpha} Prevents High-Fat Diet-Induced Liver Steatosis.
Fatty Liver
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Fatty Liver
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Fetal Growth Retardation
A novel PIK3R1 mutation of SHORT syndrome in a Chinese female with diffuse thyroid disease: a case report and review of literature.
Fetal Growth Retardation
Maternal protein restriction induces alterations in insulin signaling and ATP sensitive potassium channel protein in hypothalami of intrauterine growth restriction fetal rats.
Fetal Growth Retardation
[Perturbed hepatic phosphoinositol 3-kinase signaling pathway in the rat with intrauterine growth restriction.]
Fibroadenoma
PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.
Fibromyalgia
Electroacupuncture attenuates chronic fibromyalgia pain through the phosphorylated phosphoinositide 3-kinase signaling pathway in the mouse brain.
Fibrosarcoma
5-Azacytidine regulates matrix metalloproteinase-9 expression, and the migration and invasion of human fibrosarcoma HT1080 cells via PI3-kinase and ERK1/2 pathways.
Fibrosarcoma
miR-574-3p inhibits proliferation and invasion in esophageal cancer by targeting FAM3C and MAPK1.
Fibrosarcoma
Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells.
Fibrosarcoma
Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells.
Fibrosarcoma
Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways.
Fibrosarcoma
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Fibrosarcoma
Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308.
Fragile X Syndrome
Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
Fragile X Syndrome
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Fragile X Syndrome
Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.
Gallbladder Neoplasms
Identification of LIFR, PIK3R1, and MMP12 as Novel Prognostic Signatures in Gallbladder Cancer Using Network-Based Module Analysis.
Gallbladder Neoplasms
Molecular characteristics of biliary tract cancer.
Gallbladder Neoplasms
Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients.
Gastroesophageal Reflux
Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.
Gastrointestinal Neoplasms
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
Gastrointestinal Neoplasms
Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.
Gastrointestinal Stromal Tumors
Cross regulation of signaling pathways in gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumors
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Gastrointestinal Stromal Tumors
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Genetic Diseases, Inborn
Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth.
Genetic Diseases, Inborn
Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro.
Genetic Diseases, Inborn
Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
Genetic Diseases, Inborn
NODAL/TGF? signalling mediates the self-sustained stemness induced by PIK3CA
H1047R
homozygosity in pluripotent stem cells.
Genetic Diseases, Inborn
Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
Gingival Overgrowth
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Glioblastoma
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Glioblastoma
A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration.
Glioblastoma
Aberrant Rac pathway signalling in glioblastoma.
Glioblastoma
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Glioblastoma
Activation of Polyamine Catabolism by N1, N11-Diethylnorspermine Alters the Cellular Localization of mTOR and Downregulates mTOR Protein Level in Glioblastoma Cells.
Glioblastoma
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Glioblastoma
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Glioblastoma
Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression.
Glioblastoma
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Glioblastoma
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Glioblastoma
Cross-platform Q-TOF validation of global exo-metabolomic analysis: application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002.
Glioblastoma
CXCL12-induced glioblastoma cell migration requires intermediate-conductance Ca2+-activated K+ channel activity.
Glioblastoma
Differential involvement of p38 mitogen-activated protein kinase and phosphatidyl inositol 3-kinase in the IL-1-mediated NF-kappa B and AP-1 activation.
Glioblastoma
Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration.
Glioblastoma
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.
Glioblastoma
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Glioblastoma
Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo.
Glioblastoma
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Glioblastoma
Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis.
Glioblastoma
EGFR signals to mTOR through PKC and independently of Akt in glioma.
Glioblastoma
Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses.
Glioblastoma
Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
Glioblastoma
From epidemiology and neurodevelopment to antineoplasticity. Medroxyprogesterone reduces human glial tumor growth in vitro and C6 glioma in rat brain in vivo.
Glioblastoma
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.
Glioblastoma
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
Glioblastoma
High frequency of mutations in the PIK3CA gene helical and kinase coding regions in a group of Iranian patients with high-grade glioblastomas: five novel mutations.
Glioblastoma
Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Glioblastoma
Hypoxia Induced by Cobalt Chloride Triggers Autophagic Apoptosis of Human and Mouse Drug-Resistant Glioblastoma Cells through Targeting the PI3K-AKT-mTOR Signaling Pathway.
Glioblastoma
Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
Glioblastoma
Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
Glioblastoma
Influence of Pi3-K and PKC activity on 99mTc-(V)-DMSA uptake: correlation with tumour aggressiveness in an in vitro malignant glioblastoma cell line model.
Glioblastoma
Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
Glioblastoma
Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Glioblastoma
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Glioblastoma
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
Glioblastoma
MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.
Glioblastoma
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
Glioblastoma
MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.
Glioblastoma
Molecular Characterization of "True" Low-Grade IDH-Wildtype Astrocytomas.
Glioblastoma
Molecular targeted therapy of glioblastoma.
Glioblastoma
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Glioblastoma
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Glioblastoma
Mutations of the PIK3CA gene are rare in human glioblastoma.
Glioblastoma
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Glioblastoma
Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
Glioblastoma
Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells.
Glioblastoma
PI3K signaling in glioma--animal models and therapeutic challenges.
Glioblastoma
PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas.
Glioblastoma
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.
Glioblastoma
PIK3CA alterations in primary (de novo) and secondary glioblastomas.
Glioblastoma
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
Glioblastoma
PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
Glioblastoma
PIK3CA mutations in glioblastoma multiforme.
Glioblastoma
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis.
Glioblastoma
PIKE-A promotes glioblastoma growth by driving PPP flux through increasing G6PD expression mediated by phosphorylation of STAT3.
Glioblastoma
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Glioblastoma
PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion.
Glioblastoma
Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
Glioblastoma
PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1.
Glioblastoma
PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.
Glioblastoma
Regulation of glioblastoma cell invasion by PKC iota and RhoB.
Glioblastoma
Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation.
Glioblastoma
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Glioblastoma
Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.
Glioblastoma
Somatic mutations of PIK3R1 promote gliomagenesis.
Glioblastoma
Stoichiometric quantification of Akt phosphorylation using LC-MS/MS.
Glioblastoma
Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2.
Glioblastoma
Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
Glioblastoma
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Glioblastoma
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
Glioblastoma
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Glioblastoma
Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors.
Glioblastoma
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Glioma
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Glioma
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Glioma
Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells.
Glioma
Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)?V-Ha-Ras transgenic mouse glioma model.
Glioma
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Glioma
Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas.
Glioma
CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.
Glioma
Circ_0000020 elevates the expression of PIK3CA and facilitates the malignant phenotypes of glioma cells via targeting miR-142-5p.
Glioma
Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways.
Glioma
Cytosolic and calcium-independent phospholipase A(2) mediate glioma-enhanced proangiogenic activity of brain endothelial cells.
Glioma
Deregulated human glioma cell motility: inhibitory effect of somatostatin.
Glioma
Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo.
Glioma
Effect of PIK3CA variants on glioma-related epilepsy and response to treatment.
Glioma
From epidemiology and neurodevelopment to antineoplasticity. Medroxyprogesterone reduces human glial tumor growth in vitro and C6 glioma in rat brain in vivo.
Glioma
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Glioma
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.
Glioma
Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
Glioma
IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/?-catenin pathway.
Glioma
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Glioma
Induced expression of MMP-9 in C6 glioma cells is inhibited by PDGF via a PI 3-kinase-dependent pathway.
Glioma
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Glioma
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Glioma
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Glioma
Isoform specific inhibitors of PI3 kinase in glioma.
Glioma
LINC01198 facilitates gliomagenesis through activating PI3K/AKT pathway.
Glioma
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis.
Glioma
Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin.
Glioma
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
Glioma
Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling.
Glioma
Next-generation whole exome sequencing of glioblastoma with a primitive neuronal component.
Glioma
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Glioma
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Glioma
Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus.
Glioma
Phosphoinositide-3-kinase inhibition elevates ferritin level resulting depletion of labile iron pool and blocking of glioma cell proliferation.
Glioma
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Glioma
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
Glioma
PI3K? inhibitor AZD6482 exerts antiproliferative activity and induces apoptosis in human glioblastoma cells.
Glioma
PIK3CA alterations in primary (de novo) and secondary glioblastomas.
Glioma
PIK3CA Mutations Induce Neuronal Hyperactivity during Glioma Formation.
Glioma
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Glioma
Protein tyrosine kinase-dependent regulation of adenylate cyclase and phosphatidylinositol 3-kinase activates the expression of glial fibrillary acidic protein upon induction of differentiation in rat c6 glioma.
Glioma
PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway.
Glioma
Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines.
Glioma
Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1.
Glioma
Signal transduction molecules in gliomas of all grades.
Glioma
Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.
Glioma
Spatiotemporal genomic architecture informs precision oncology in glioblastoma.
Glioma
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Glioma
Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Glioma
Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance.
Glioma
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
Glioma
The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.
Glioma
Using isoform-specific inhibitors to target lipid kinases.
Glioma
Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas.
Glioma
Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells.
Glomerulonephritis
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Glomerulonephritis
PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.
Glucagonoma
Glucagon release is regulated by tyrosine phosphatase and PI3-kinase activity.
Glucose Intolerance
Class IA phosphatidylinositol 3-kinase in pancreatic ? cells controls insulin secretion by multiple mechanisms.
Glucose Intolerance
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.
Glucose Intolerance
Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation.
Goiter
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Granulomatous Disease, Chronic
Advances and highlights in primary immunodeficiencies in 2017.
Hamartoma
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Hamartoma
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
Hamartoma Syndrome, Multiple
Cowden's syndrome with immunodeficiency.
Hamartoma Syndrome, Multiple
[Germline mutations in PIK3CA and AKT1 in Cowden syndrome and related diseases].
Head and Neck Neoplasms
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
Head and Neck Neoplasms
Carcinogenesis of PIK3CA.
Head and Neck Neoplasms
Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Head and Neck Neoplasms
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Head and Neck Neoplasms
FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration.
Head and Neck Neoplasms
Lessons learned from next-generation sequencing in head and neck cancer.
Head and Neck Neoplasms
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Head and Neck Neoplasms
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Head and Neck Neoplasms
Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Head and Neck Neoplasms
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
Head and Neck Neoplasms
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
Head and Neck Neoplasms
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
Head and Neck Neoplasms
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Head and Neck Neoplasms
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
Head and Neck Neoplasms
Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer.
Head and Neck Neoplasms
Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma.
Head and Neck Neoplasms
Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures.
Head and Neck Neoplasms
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
Head and Neck Neoplasms
Translational Genomics and Recent Advances in Oral Squamous Cell Carcinoma.
Hearing Loss
Effects of epigallocatechin-3-gallate on proliferation and differentiation of mouse cochlear neural stem cells: Involvement of PI3K/Akt signaling pathway.
Heart Diseases
Genetic ablation of Cullin-RING E3 ubiquitin ligase 7 restrains pressure overload-induced myocardial fibrosis.
Heart Diseases
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Heart Diseases
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Heart Diseases
Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease.
Heart Diseases
Role of phosphoinositide 3-kinases in regulating cardiac function.
Heart Diseases
Role of PI3 kinase gamma in excitation-contraction coupling and heart disease.
Heart Failure
Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase ? activity in pressure overload-induced cardiac failure.
Heart Failure
Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure.
Heart Failure
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
Heart Failure
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.
Heart Failure
Leukocyte and cardiac phosphoinositide 3-kinase ? activity in pressure overload-induced cardiac failure.
Heart Failure
Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase ? in mouse.
Heart Failure
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Heart Failure
Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease.
Heart Failure
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure.
Heart Failure
PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA.
Heart Failure
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
Heart Failure
Regulation of heart rate and the pacemaker current by phosphoinositide 3-kinase signaling.
Heart Failure
Role of phosphoinositide 3-kinase in cardiac function and heart failure.
Heart Failure
Scaffolding Function of PI3Kgamma Emerges from Enzyme's Shadow.
Heart Failure
Selective activation of PI3Kalpha/Akt/GSK-3beta signalling and cardiac compensatory hypertrophy during recovery from heart failure.
Heart Failure
Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression.
Heart Failure
Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure.
Heart Failure
The role of PI3-K/Akt signal pathway in the antagonist effect of CEPO on CHF rats.
Heart Failure
[Effects of neuregulin on cardiac myocyte apoptosis and PI-3K signal transduction pathway in rapid pacing-induced heart failure in rhesus monkeys]
Hemangioma
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Hemangioma, Cavernous, Central Nervous System
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.
Hemangiosarcoma
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Hemangiosarcoma
Active TGF-? signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Hemangiosarcoma
Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.
Hemangiosarcoma
Lgr5-positive endothelial progenitor cells occupy a tumor and injury prone niche in the kidney vasa recta.
Hemangiosarcoma
PIK3CA mutations matter for cancer in dogs.
Hemangiosarcoma
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Hematologic Neoplasms
2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3K? Selective Inhibitors.
Hematologic Neoplasms
Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway.
Hematologic Neoplasms
Discovery of Orally Efficacious Phosphoinositide 3-Kinase ? Inhibitors with Improved Metabolic Stability.
Hematologic Neoplasms
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Hematologic Neoplasms
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Hematologic Neoplasms
Phosphoinositide 3-kinase inhibitors in lymphoma.
Hematologic Neoplasms
Structural, Biochemical and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-kinase Delta.
Hematologic Neoplasms
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Hematologic Neoplasms
The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL.
Hemimegalencephaly
PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
Hemimegalencephaly
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Hepatitis
Phosphoinositide 3-kinase gamma inhibitor ameliorates concanavalin A-induced hepatic injury in mice.
Hepatitis B
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Hepatitis B
Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma.
Hepatitis B
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Hepatitis B
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin.
Hepatitis B
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor {alpha}-mediated apoptosis by activation of phosphoinositol 3-kinase and {beta}-catenin.
Hepatitis B
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Hepatitis C
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Hepatitis C
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Hepatitis C
The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.
Hepatoblastoma
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Hepatomegaly
[Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase ? syndrome 2].
Herpes Simplex
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Herpes Simplex
PI3-Kinase signaling may affect multiple steps during herpes simplex virus-1 entry.
Herpes Simplex
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Herpes Zoster
Phosphoinositide 3-kinase is involved in the induction of the human sperm acrosome reaction downstream of tyrosine phosphorylation.
Herpesviridae Infections
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Histiocytosis
Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis.
Histiocytosis, Langerhans-Cell
Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis.
HIV Infections
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).
Hodgkin Disease
A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Huntington Disease
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Hydrocephalus
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Hyper-IgM Immunodeficiency Syndrome
Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.
Hyper-IgM Immunodeficiency Syndrome
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
Hyper-IgM Immunodeficiency Syndrome
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Hyperalgesia
Inflammatory cytokines in midbrain periaqueductal gray contribute to diabetic induced pain hypersensitivity through phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway.
Hyperalgesia
Mechanisms Mediating High-Molecular-Weight Hyaluronan-Induced Antihyperalgesia.
Hyperalgesia
PI3K?/AKT signaling in high molecular weight hyaluronan (HMWH)-induced anti-hyperalgesia and reversal of nociceptor sensitization.
Hyperglycemia
Hyperglycemia activates glucose transport in rat skeletal muscle via a Ca(2+)-dependent mechanism.
Hyperglycemia
Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling.
Hyperglycemia
Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver.
Hyperglycemia
Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle.
Hyperglycemia
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Hyperglycemia
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Hyperinsulinism
ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia.
Hyperinsulinism
Defect in long-term activation of phosphatidylinositol 3-kinase by insulin in vivo: studies in insulin-resistant hHTg rats.
Hyperinsulinism
Early growth response gene-1 expression in vascular smooth muscle cells effects of insulin and oxidant stress.
Hyperinsulinism
Effects of chronic undernutrition on glucose uptake and glucose transporter proteins in rat heart.
Hyperinsulinism
Effects of exercise and insulin on insulin signaling proteins in human skeletal muscle.
Hyperinsulinism
Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro.
Hyperinsulinism
Elevated fasting insulin concentrations associate with impaired insulin signaling in skeletal muscle of healthy subjects independent of obesity.
Hyperinsulinism
Hyperinsulinemia impairs functions of circulating endothelial progenitor cells.
Hyperinsulinism
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.
Hyperinsulinism
Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells.
Hyperinsulinism
Insulin and exercise differentially regulate PI3-kinase and glycogen synthase in human skeletal muscle.
Hyperinsulinism
Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation.
Hyperinsulinism
Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH.
Hyperinsulinism
Insulin signaling in human skeletal muscle: time course and effect of exercise.
Hyperinsulinism
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.
Hyperinsulinism
Regular exercise enhances insulin activation of IRS-1-associated PI3-kinase in human skeletal muscle.
Hyperinsulinism
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Hypersensitivity
Abdominal Massage Reduces Visceral Hypersensitivity via Regulating GDNF and PI3K/AKT Signal Pathway in a Rat Model of Irritable Bowel Syndrome.
Hypersensitivity
Activation of protein kinase B/Akt signaling pathway contributes to mechanical hypersensitivity induced by capsaicin.
Hypersensitivity
Essential role for the p110delta phosphoinositide 3-kinase in the allergic response.
Hypersensitivity
Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.
Hypersensitivity
Inhibition of phosphoinositide 3-kinase ? attenuates inflammation, obesity, and cardiovascular risk factors.
Hypersensitivity
Isoform-specific functions of phosphoinositide 3-kinases: p110delta but not p110gamma promotes optimal allergic responses in vivo.
Hypersensitivity
Maternal food restriction enhances insulin-induced GLUT-4 translocation and insulin signaling pathway in skeletal muscle from suckling rats.
Hypersensitivity
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.
Hypersensitivity
PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.
Hypersensitivity
Regulation of p110delta PI 3-kinase gene expression.
Hypersensitivity
Regulation of phosphatidylinositol 3-kinase by insulin in rat skeletal muscle.
Hypersensitivity
Resveratrol rescued the pain related hypersensitivity for Cntnap2-deficient mice.
Hypersensitivity
Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing.
Hypersensitivity
Targeting phosphoinositide 3-kinase: moving towards therapy.
Hypersensitivity
Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.
Hypersensitivity
Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects.
Hypersplenism
Knockdown of PIK3R1 by shRNA inhibits the activity of the splenic macrophages associated with hypersplenism due to portal hypertension.
Hypertension
Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85alpha) with Type 2 diabetes mellitus and hypertension in the Chinese Han population.
Hypertension
Increased PI3-kinase in presympathetic brain areas of the spontaneously hypertensive rat.
Hypertension
Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Hypertension
Local angiotensin II aggravates cardiac remodeling in hypertension.
Hypertension
Phosphoinositide 3-kinase ? deficiency attenuates kidney injury and fibrosis in angiotensin II-induced hypertension.
Hypertension
Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats.
Hypertension
PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110delta the culprit?
Hypertension
Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma.
Hypertension
Redox-Sensitive Oxidation and Phosphorylation of PTEN Contribute to Enhanced Activation of PI3K/Akt Signaling in Rostral Ventrolateral Medulla and Neurogenic Hypertension in Spontaneously Hypertensive Rats.
Hypertension
Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension.
Hypertension
Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing.
Hypertension, Portal
Knockdown of PIK3R1 by shRNA inhibits the activity of the splenic macrophages associated with hypersplenism due to portal hypertension.
Hypertension, Pulmonary
NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
Hypertrophy, Right Ventricular
Ligustrazine Suppresses Platelet-Derived Growth Factor-BB-Induced Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammation by Regulating the PI3K/AKT Signaling Pathway.
Hypoglycemia
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Hypoglycemia
Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway.
Hypoglycemia
Role of the liver in glucose homeostasis in PI 3-kinase p85alpha-deficient mice.
Hypotension
Neuronal nitric oxide synthase-dependent elevation in adiponectin in the rostral ventrolateral medulla underlies g protein-coupled receptor 18-mediated hypotension in conscious rats.
Hypothyroidism
Roles of ERK1/2 and PI3K/AKT signaling pathways in mitochondria-mediated apoptosis in testes of hypothyroid rats.
Immune System Diseases
Class I phosphoinositide 3-kinases.
Immune System Diseases
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Immune System Diseases
Epstein-Barr Virus Susceptibility in Activated PI3K? Syndrome (APDS) Immunodeficiency.
Immune System Diseases
Recent discovery of phosphoinositide 3-kinase ? inhibitors for the treatment of immune diseases and cancers.
Infections
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Infections
A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Infections
A role for host phosphoinositide 3-kinase and cytoskeletal remodeling during Cryptosporidium parvum infection.
Infections
A role for phosphoinositide 3-kinase in bacterial invasion.
Infections
A sulfated glucuronorhamnan from the green seaweed Monostroma nitidum: Characteristics of its structure and antiviral activity.
Infections
Activation of cell signaling pathways is dependant on the biotype of bovine viral diarrhea viruses type 2.
Infections
Activation of host cell phosphatidylinositol 3-kinases by Trypanosoma cruzi infection.
Infections
Adenovirus Infection Results in Alterations of Insulin Signaling and Glucose Homeostasis.
Infections
Adjuvant-induced survival signaling in clonally expanded T cells is associated with transient increases in pAkt levels and sustained uptake of glucose.
Infections
Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide.
Infections
Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis.
Infections
APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Infections
Autophagy Benefits the Replication of Egg Drop Syndrome Virus in Duck Embryo Fibroblasts.
Infections
Avian reovirus triggers autophagy in primary chicken fibroblast cells and Vero cells to promote virus production.
Infections
Berberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3K.
Infections
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Infections
CIB1 synergizes with EphrinA2 to regulate Kaposi's sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells.
Infections
Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori Infection.
Infections
Constitutively active phosphatidylinositol 3-kinase and AKT are sufficient to stimulate the epithelial Na+/H+ exchanger 3.
Infections
Corneal cell survival in adenovirus type 19 infection requires phosphoinositide 3-kinase/Akt activation.
Infections
Critical Roles of Phosphoinositide 3-Kinase ? in the Humoral Immune Response to Trypanosoma congolense Infection.
Infections
De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly.
Infections
Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?
Infections
Different expression of apoptotic proteins between HBV-infected and non-HBV-infected hepatocellular carcinoma.
Infections
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Infections
Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase ? Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Infections
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Infections
EphrinA2 regulates clathrin mediated KSHV endocytosis in fibroblast cells by coordinating integrin-associated signaling and c-Cbl directed polyubiquitination.
Infections
ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
Infections
Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.
Infections
Exhaustion of the CD8
Infections
Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans.
Infections
HACE1, an E3 ubiquitin-protein ligase, Mitigates Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Infection Induced Oxidative Stress by Promoting Nrf2 Activity.
Infections
Human adenovirus type 36 enhances glucose uptake in diabetic and nondiabetic human skeletal muscle cells independent of insulin signaling.
Infections
Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.
Infections
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
Infections
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
Infections
Induction of Central Host Signaling Kinases during Pneumococcal Infection of Human THP-1 Cells.
Infections
Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.
Infections
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Infections
Initiation of human astrovirus type 1 infection was blocked by inhibitors of phosphoinositide 3-kinase.
Infections
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Infections
Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity.
Infections
KSHV Entry and Trafficking in Target Cells-Hijacking of Cell Signal Pathways, Actin and Membrane Dynamics.
Infections
Lipid rafts of primary endothelial cells are essential for Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for microtubule dynamics and nuclear delivery of viral DNA but dispensable for binding and entry.
Infections
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
Infections
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Infections
MTOR-Driven Metabolic Reprogramming Regulates Legionella pneumophila Intracellular Niche Homeostasis.
Infections
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Infections
Outer membrane protein A expression in Enterobacter sakazakii is required to induce microtubule condensation in human brain microvascular endothelial cells for invasion.
Infections
Overexpression of interferon-gamma-inducible GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway and inhibition of viral replication.
Infections
Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding.
Infections
PDPK1 regulates autophagosome biogenesis by binding to PIK3C3.
Infections
Phagocytic Entry of Legionella pneumophila into Macrophages through Phosphatidylinositol 3,4,5-Trisphosphate-Independent Pathway.
Infections
Phosphatidylinositol 3-kinase is required for rhinovirus-induced airway epithelial cell interleukin-8 expression.
Infections
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Infections
Phosphatidylinositol 3-kinase/Akt-dependent and -independent protection against apoptosis in normal human melanocytes.
Infections
Phosphoinositide 3-kinase ? gene mutation predisposes to respiratory infection and airway damage.
Infections
Phosphoinositide 3-Kinase ? Inhibition Improves Neutrophil Bacterial Killing in Critically Ill Patients at High Risk of Infection.
Infections
Phosphoinositide 3-kinase is required for insulin-induced but not for growth hormone- or hyperosmolarity-induced glucose uptake in 3T3-L1 adipocytes.
Infections
PI3K signaling in chronic obstructive pulmonary disease: mechanisms, targets, and therapy.
Infections
Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
Infections
Protein phosphatase 2A and phosphatidylinositol 3-kinase regulate the activity of Sp1-responsive promoters.
Infections
Respiratory syncytial virus inhibits apoptosis and induces NF-kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway.
Infections
Rhinovirus activates interleukin-8 expression via a Src/p110beta phosphatidylinositol 3-kinase/Akt pathway in human airway epithelial cells.
Infections
RhoA-GTPase facilitates entry of Kaposi's sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner.
Infections
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Infections
Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes.
Infections
Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neurons.
Infections
Single cell mass cytometry reveals remodeling of human T cell phenotypes by varicella zoster virus.
Infections
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
Infections
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
Infections
The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.
Infections
The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
Infections
Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis.
Infertility, Male
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Inflammatory Bowel Diseases
How autophagy controls the intestinal epithelial barrier.
Inflammatory Bowel Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Inflammatory Bowel Diseases
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Inflammatory Bowel Diseases
Phosphoinositide 3-Kinase P110?-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation.
Inflammatory Bowel Diseases
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Inflammatory Bowel Diseases
The roles of microbial products in the development of colorectal cancer: a review.
Inflammatory Breast Neoplasms
Identification of frequent somatic mutations in inflammatory breast cancer.
Influenza, Human
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Influenza, Human
Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.
Influenza, Human
Effect of influenza A virus non-structural protein 1(NS1) on a mouse model of diabetes mellitus induced by Streptozotocin.
Influenza, Human
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Influenza, Human
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Influenza, Human
Reorganization of the host cell Crk(L)-PI3 kinase signaling complex by the influenza A virus NS1 protein.
Influenza, Human
Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein.
Infratentorial Neoplasms
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.
Insulin Resistance
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies.
Insulin Resistance
A High-sugar High-fat Diet Induced Metabolic Syndrome Shows some Symptoms of Alzheimer's Disease in Rats.
Insulin Resistance
A single-nucleotide polymorphism in the p110beta gene promoter is associated with partial protection from insulin resistance in severely obese adolescents.
Insulin Resistance
Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.
Insulin Resistance
Adipose tissue insulin sensitivity and macrophage recruitment: Does PI3K pick the pathway?
Insulin Resistance
Alterations in insulin-induced postreceptor signaling in adipocytes of the Otsuka Long-Evans Tokushima fatty rat strain.
Insulin Resistance
Anaesthesia generates neuronal insulin resistance by inducing hypothermia.
Insulin Resistance
Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling.
Insulin Resistance
Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a Cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children.
Insulin Resistance
Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome.
Insulin Resistance
Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice.
Insulin Resistance
Association of the polymorphisms in the 5'-untranslated region of PTEN gene with type 2 diabetes in a Japanese population.
Insulin Resistance
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Insulin Resistance
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Insulin Resistance
Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats.
Insulin Resistance
Calorie restriction increases the ratio of phosphatidylinositol 3-kinase catalytic to regulatory subunits in rat skeletal muscle.
Insulin Resistance
Calorie Restriction-Induced Increase in Skeletal Muscle Insulin Sensitivity Is Not Prevented by Overexpression of the p55? Subunit of Phosphoinositide 3-Kinase.
Insulin Resistance
Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver.
Insulin Resistance
Chronic 17beta-estradiol treatment improves skeletal muscle insulin signaling pathway components in insulin resistance associated with aging.
Insulin Resistance
Chronic hyperinsulinism induced down-regulation of insulin post-receptor signaling transduction in Hep G2 cells.
Insulin Resistance
Commentary on Essential roles of PI(3)K-p110beta in cell growth, metabolism, and tumorigenesis Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Insulin Resistance
Comparison of insulin signaling gene expression in insulin sensitive tissues between cats and dogs.
Insulin Resistance
Decreased gene expression of insulin signaling genes in insulin sensitive tissues of obese cats.
Insulin Resistance
Defect in long-term activation of phosphatidylinositol 3-kinase by insulin in vivo: studies in insulin-resistant hHTg rats.
Insulin Resistance
Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.
Insulin Resistance
Diet-induced obesity alters signalling pathways and induces atrophy and apoptosis in skeletal muscle in a prediabetic rat model.
Insulin Resistance
Dietary chokeberry and dried jujube fruit attenuates high-fat and high-fructose diet-induced dyslipidemia and insulin resistance via activation of the IRS-1/PI3K/Akt pathway in C57BL/6?J mice.
Insulin Resistance
Different subcellular distribution and regulation of expression of insulin receptor substrate (IRS)-3 from those of IRS-1 and IRS-2.
Insulin Resistance
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
Insulin Resistance
Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase.
Insulin Resistance
Early growth response gene-1 expression in vascular smooth muscle cells effects of insulin and oxidant stress.
Insulin Resistance
Effect of sidt2 Gene on Cell Insulin Resistance and Its Molecular Mechanism.
Insulin Resistance
Effects of Aerobic Exercise Combined with Panaxatriol Derived from Ginseng on Insulin Resistance and Skeletal Muscle Mass in Type 2 Diabetic Mice.
Insulin Resistance
Effects of contractile activity on tyrosine phosphoproteins and PI 3-kinase activity in rat skeletal muscle.
Insulin Resistance
Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity.
Insulin Resistance
Effects of Insulin on the Vasculature.
Insulin Resistance
Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior.
Insulin Resistance
Elevated basal PI 3-kinase activity and reduced insulin signaling in sucrose-induced hepatic insulin resistance.
Insulin Resistance
Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets.
Insulin Resistance
Energy balancing by fat Pik3ca.
Insulin Resistance
Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats.
Insulin Resistance
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Insulin Resistance
Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation.
Insulin Resistance
Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion.
Insulin Resistance
Exercise training prevents maturation-induced decreases in insulin receptor substrate-1 and phosphatidylinositol 3-kinase in rat skeletal muscle.
Insulin Resistance
Exposure to maternal obesity during suckling outweighs in utero exposure in programming for post-weaning adiposity and insulin resistance in rats.
Insulin Resistance
Fatty acid induced insulin resistance in rat-1 fibroblasts overexpressing human insulin receptors: impaired insulin-stimulated mitogen-activated protein kinase activity.
Insulin Resistance
Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda /zeta but not on glycogen synthase kinase-3.
Insulin Resistance
Gene expression of insulin signal-transduction pathway intermediates is lower in rats fed a beef tallow diet than in rats fed a safflower oil diet.
Insulin Resistance
Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle.
Insulin Resistance
Glucose Transporters in Diabetic Kidney Disease-Friends or Foes?
Insulin Resistance
Glucose-induced insulin resistance of phosphatidylinositol 3'-OH kinase and AKT/PKB is mediated by the hexosamine biosynthesis pathway.
Insulin Resistance
Green tea polyphenol extract regulates the expression of genes involved in glucose uptake and insulin signaling in rats fed a high fructose diet.
Insulin Resistance
Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes.
Insulin Resistance
Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.
Insulin Resistance
High-fat diet and leptin treatment alter skeletal muscle insulin-stimulated phosphatidylinositol 3-kinase activity and glucose transport.
Insulin Resistance
Human target validation of phosphoinositide 3-kinase (PI3K)?; effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K? inhibitor.
Insulin Resistance
Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver.
Insulin Resistance
Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.
Insulin Resistance
Impact of rs361072 in the phosphoinositide 3-kinase p110beta gene on whole-body glucose metabolism and subunit protein expression in skeletal muscle.
Insulin Resistance
Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance.
Insulin Resistance
Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients.
Insulin Resistance
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
Insulin Resistance
Improvement of insulin sensitivity in obese Zucker rats by myricetin extracted from Abelmoschus moschatus.
Insulin Resistance
In obese and non-obese adults, the cis-regulatory rs361072 promoter variant of PIK3CB is associated with insulin resistance not with type 2 diabetes.
Insulin Resistance
In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity.
Insulin Resistance
In vivo administration of glucosamine inhibited phosphatidylinositol 3-kinase activity without affecting tyrosine phosphorylation of the insulin receptor or insulin receptor substrate in rat adipocytes.
Insulin Resistance
In vivo insulin signaling through PI3-kinase is impaired in skeletal muscle of adult rat offspring exposed to ethanol in utero.
Insulin Resistance
In vivo knockdown of p85alpha with an antisense oligonucleotide improves insulin sensitivity in Lep(ob/ob) and diet-induced obese mice.
Insulin Resistance
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.
Insulin Resistance
Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.
Insulin Resistance
Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle.
Insulin Resistance
Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess.
Insulin Resistance
Influence and related mechanism of Retn gene expression on glucose uptake in 3T3-L1 cells.
Insulin Resistance
Inhibition of endogenous SHIP2 ameliorates insulin resistance caused by chronic insulin treatment in 3T3-L1 adipocytes.
Insulin Resistance
Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle.
Insulin Resistance
Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways.
Insulin Resistance
Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells.
Insulin Resistance
Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport.
Insulin Resistance
Insulin regulation of sterol regulatory element-binding protein-1 expression in L-6 muscle cells and 3T3 L1 adipocytes.
Insulin Resistance
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Insulin Resistance
Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.
Insulin Resistance
Insulin resistance in fat cells from obese Zucker rats--evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4.
Insulin Resistance
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Insulin Resistance
Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Insulin Resistance
Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH.
Insulin Resistance
Insulin Resistance: Pathophysiology and Rationale for Treatment.
Insulin Resistance
Insulin signal transduction and glucose transport in human adipocytes: effects of obesity and low calorie diet.
Insulin Resistance
Insulin signal transduction by a mutant human insulin receptor lacking the NPEY sequence. Evidence for an alternate mitogenic signaling pathway that is independent of Shc phosphorylation.
Insulin Resistance
Insulin signaling and life span.
Insulin Resistance
Insulin signaling stimulates insulin transport by bovine aortic endothelial cells.
Insulin Resistance
Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats.
Insulin Resistance
Latent Inflammation and Insulin Resistance in Adipose Tissue.
Insulin Resistance
LBP-4a improves insulin resistance via translocation and activation of GLUT4 in OLETF rats.
Insulin Resistance
Lipid phosphatases as drug discovery targets for type 2 diabetes.
Insulin Resistance
Lipopolysaccharide impairs insulin sensitivity via activation of phosphoinositide 3-kinase in adipocytes.
Insulin Resistance
Long-term denervation impairs insulin receptor substrate-1-mediated insulin signaling in skeletal muscle.
Insulin Resistance
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.
Insulin Resistance
Maternal protein restriction affects postnatal growth and the expression of key proteins involved in lifespan regulation in mice.
Insulin Resistance
Mediation of beta-endorphin in exercise-induced improvement in insulin resistance in obese Zucker rats.
Insulin Resistance
Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus.
Insulin Resistance
Modulation of human insulin receptor substrate-1 tyrosine phosphorylation by protein kinase Cdelta.
Insulin Resistance
Molecular mechanisms of insulin action in normal and insulin-resistant states.
Insulin Resistance
Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats.
Insulin Resistance
Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity.
Insulin Resistance
Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta.
Insulin Resistance
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Insulin Resistance
Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: Influence of insulin resistance and oxidative stress.
Insulin Resistance
NO-Dependent Akt Inactivation by S-Nitrosylation as a Possible Mechanism of STZ-Induced Neuronal Insulin Resistance.
Insulin Resistance
Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR.
Insulin Resistance
Novel PIK3R1 mutation of SHORT syndrome: A case report with a 6-month follow up.
Insulin Resistance
Nutrient sensing in the mTOR/S6K1 signalling pathway.
Insulin Resistance
Nutritional upregulation of p85alpha expression is an early molecular manifestation of insulin resistance.
Insulin Resistance
Obesity, insulin resistance and hepatic perfusion.
Insulin Resistance
Oleate protects against palmitate-induced insulin resistance in L6 myotubes.
Insulin Resistance
Opioid ?-receptors as new target for insulin resistance.
Insulin Resistance
Overfeeding During Lactation in Rats is Associated with Cardiovascular Insulin Resistance in the Short-Term.
Insulin Resistance
Oxidative stress impairs insulin but not platelet-derived growth factor signalling in 3T3-L1 adipocytes.
Insulin Resistance
Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase.
Insulin Resistance
p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity.
Insulin Resistance
Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.
Insulin Resistance
Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population.
Insulin Resistance
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
Insulin Resistance
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.
Insulin Resistance
Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles.
Insulin Resistance
PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice.
Insulin Resistance
PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.
Insulin Resistance
Polymorphism in postinsulin receptor signaling pathway is not associated with polycystic ovary syndrome.
Insulin Resistance
Post-receptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.
Insulin Resistance
Postreceptor crosstalk on PI3K/Akt between GH and insulin in non-catch-up growth rats born small for gestational age.
Insulin Resistance
Preoperative feeding does not reverse postoperative insulin resistance in skeletal muscle in the rat.
Insulin Resistance
Progesterone inhibits glucose uptake by affecting diverse steps of insulin signaling in 3T3-L1 adipocytes.
Insulin Resistance
Programming of central and peripheral insulin resistance by low birthweight and postnatal catch-up growth in male mice.
Insulin Resistance
Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in finnish subjects.
Insulin Resistance
Propranolol Improves Impaired Hepatic PI3K/Akt Signaling Post Burn Injury.
Insulin Resistance
Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes.
Insulin Resistance
Reduction of PTP1B induces differential expression of PI3-kinase (p85alpha) isoforms.
Insulin Resistance
Regulation of insulin receptor substrate-2 tyrosine phosphorylation in animal models of insulin resistance.
Insulin Resistance
Regulation of IRS-2 tyrosine phosphorylation in fasting and diabetes.
Insulin Resistance
Regulation of phosphatidylinositol 3-kinase by insulin in rat skeletal muscle.
Insulin Resistance
Rescuing 3T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of rapamycin/p70 S6 kinase (S6K1) pathway and serine phosphorylation of insulin receptor substrate-1: effect of reduced expression of p85alpha subunit of phosphatidylinositol 3-kinase and S6K1 kinase.
Insulin Resistance
Role of the liver in glucose homeostasis in PI 3-kinase p85alpha-deficient mice.
Insulin Resistance
Skeletal muscle insulin resistance after trauma: insulin signaling and glucose transport.
Insulin Resistance
Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation.
Insulin Resistance
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
Insulin Resistance
Studies of variability in the PTEN gene among Danish caucasian patients with Type II diabetes mellitus.
Insulin Resistance
The beneficial effects of N-acetyl cysteine (NAC) against obesity associated complications: A systematic review of pre-clinical studies.
Insulin Resistance
The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage.
Insulin Resistance
The mechanism of insulin-induced signal transduction mediated by the insulin receptor substrate family.
Insulin Resistance
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.
Insulin Resistance
The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.
Insulin Resistance
The Redox Regulation of PI 3-Kinase-Dependent Signaling.
Insulin Resistance
The silent PPARgamma exon 6 CAC(His) --> CAT(His) polymorphism does not affect the plasma leptin levels in a collective of first degree relatives of type 2 diabetes patients from South West Germany.
Insulin Resistance
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Insulin Resistance
TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells.
Insulin Resistance
Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor.
Insulin Resistance
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Insulin Resistance
Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.
Insulin Resistance
[Effect of chronic ethanol intake on insulin receptor, insulin receptor subsrate-1 and phosphoinositide 3-kinase mRNA expression in skeletal muscle of rats]
Insulin Resistance
[Induction of insulin resistance induced by PI-3K inhibitor in porcine granulosa cells]
Insulinoma
Essential role of phosphoinositide 3-kinase in leptin-induced K(ATP) channel activation in the rat CRI-G1 insulinoma cell line.
Insulinoma
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Intellectual Disability
Germline pathogenic variant in PIK3CA leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay.
Intellectual Disability
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Intestinal Neoplasms
Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.
Intestinal Neoplasms
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Ischemic Stroke
Neuroprotective mechanisms of miR-124 activating PI3K/Akt signaling pathway in ischemic stroke.
Keratoconus
Modeling Keratoconus Using Induced Pluripotent Stem Cells.
Keratosis
FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.
Keratosis
FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Keratosis
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Keratosis
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Keratosis
Somatic FGFR3 and PIK3CA mutations are present in familial seborrhoeic keratoses.
Keratosis
Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?
Keratosis, Actinic
Review of the European Society for Photodynamic Therapy (Euro-PDT) Annual Congress 2020.
Keratosis, Seborrheic
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Keratosis, Seborrheic
Two cases of seborrheic keratosis of the external ear canal: involvement of PIK3CA and FGFR3 genes.
Ketosis
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Kidney Neoplasms
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.
Kidney Neoplasms
Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.
Kidney Neoplasms
Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions.
Kidney Neoplasms
Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.
Kidney Neoplasms
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
Kidney Neoplasms
Molecular imaging of phosphorylation events for drug development.
Kidney Neoplasms
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Kidney Neoplasms
Regulation of PI 3-K, PTEN, p53, and mTOR in Malignant and Benign Tumors Deficient in Tuberin.
Kidney Neoplasms
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
Kidney Neoplasms
Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations.
Klippel-Trenaunay-Weber Syndrome
A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome.
Klippel-Trenaunay-Weber Syndrome
Klippel-Trenaunay Syndrome.
Klippel-Trenaunay-Weber Syndrome
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Klippel-Trenaunay-Weber Syndrome
Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
Klippel-Trenaunay-Weber Syndrome
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
Klippel-Trenaunay-Weber Syndrome
Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
Klippel-Trenaunay-Weber Syndrome
[PIK3CA-related overgrowth syndrome (PROS)].
Laryngeal Neoplasms
New miRNA expression abnormalities in laryngeal squamous cell carcinoma.
Laryngeal Neoplasms
Over-expression of MEOX2 promotes apoptosis through inhibiting the PI3K/Akt pathway in laryngeal cancer cells.
Leiomyoma
Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of ?-catenin and of signaling interactions.
Leiomyosarcoma
Differential Expression of IRS-1 and IRS-2 in Uterine Leiomyosarcomas with Distinct Oncogenic Phenotypes: Lack of Correlation with Downstream Signaling Events.
Leiomyosarcoma
The Phosphatidylinositol 3' Kinase-Akt-mammalian Target of Rapamycin Pathway in Smooth Muscle Tumors of the Uterus: Selected Protein Expression Patterns and Their Clinicopathologic Implications.
Lentigo
FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.
Lentigo
FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Lentigo
The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo.
Leukemia
A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.
Leukemia
A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
Leukemia
Association of the Src homology 2 domain-containing leukocyte phosphoprotein of 76 kD (SLP-76) with the p85 subunit of phosphoinositide 3-kinase.
Leukemia
BCR/ABL regulation of PI-3 kinase activity.
Leukemia
Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.
Leukemia
Calming down T cell acute leukemia.
Leukemia
Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates.
Leukemia
Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.
Leukemia
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Leukemia
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Leukemia
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.
Leukemia
H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells.
Leukemia
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Leukemia
Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway.
Leukemia
Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Leukemia
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Leukemia
Leukemia inhibitory factor promotes olfactory sensory neuronal survival via phosphoinositide 3-kinase pathway activation and Bcl-2.
Leukemia
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
Leukemia
PI 3-K signaling pathway suppresses PMA-induced expression of p21WAF1/Cip1 in human leukemia cells.
Leukemia
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Leukemia
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Leukemia
Rac and phosphatidylinositol 3-kinase regulate the protein kinase B in Fc epsilon RI signaling in RBL 2H3 mast cells.
Leukemia
Rac is required for v-Abl tyrosine kinase to activate mitogenesis.
Leukemia
Reprogramming of the Epigenome by MLL1 Links Early-Life Environmental Exposures to Prostate Cancer Risk.
Leukemia
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Leukemia
RKTG overexpression inhibits proliferation and induces apoptosis of human leukemia cells via suppression of the ERK and PI3K/AKT signaling pathways.
Leukemia
Side-chain modified vitamin D analogs require activation of both PI 3-K and erk1,2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells.
Leukemia
Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Leukemia
Silencing the PIK3CA Gene Enhances the Sensitivity of Childhood Leukemia Cells to Chemotherapy Drugs by Suppressing the Phosphorylation of Akt.
Leukemia
TAPP2 links phosphoinositide 3-kinase signaling to B cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B cell leukemia.
Leukemia
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
Leukemia
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Leukemia
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
Leukemia
The Phosphoinositide 3-Kinase p110? Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
Leukemia
The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells.
Leukemia
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Leukemia
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Leukemia
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Leukemia, B-Cell
Silencing the PIK3CA Gene Enhances the Sensitivity of Childhood Leukemia Cells to Chemotherapy Drugs by Suppressing the Phosphorylation of Akt.
Leukemia, B-Cell
TAPP2 links phosphoinositide 3-kinase signaling to B cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B cell leukemia.
Leukemia, Erythroblastic, Acute
Protein kinase C delta specifically associates with phosphatidylinositol 3-kinase following cytokine stimulation.
Leukemia, Erythroblastic, Acute
Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease.
Leukemia, Erythroblastic, Acute
The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis.
Leukemia, Lymphocytic, Chronic, B-Cell
Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
Leukemia, Lymphocytic, Chronic, B-Cell
Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
How I Manage CLL with Venetoclax-Based Treatments.
Leukemia, Lymphocytic, Chronic, B-Cell
Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Leukemia, Lymphocytic, Chronic, B-Cell
PI3-kinase inhibitors in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.
Leukemia, Lymphocytic, Chronic, B-Cell
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation.
Leukemia, Lymphocytic, Chronic, B-Cell
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101).
Leukemia, Lymphoid
Dynamics of the Phosphoinositide 3-Kinase p110? Interaction with p85? and Membranes Reveals Aspects of Regulation Distinct from p110?.
Leukemia, Lymphoid
The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Leukemia, Myeloid
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.
Leukemia, Myeloid, Acute
Arsenic Disulfide Synergizes with the Phosphoinositide 3-Kinase Inhibitor PI-103 to Eradicate Acute Myeloid Leukemia Stem Cells by Inducing Differentiation.
Leukemia, Myeloid, Acute
Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3K? inhibitor: Design, synthesis and biological evaluation.
Leukemia, Myeloid, Acute
Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations.
Leukemia, Myeloid, Acute
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
Leukemia, Myeloid, Acute
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Leukemia, Myeloid, Acute
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.
Leukemia, Myeloid, Acute
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Leukemia, Myeloid, Acute
Nuclear inositol lipid metabolism: more than just second messenger generation?
Leukemia, Myeloid, Acute
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Leukemia, Myeloid, Acute
Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring.
Leukemia, Myeloid, Acute
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry.
Leukemia, Myeloid, Acute
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
Leukemia, Promyelocytic, Acute
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Leukemia, Promyelocytic, Acute
Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Leukemia, T-Cell
H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells.
Leukemia-Lymphoma, Adult T-Cell
Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL).
Leukemia-Lymphoma, Adult T-Cell
HTLV-I Tax regulates the cellular proliferation through the down-regulation of PIP3-phosphatase expressions via the NF-?B pathway.
Leukemia-Lymphoma, Adult T-Cell
Human T-cell leukemia virus type I tax down-regulates the expression of phosphatidylinositol 3,4,5-trisphosphate inositol phosphatases via the NF-kappaB pathway.
Leukocytosis
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Leukoencephalopathies
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Lichen Planus
FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Lichen Planus, Oral
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Lipoblastoma
Lipoblastoma phenotype contains a somatic PIK3CA mutation.
Lipodystrophy
SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
Lipodystrophy
Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy.
Lipodystrophy
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Lipoma
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Lipoma
PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth.
Lipoma
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Lipoma
Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma.
Lipomatosis
Clinical and Molecular Investigation of Familial Multiple Lipomatosis: Variants in the HMGA2 Gene.
Lipomatosis
Congenital infiltrating lipomatosis of the face with lingual mucosal neuromas associated with a PIK3CA mutation.
Lipomatosis
Facial Infiltrating Lipomatosis Contains Somatic PIK3CA Mutations in Multiple Tissues.
Lipomatosis
PIK3CA activating mutations in facial infiltrating lipomatosis.
Lipomatosis
PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth.
Lipomatosis
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Lipomatosis
Somatic mosaicism for the p.His1047Arg mutation in PIK3CA in a girl with mesenteric lipomatosis.
Lipomatosis
Somatic PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis.
Lipomatosis
[PIK3CA-related overgrowth syndrome (PROS)].
Liposarcoma
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Liposarcoma
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Liposarcoma
Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Liposarcoma
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
Liposarcoma
Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma.
Liposarcoma, Myxoid
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Liposarcoma, Myxoid
Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.
Liposarcoma, Myxoid
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
Liver Cirrhosis
Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway.
Liver Cirrhosis
Phosphoinositide 3-kinase gamma inhibitor ameliorates concanavalin A-induced hepatic injury in mice.
Liver Cirrhosis
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Liver Diseases
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Liver Diseases
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Liver Neoplasms
Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Liver Neoplasms
Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Liver Neoplasms
Hematopoietic-substrate-1 associated protein X-1 (HAX-1) regulates liver cancer cells growth, metastasis, and angiogenesis through Akt.
Liver Neoplasms
Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid.
Liver Neoplasms
MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling.
Liver Neoplasms
Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.
Liver Neoplasms
Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3?/?-catenin signalling.
Liver Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Liver Neoplasms
The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers.
Liver Neoplasms
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
Liver Neoplasms
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Long QT Syndrome
Acquired long QT syndrome and phosphoinositide 3-kinase.
Long QT Syndrome
Increased Late Sodium Current Contributes to the Electrophysiological Effects of Chronic, but Not Acute, Dofetilide Administration.
Long QT Syndrome
Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome.
Lung Diseases
Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
Lung Diseases
Oxidative Imbalance as a Crucial Factor in Inflammatory Lung Diseases: Could Antioxidant Treatment Constitute a New Therapeutic Strategy?
Lung Diseases
Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
Lung Diseases
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Lung Injury
Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.
Lung Injury
Phosphoinositide-3 kinase {gamma} required for LPS-induced transepithelial neutrophil trafficking in the lung.
Lung Neoplasms
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Lung Neoplasms
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Lung Neoplasms
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
Lung Neoplasms
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
Lung Neoplasms
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Lung Neoplasms
Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
Lung Neoplasms
Activation of Akt involves resistance to NF-?B inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells.
Lung Neoplasms
Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer.
Lung Neoplasms
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Lung Neoplasms
Anticancer activity of 2'-hydroxyflavanone towards lung cancer.
Lung Neoplasms
Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line.
Lung Neoplasms
Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Lung Neoplasms
Asymmetric real-time PCR and multiplex melting curve analysis with TaqMan probes for detecting PIK3CA mutations.
Lung Neoplasms
Bauerane Induces S-Phase Cell Cycle Arrest, Apoptosis, and Inhibition of Proliferation of A549 Human Lung Cancer Cells Through the Phosphoinositide 3-Kinase (PI3K)/AKT and Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway.
Lung Neoplasms
Bcl-X(L) and STAT3 mediate malignant actions of gamma-irradiation in lung cancer cells.
Lung Neoplasms
BYL719, a selective inhibitor of phosphoinositide 3-Kinase ?, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Lung Neoplasms
Cancer genes in lung cancer: racial disparities: are there any?
Lung Neoplasms
Catalog of Lung Cancer Gene Mutations Among Chinese Patients.
Lung Neoplasms
Chromosomal and genomic changes in lung cancer.
Lung Neoplasms
Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer.
Lung Neoplasms
Clinical perspective of afatinib in non-small cell lung cancer.
Lung Neoplasms
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Lung Neoplasms
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Lung Neoplasms
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers.
Lung Neoplasms
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Lung Neoplasms
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.
Lung Neoplasms
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Lung Neoplasms
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Lung Neoplasms
Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Lung Neoplasms
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Lung Neoplasms
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI 3-kinase in KRAS mutant lung cancer.
Lung Neoplasms
Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis.
Lung Neoplasms
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Lung Neoplasms
Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling.
Lung Neoplasms
Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer.
Lung Neoplasms
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Lung Neoplasms
Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer.
Lung Neoplasms
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Lung Neoplasms
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Lung Neoplasms
ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase.
Lung Neoplasms
Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
Lung Neoplasms
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Lung Neoplasms
Effects of Collagen IV on Cisplatin-Induced Apoptosis of Non-Small Cell Lung Cancer Cells.
Lung Neoplasms
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.
Lung Neoplasms
EMT twists the road to PI3K.
Lung Neoplasms
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation.
Lung Neoplasms
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Lung Neoplasms
Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.
Lung Neoplasms
Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer.
Lung Neoplasms
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Lung Neoplasms
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Lung Neoplasms
Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.
Lung Neoplasms
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
Lung Neoplasms
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
Lung Neoplasms
Identification of lung cancer oncogenes based on the mRNA expression and single nucleotide polymorphism profile data.
Lung Neoplasms
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Lung Neoplasms
Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas.
Lung Neoplasms
Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.
Lung Neoplasms
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.
Lung Neoplasms
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Lung Neoplasms
Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
Lung Neoplasms
Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer.
Lung Neoplasms
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Lung Neoplasms
Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
Lung Neoplasms
Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
Lung Neoplasms
Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.
Lung Neoplasms
Interferon-? signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.
Lung Neoplasms
Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients.
Lung Neoplasms
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Lung Neoplasms
LY294002, an inhibitor of PI-3K, enhances heat sensitivity independently of p53 status in human lung cancer cells.
Lung Neoplasms
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
Lung Neoplasms
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases.
Lung Neoplasms
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer.
Lung Neoplasms
MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer.
Lung Neoplasms
miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition.
Lung Neoplasms
MiR-486-5p Serves as a Good Biomarker in Nonsmall Cell Lung Cancer and Suppresses Cell Growth With the Involvement of a Target PIK3R1.
Lung Neoplasms
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Lung Neoplasms
Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Lung Neoplasms
Molecular profiling of non-small cell lung cancer.
Lung Neoplasms
Molecular spectrum of PIK3CA gene mutations in patients with nonsmall-cell lung cancer in Turkey.
Lung Neoplasms
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer.
Lung Neoplasms
Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
Lung Neoplasms
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Lung Neoplasms
Multiplexed assays for detection of mutations in PIK3CA.
Lung Neoplasms
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
Lung Neoplasms
Mutationally Activated PIK3CAH1047R Cooperates With BRAFV600E In Lung Cancer Progression.
Lung Neoplasms
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Lung Neoplasms
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Lung Neoplasms
Next?generation sequencing?based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her?2 and TP53 mutations in patients with non?small cell lung cancer.
Lung Neoplasms
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
Lung Neoplasms
No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
Lung Neoplasms
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Lung Neoplasms
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Lung Neoplasms
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Lung Neoplasms
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Lung Neoplasms
Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells.
Lung Neoplasms
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Lung Neoplasms
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Lung Neoplasms
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Lung Neoplasms
Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt.
Lung Neoplasms
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Lung Neoplasms
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Lung Neoplasms
PI3K expression predicts overall survival in lung adenocarcinoma.
Lung Neoplasms
PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[?]indene Derivative in Lung Cancer Cells.
Lung Neoplasms
PIK3CA gene amplification in Japanese non-small cell lung cancer.
Lung Neoplasms
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Lung Neoplasms
PIK3CA mutation and amplification in human lung cancer.
Lung Neoplasms
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Lung Neoplasms
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Lung Neoplasms
PIK3CA mutation status in Japanese lung cancer patients.
Lung Neoplasms
PIK3CA mutations and copy number gains in human lung cancers.
Lung Neoplasms
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
Lung Neoplasms
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
Lung Neoplasms
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Lung Neoplasms
PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Lung Neoplasms
PIK3CA Mutations in Resected Small Cell Lung Cancer.
Lung Neoplasms
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Lung Neoplasms
Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis.
Lung Neoplasms
Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.
Lung Neoplasms
Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Lung Neoplasms
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Lung Neoplasms
Prognostic significance of phosphoinositide 3-kinase p110? and p110? isoforms in non-small cell lung cancer.
Lung Neoplasms
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
Lung Neoplasms
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Lung Neoplasms
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Lung Neoplasms
Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR.
Lung Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Lung Neoplasms
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Lung Neoplasms
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Lung Neoplasms
Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips.
Lung Neoplasms
Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.
Lung Neoplasms
Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
Lung Neoplasms
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Lung Neoplasms
Targeted therapies in development for non-small cell lung cancer.
Lung Neoplasms
Targeting mTOR signaling in lung cancer.
Lung Neoplasms
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Lung Neoplasms
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Lung Neoplasms
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Lung Neoplasms
Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
Lung Neoplasms
The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells.
Lung Neoplasms
The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA.
Lung Neoplasms
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Lung Neoplasms
The fibronectin EDA splicing variant induces epithelial-mesenchymal transition in lung cancer cells through integrin {alpha}9{beta}1-mediated activation of PI3-K and Erk.
Lung Neoplasms
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Lung Neoplasms
The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer.
Lung Neoplasms
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Lung Neoplasms
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.
Lung Neoplasms
The Proto-oncogene PKC? regulates the alternative splicing of Bcl-x pre-mRNA.
Lung Neoplasms
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
Lung Neoplasms
Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.
Lung Neoplasms
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
Lung Neoplasms
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer.
Lung Neoplasms
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Lung Neoplasms
Tripchlorolide induces autophagy in lung cancer cells by inhibiting the PI3K/AKT/mTOR pathway and improves cisplatin sensitivity in A549/DDP cells.
Lung Neoplasms
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Lung Neoplasms
[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
Lung Neoplasms
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
Lung Neoplasms
[Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
Lupus Erythematosus, Systemic
Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion.
Lupus Erythematosus, Systemic
Enhanced Phosphoinositide 3-Kinase {delta} Activity Is a Frequent Event in Systemic Lupus Erythematosus That Confers Resistance to Activation-Induced T Cell Death.
Lupus Erythematosus, Systemic
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
Lymphadenopathy
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Lymphadenopathy
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase ? syndrome 2: A cohort study.
Lymphadenopathy
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Lymphadenopathy
Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.
Lymphadenopathy
Effective "activated PI3K? syndrome"-targeted therapy with the PI3K? inhibitor leniolisib.
Lymphadenopathy
Exhaustion of the CD8
Lymphadenopathy
Genetic Defects in Phosphoinositide 3-Kinase ? Influence CD8+ T Cell Survival, Differentiation, and Function.
Lymphadenopathy
Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.
Lymphadenopathy
PI3K? and primary immunodeficiencies.
Lymphadenopathy
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Lymphadenopathy
The Treatment of Activated PI3K? Syndrome.
Lymphangioma
A Child With Lymphangioma Due to Somatic Mutation in PIK3CA Successfully Treated With Everolimus.
Lymphangioma
Enlarging cystic lymphangioma of the mediastinum in an adult: is this a neoplastic lesion related to the recently discovered PIK3CA mutation?
Lymphangioma, Cystic
Enlarging cystic lymphangioma of the mediastinum in an adult: is this a neoplastic lesion related to the recently discovered PIK3CA mutation?
Lymphatic Metastasis
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Lymphatic Metastasis
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Lymphatic Metastasis
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Lymphatic Metastasis
Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Lymphatic Metastasis
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Lymphatic Metastasis
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Lymphatic Metastasis
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Lymphatic Metastasis
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
Lymphatic Metastasis
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Lymphatic Metastasis
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Lymphatic Metastasis
Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
Lymphatic Metastasis
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
Lymphatic Metastasis
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Lymphatic Metastasis
Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.
Lymphatic Metastasis
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
Lymphatic Metastasis
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Lymphatic Metastasis
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Lymphatic Metastasis
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
Lymphatic Metastasis
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
Lymphatic Metastasis
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
Lymphatic Metastasis
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Lymphatic Metastasis
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Lymphatic Metastasis
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
Lymphatic Metastasis
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Lymphatic Metastasis
Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.
Lymphatic Metastasis
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Lymphatic Metastasis
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Lymphatic Metastasis
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Lymphocytosis
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Lymphoma
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.
Lymphoma
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
Lymphoma
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma
Calming down T cell acute leukemia.
Lymphoma
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-? Syndrome 2 in an Adult Patient.
Lymphoma
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Lymphoma
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Lymphoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Lymphoma
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Lymphoma
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Lymphoma
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Lymphoma
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Lymphoma
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.
Lymphoma
High co-expression of PD-L1 and HIF-1? correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Lymphoma
Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor.
Lymphoma
Identification of Top-ranked Proteins within a Directional Protein Interaction Network using the PageRank Algorithm: Applications in Humans and Plants.
Lymphoma
Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Lymphoma
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Lymphoma
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Lymphoma
Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.
Lymphoma
MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis.
Lymphoma
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Lymphoma
Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
Lymphoma
Novel Therapeutic Targets in Non-small Cell Lung Cancer.
Lymphoma
Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis.
Lymphoma
p110delta is required for innate immunity to transplantable lymphomas.
Lymphoma
Pharmacotherapeutic Management of Pediatric Lymphoma.
Lymphoma
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Lymphoma
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Lymphoma
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.
Lymphoma
Phosphoinositide 3-kinase inhibitors in lymphoma.
Lymphoma
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
Lymphoma
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Lymphoma
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/? in relapsed refractory B cell lymphoma.
Lymphoma
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Lymphoma
Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells.
Lymphoma
Propofol mediates signal transducer and activator of transcription 3 activation and crosstalk with phosphoinositide 3-kinase/AKT.
Lymphoma
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line.
Lymphoma
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Lymphoma
Regulation of phosphoinositide 3-kinase signaling by oxidants: hydrogen peroxide selectively enhances immunoreceptor-induced recruitment of phosphatidylinositol (3,4) bisphosphate-binding PH domain proteins.
Lymphoma
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Lymphoma
SHC014748M, a novel selective inhi-bitor of PI3K?, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Lymphoma
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
Lymphoma
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Lymphoma
Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of ?-catenin and of signaling interactions.
Lymphoma
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
Lymphoma
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Lymphoma
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Lymphoma
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
Lymphoma
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
Lymphoma
The genetic landscape of mutations in Burkitt lymphoma.
Lymphoma
The role of microRNA-150 as a tumor suppressor in malignant lymphoma.
Lymphoma
The Role of PI3K Inhibition in Lymphoid Malignancies.
Lymphoma
Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.
Lymphoma, B-Cell
8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549?cells.
Lymphoma, B-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma, B-Cell
CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.
Lymphoma, B-Cell
Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 Silencing
Lymphoma, B-Cell
Cinobufagin Induces Cell Cycle Arrest at the G2/M Phase and Promotes Apoptosis in Malignant Melanoma Cells.
Lymphoma, B-Cell
Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro.
Lymphoma, B-Cell
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Lymphoma, B-Cell
Effect of apigenin on apoptosis induced by renal ischemia/reperfusion injury in vivo and in vitro.
Lymphoma, B-Cell
Germacrone protects against oxygen-glucose deprivation/reperfusion injury by inhibiting autophagy processes in PC12 cells.
Lymphoma, B-Cell
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Lymphoma, B-Cell
Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.
Lymphoma, B-Cell
MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis.
Lymphoma, B-Cell
MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway.
Lymphoma, B-Cell
MicroRNA-146b induces the PI3K/Akt/NF-?B signaling pathway to reduce vascular inflammation and apoptosis in myocardial infarction by targeting PTEN.
Lymphoma, B-Cell
miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Lymphoma, B-Cell
Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
Lymphoma, B-Cell
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Lymphoma, B-Cell
Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase ? syndrome.
Lymphoma, B-Cell
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Lymphoma, B-Cell
PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma.
Lymphoma, B-Cell
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
Lymphoma, B-Cell
PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
Lymphoma, B-Cell
Propofol mediates signal transducer and activator of transcription 3 activation and crosstalk with phosphoinositide 3-kinase/AKT.
Lymphoma, B-Cell
PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis.
Lymphoma, B-Cell
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line.
Lymphoma, B-Cell
Rapid Eye Movement Sleep Deprivation Combined With Fluoxetine Protects Against Depression-Induced Damage and Apoptosis in Rat Hippocampi via A1 Adenosine Receptor.
Lymphoma, B-Cell
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Lymphoma, B-Cell
Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis.
Lymphoma, B-Cell
Triptolide induces DNA breaks, activates caspase-3-dependent apoptosis and sensitizes B-cell lymphoma to poly(ADP-ribose) polymerase 1 and phosphoinositide 3-kinase inhibitors.
Lymphoma, B-Cell, Marginal Zone
Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.
Lymphoma, Follicular
APRIL mediates follicular lymphoma B cell proliferation and cyclin D1 expression through PI3-kinase regulated mTOR activation.
Lymphoma, Large B-Cell, Diffuse
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma, Large B-Cell, Diffuse
Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
Lymphoma, Large B-Cell, Diffuse
PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Lymphoma, Large-Cell, Anaplastic
Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis.
Lymphoma, Large-Cell, Anaplastic
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Lymphoma, Mantle-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma, Mantle-Cell
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Lymphoma, Mantle-Cell
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.
Lymphoma, Non-Hodgkin
Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.
Lymphoma, Non-Hodgkin
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Lymphoma, Non-Hodgkin
Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Lymphoma, Non-Hodgkin
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Lymphoma, Primary Effusion
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Lymphoma, T-Cell
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Lymphoma, T-Cell, Cutaneous
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K ?/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Lymphopenia
A novel monoallelic gain of function mutation in p110? causing atypical activated phosphoinositide 3-kinase ? syndrome (APDS-1).
Lymphopenia
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Lymphoproliferative Disorders
Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase.
Lymphoproliferative Disorders
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Lymphoproliferative Disorders
Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.
Malformations of Cortical Development
PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
Mammary Neoplasms, Animal
Multiplex Gene Expression Profiling of 16 Target Genes in Neoplastic and Non-Neoplastic Canine Mammary Tissues Using Branched-DNA Assay.
Mania
Manic episode occurring during investigational treatment with pan-class I phosphoinositide 3-kinase inhibitor in a patient with breast cancer.
Measles
Measles virus induces expression of SIP110, a constitutively membrane clustered lipid phosphatase, which inhibits T cell proliferation.
Medulloblastoma
A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma.
Medulloblastoma
A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110{gamma} Isoform in Medulloblastoma Cell Proliferation and Chemoresistance.
Medulloblastoma
Childhood tumors of the nervous system as disorders of normal development.
Medulloblastoma
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Medulloblastoma
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Medulloblastoma
Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.
Medulloblastoma
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Medulloblastoma
Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
Medulloblastoma
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines.
Medulloblastoma
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Medulloblastoma
The Phosphoinositide 3-Kinase p110? Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
Megalencephaly
Caught in the AKT: identification of a de novo pathway in MCAP and MPPH and its therapeutic implications.
Megalencephaly
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Megalencephaly
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes.
Megalencephaly
Detection of a mosaic PIK3CA mutation in dental DNA from a child with megalencephaly capillary malformation syndrome.
Megalencephaly
Germline pathogenic variant in PIK3CA leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay.
Megalencephaly
Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
Megalencephaly
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Megalencephaly
Megalencephaly syndromes associated with mutations of core components of the PI3K-AKT-MTOR pathway: PIK3CA, PIK3R2, AKT3, and MTOR.
Megalencephaly
Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations.
Megalencephaly
Novel features of PIK3CA-Related Overgrowth Spectrum: Lesson from an aborted fetus presenting a de novo constitutional PIK3CA mutation.
Megalencephaly
PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
Megalencephaly
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Megalencephaly
Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway.
Megalencephaly
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Megalencephaly
[PIK3CA-related overgrowth syndrome (PROS)].
Melanoma
A Potent Inhibitor of Phosphoinositide 3-Kinase (PI3K) and Mitogen Activated Protein (MAP) Kinase Signalling, Quercetin (3, 3', 4', 5, 7-Pentahydroxyflavone) Promotes Cell Death in Ultraviolet (UV)-B-Irradiated B16F10 Melanoma Cells.
Melanoma
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Melanoma
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Melanoma
Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.
Melanoma
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Melanoma
Basic fibroblast growth factor-mediated overexpression of vascular endothelial growth factor in 1F6 human melanoma cells is regulated by activation of PI-3K and p38 MAPK.
Melanoma
Beyond BRAF in Melanoma.
Melanoma
BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation.
Melanoma
C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Melanoma
Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mTOR Pathways.
Melanoma
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
Melanoma
Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner.
Melanoma
Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
Melanoma
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Melanoma
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
Melanoma
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
Melanoma
Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
Melanoma
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Melanoma
Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
Melanoma
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Melanoma
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma.
Melanoma
Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses.
Melanoma
Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
Melanoma
Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.
Melanoma
Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Melanoma
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Melanoma
Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Melanoma
Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt.
Melanoma
Identification of the interaction network of hub genes for melanoma treated with vemurafenib based on microarray data.
Melanoma
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Melanoma
Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation.
Melanoma
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.
Melanoma
Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3-K, MKK4 and MKK7 in human melanoma.
Melanoma
KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Melanoma
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Melanoma
MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.
Melanoma
Molecular Profiling of Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma and Cutaneous Melanoma.
Melanoma
Multiplexed assays for detection of mutations in PIK3CA.
Melanoma
Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Melanoma
Mutations of PIK3CA are rare in cutaneous melanoma.
Melanoma
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma.
Melanoma
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.
Melanoma
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Melanoma
Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Melanoma
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Melanoma
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
Melanoma
PI3-kinase is involved in mitogenic signaling by the oncogenic receptor tyrosine kinase Xiphophorus melanoma receptor kinase in fish melanoma.
Melanoma
PI3-kinase subunits are infrequent somatic targets in melanoma.
Melanoma
PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion.
Melanoma
PIK3CA-Mutated Melanoma Cells Rely on Cooperative Signaling through mTORC1/2 for Sustained Proliferation.
Melanoma
Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method.
Melanoma
RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development.
Melanoma
Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy.
Melanoma
ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis.
Melanoma
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
Melanoma
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Melanoma
The Genetic Germline Background of Single and Multiple Primary Melanomas.
Melanoma
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.
Melanoma
The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer.
Melanoma
The Phosphoinositide 3-Kinase? Selective Inhibitor, BYL719, Enhances the Effect of the Protein Kinase C Inhibitor, AEB071, in GNAQ/GNA11 Mutant Uveal Melanoma Cells.
Melanoma
The role of phosphoinositide 3-kinase in the sorting and transport of newly synthesized tyrosinase-related protein-1 (TRP-1).
Melanoma
Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
Melanoma
Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma.
Melanoma
Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice.
Melanoma
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy.
Melanoma
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
Melanoma
[Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
Memory Disorders
Bis(propyl)-cognitin Prevents ?-amyloid-induced Memory Deficits as Well as Synaptic Formation and Plasticity Impairments via the Activation of PI3-K Pathway.
Memory Disorders
Caffeic acid phenethyl ester rescued streptozotocin-induced memory loss through PI3-kinase dependent pathway.
Memory Disorders
Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's disease: Involvement of PI3-kinase, eNOS and NF?B.
Meningioma
A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Meningioma
Calcifying pseudoneoplasm of neuroaxis (CAPNON): a comprehensive immunohistochemical and morphological characterization of five cases.
Meningioma
Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
Meningioma
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
Meningioma
Curcumin Inhibits HGF-Induced EMT by Regulating c-MET-Dependent PI3K/Akt/mTOR Signaling Pathways in Meningioma.
Meningioma
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Meningioma
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.
Meningioma
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.
Meningioma
High-grade meningiomas: biology and implications.
Meningioma
Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.
Meningioma
Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.
Meningioma
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Meningioma
Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.
Meningioma
New molecular targets in meningiomas: the present and the future.
Meningioma
Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.
Meningioma
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Meningioma
PIK3CA mutations in meningioma.
Meningioma
Progestin-associated shift of meningioma mutational landscape.
Meningioma
Rare mutation of PIK3CA in meningiomas.
Meningioma
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Meningioma
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.
Meningioma
SWI/SNF chromatin remodeling complex alterations in meningioma.
Meningitis, Pneumococcal
Diosmetin Suppresses Neuronal Apoptosis and Inflammation by Modulating the Phosphoinositide 3-Kinase (PI3K)/AKT/Nuclear Factor-?B (NF-?B) Signaling Pathway in a Rat Model of Pneumococcal Meningitis.
Mesothelioma
Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.
Mesothelioma
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Mesothelioma, Malignant
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.
Metabolic Diseases
Inhibition of phosphoinositide 3-kinase ? attenuates inflammation, obesity, and cardiovascular risk factors.
Metabolic Syndrome
Cracking the context-specific PI3K signaling code.
Metabolic Syndrome
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Metabolic Syndrome
Neuroprotective effects of estrogens: cross-talk between estrogen and intracellular insulin signalling.
Metabolic Syndrome
[Insulin resistance - its causes and therapy possibilities].
Microcephaly
De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly.
Mouth Neoplasms
Absence of the frequently reported PIK3CA, CASP8, and NOTCH1 mutations in South Indian oral cancers.
Mouth Neoplasms
Clinical significance of TC21 overexpression in oral cancer.
Mouth Neoplasms
Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer.
Mouth Neoplasms
Genetic deregulation of the PIK3CA oncogene in oral cancer.
Mouth Neoplasms
Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.
Mouth Neoplasms
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
Mouth Neoplasms
Surfactin from Bacillus subtilis attenuates ambient air particulate matter-promoted human oral cancer cells metastatic potential.
Mucositis
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Multiple Endocrine Neoplasia
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Multiple Endocrine Neoplasia Type 2b
Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Multiple Myeloma
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.
Multiple Myeloma
Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Multiple Myeloma
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Multiple Myeloma
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.
Multiple Myeloma
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Multiple Myeloma
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Multiple Myeloma
Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.
Multiple Myeloma
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
Multiple Myeloma
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Multiple Sclerosis
Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis.
Multiple Sclerosis
Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis.
Multiple Sclerosis
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase ? (PI3K?) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
Multiple Sclerosis
PI3K? drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation.
Multiple System Atrophy
Immunohistochemical localization of phosphoinositide 3-kinase in brains with multiple system atrophy.
Muscular Atrophy, Spinal
Fine mapping of human PI 3-kinase associated p85 alpha transcripts in the YAC contig surrounding the spinal muscular atrophy gene.
Muscular Dystrophy, Emery-Dreifuss
Differentiation of C2C12 myoblasts expressing lamin A mutated at a site responsible for Emery-Dreifuss muscular dystrophy is improved by inhibition of the MEK-ERK pathway and stimulation of the PI3-kinase pathway.
Mycosis Fungoides
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas.
Myelitis, Transverse
Transverse myelitis in a patient with activated phosphoinositide 3-kinase ? syndrome type 1.
Myelodysplastic Syndromes
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Myocardial Infarction
Antidiabetic drug pioglitazone protects the heart via activation of PPAR-{gamma} receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.
Myocardial Infarction
Effects of PI3Kgamma inhibition using AS-605240 in acute myocardial infarction.
Myocardial Infarction
Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.
Myocardial Infarction
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
Myocardial Infarction
[Cardiovascular effects of incretin-based therapies].
Myocardial Ischemia
Cardiovascular effects of incretin-based therapies.
Myocardial Ischemia
Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning.
Myocardial Ischemia
PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway.
Myocarditis
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Myocarditis
[Intervention effect of PI3Kgamma inhibitor AS605240 on autoimmune myocarditis in mice]
Nasopharyngeal Carcinoma
Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase.
Nasopharyngeal Carcinoma
Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Correction to: Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase.
Nasopharyngeal Carcinoma
Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85.
Nasopharyngeal Carcinoma
MiR-122 exerts anti-proliferative and apoptotic effects on nasopharyngeal carcinoma cells via the PI3K/AKT signaling pathway.
Nasopharyngeal Carcinoma
miR-144-3p facilitates nasopharyngeal carcinoma via crosstalk with PTEN.
Nasopharyngeal Carcinoma
miR-331-3p Inhibits Proliferation and Promotes Apoptosis of Nasopharyngeal Carcinoma Cells by Targeting elf4B-PI3K-AKT Pathway.
Nasopharyngeal Carcinoma
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
Nasopharyngeal Carcinoma
PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival.
Nasopharyngeal Carcinoma
PIK3CA mutations in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).
Nasopharyngeal Carcinoma
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.
Nasopharyngeal Carcinoma
Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis.
Nasopharyngeal Carcinoma
[Effects of basic fibroblast growth factor on protein kinase B activity and c-fos expression in CNE- I nasopharyngeal carcinoma cell line]
Nasopharyngeal Carcinoma
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
Nasopharyngeal Carcinoma
[The expression of PIK3CA in nasopharyngeal carcinoma].
Neoplasm Metastasis
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
Neoplasm Metastasis
?-Fetoprotein-Producing Hepatoid Gastric Adenocarcinoma With Osteoclast-Like Giant Cells and Neuroendocrine Differentiation: A Case Study With Molecular Profiling.
Neoplasm Metastasis
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Neoplasm Metastasis
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.
Neoplasm Metastasis
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
Neoplasm Metastasis
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Neoplasm Metastasis
Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-? signaling axes.
Neoplasm Metastasis
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
Neoplasm Metastasis
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Neoplasm Metastasis
Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Neoplasm Metastasis
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Neoplasm Metastasis
Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.
Neoplasm Metastasis
Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.
Neoplasm Metastasis
APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Neoplasm Metastasis
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Neoplasm Metastasis
Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
Neoplasm Metastasis
Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Neoplasm Metastasis
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Neoplasm Metastasis
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Neoplasm Metastasis
circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer.
Neoplasm Metastasis
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
Neoplasm Metastasis
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Neoplasm Metastasis
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Neoplasm Metastasis
Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
Neoplasm Metastasis
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Neoplasm Metastasis
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Neoplasm Metastasis
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Neoplasm Metastasis
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Neoplasm Metastasis
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Neoplasm Metastasis
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Neoplasm Metastasis
Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Neoplasm Metastasis
Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases.
Neoplasm Metastasis
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.
Neoplasm Metastasis
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Neoplasm Metastasis
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Neoplasm Metastasis
Dihydroartemisinin selectively inhibits PDGFR?-positive ovarian cancer growth and metastasis through inducing degradation of PDGFR? protein.
Neoplasm Metastasis
Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses.
Neoplasm Metastasis
Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.
Neoplasm Metastasis
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Neoplasm Metastasis
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Neoplasm Metastasis
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Neoplasm Metastasis
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Neoplasm Metastasis
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Neoplasm Metastasis
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Neoplasm Metastasis
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Neoplasm Metastasis
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Neoplasm Metastasis
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Neoplasm Metastasis
Gene heterogeneity in metastasis of colorectal cancer to the lung.
Neoplasm Metastasis
Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression.
Neoplasm Metastasis
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Neoplasm Metastasis
Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours.
Neoplasm Metastasis
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Neoplasm Metastasis
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative.
Neoplasm Metastasis
Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread.
Neoplasm Metastasis
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
Neoplasm Metastasis
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Neoplasm Metastasis
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
Neoplasm Metastasis
Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis.
Neoplasm Metastasis
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Neoplasm Metastasis
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Neoplasm Metastasis
Identification of differentially expressed genes in salivary adenoid cystic carcinoma cells associated with metastasis.
Neoplasm Metastasis
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Neoplasm Metastasis
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Neoplasm Metastasis
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Neoplasm Metastasis
Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Neoplasm Metastasis
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Neoplasm Metastasis
Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis.
Neoplasm Metastasis
Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.
Neoplasm Metastasis
Interactions of multiple gene alterations in colorectal liver metastases.
Neoplasm Metastasis
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Neoplasm Metastasis
Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
Neoplasm Metastasis
KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Neoplasm Metastasis
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer.
Neoplasm Metastasis
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer.
Neoplasm Metastasis
KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
Neoplasm Metastasis
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Neoplasm Metastasis
Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer.
Neoplasm Metastasis
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
Neoplasm Metastasis
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Neoplasm Metastasis
Long non-coding RNA THOR promotes cell proliferation and metastasis in hepatocellular carcinoma.
Neoplasm Metastasis
Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
Neoplasm Metastasis
LOXL1-AS1 Drives The Progression Of Gastric Cancer Via Regulating miR-142-5p/PIK3CA Axis.
Neoplasm Metastasis
LRRC4 Suppresses E-Cadherin-Dependent Collective Cell Invasion and Metastasis in Epithelial Ovarian Cancer.
Neoplasm Metastasis
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma.
Neoplasm Metastasis
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
Neoplasm Metastasis
MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.
Neoplasm Metastasis
miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA.
Neoplasm Metastasis
miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway.
Neoplasm Metastasis
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.
Neoplasm Metastasis
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Neoplasm Metastasis
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach.
Neoplasm Metastasis
Molecular Targets of Genistein and Its Related Flavonoids to Exert Anticancer Effects.
Neoplasm Metastasis
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Neoplasm Metastasis
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Neoplasm Metastasis
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Neoplasm Metastasis
Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
Neoplasm Metastasis
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Neoplasm Metastasis
Mutations of key driver genes in colorectal cancer progression and metastasis.
Neoplasm Metastasis
Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.
Neoplasm Metastasis
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Neoplasm Metastasis
Mutations of PIK3CA are rare in cutaneous melanoma.
Neoplasm Metastasis
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Neoplasm Metastasis
Neurotensin promotes cholangiocarcinoma metastasis via the EGFR/AKT pathway.
Neoplasm Metastasis
NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
Neoplasm Metastasis
Oncogene mutational profile in nasopharyngeal carcinoma.
Neoplasm Metastasis
Oncogenic PI3K and its role in cancer.
Neoplasm Metastasis
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Neoplasm Metastasis
Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Neoplasm Metastasis
Overexpression of Hypoxia Inducible Factor-1 Alpha is an Independent Risk Factor for Recurrence After Curative Resection of Colorectal Liver Metastases.
Neoplasm Metastasis
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Neoplasm Metastasis
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
Neoplasm Metastasis
p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC.
Neoplasm Metastasis
Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer.
Neoplasm Metastasis
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Neoplasm Metastasis
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Neoplasm Metastasis
Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Neoplasm Metastasis
Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Neoplasm Metastasis
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
Neoplasm Metastasis
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Neoplasm Metastasis
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.
Neoplasm Metastasis
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Neoplasm Metastasis
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.
Neoplasm Metastasis
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
Neoplasm Metastasis
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
Neoplasm Metastasis
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
Neoplasm Metastasis
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Neoplasm Metastasis
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
Neoplasm Metastasis
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Neoplasm Metastasis
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Neoplasm Metastasis
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
Neoplasm Metastasis
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Neoplasm Metastasis
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in Breast Cancer.
Neoplasm Metastasis
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Neoplasm Metastasis
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
Neoplasm Metastasis
PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.
Neoplasm Metastasis
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Neoplasm Metastasis
Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics.
Neoplasm Metastasis
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Neoplasm Metastasis
Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study.
Neoplasm Metastasis
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Neoplasm Metastasis
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Neoplasm Metastasis
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Neoplasm Metastasis
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Neoplasm Metastasis
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
Neoplasm Metastasis
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.
Neoplasm Metastasis
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Neoplasm Metastasis
RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.
Neoplasm Metastasis
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Neoplasm Metastasis
Role of Cadherins in Cancer-A Review.
Neoplasm Metastasis
Role of Forkhead Box Class O proteins in cancer progression and metastasis.
Neoplasm Metastasis
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Neoplasm Metastasis
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.
Neoplasm Metastasis
Silencing TAK1 alters gene expression signatures in bladder cancer cells.
Neoplasm Metastasis
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Neoplasm Metastasis
Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.
Neoplasm Metastasis
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.
Neoplasm Metastasis
Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.
Neoplasm Metastasis
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Neoplasm Metastasis
Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K.
Neoplasm Metastasis
Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue.
Neoplasm Metastasis
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Neoplasm Metastasis
Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience.
Neoplasm Metastasis
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
Neoplasm Metastasis
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
Neoplasm Metastasis
The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer.
Neoplasm Metastasis
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Neoplasm Metastasis
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Neoplasm Metastasis
Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Neoplasm Metastasis
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
Neoplasm Metastasis
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Neoplasm Metastasis
Upregulation of microRNA-31 targeting integrin ?5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
Neoplasm Metastasis
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
Neoplasm Metastasis
[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumors to PI3-Kinase inhibition with the novel agent GDC-0941.
Neoplasm Metastasis
[A study of the relationship between the mutation of PIK3CA, PTEN and the occurrence of liver metastasis of colorectal cancer: survival analysis].
Neoplasm Metastasis
[Aspirin and colorectal cancer].
Neoplasm Metastasis
[Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
Neoplasm Metastasis
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Neoplasm Metastasis
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Neoplasm Micrometastasis
Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Neoplasm, Residual
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Neoplasm, Residual
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Neoplasms
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
Neoplasms
14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s).
Neoplasms
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth.
Neoplasms
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Neoplasms
3D modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Neoplasms
3q26 Amplifications in Cervical Squamous Carcinomas.
Neoplasms
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.
Neoplasms
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Neoplasms
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Neoplasms
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
Neoplasms
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Neoplasms
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies.
Neoplasms
A case report of tongue metastasis from lung squamous cell carcinoma and literature review.
Neoplasms
A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies.
Neoplasms
A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma.
Neoplasms
A cohort study of p27 localization in colon cancer, body mass index, and patient survival.
Neoplasms
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Neoplasms
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Neoplasms
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Neoplasms
A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma.
Neoplasms
A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer.
Neoplasms
A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Neoplasms
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Neoplasms
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Neoplasms
A drug targeting only p110? can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
Neoplasms
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Neoplasms
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Neoplasms
A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
Neoplasms
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.
Neoplasms
A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.
Neoplasms
A Genomic and Clinicopathologic Study of Non-Small Cell Lung Cancers with Discordant ROS1 Gene Status by Fluorescent In Situ Hybridization and Immunohistochemical Analysis.
Neoplasms
A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response.
Neoplasms
A high-throughput liposome substrate assay with automated lipid extraction process for PI 3-kinase.
Neoplasms
A High-Throughput Screen with Isogenic PTEN+/+ and PTEN-/- Cells Identifies CID1340132 as a Novel Compound That Induces Apoptosis in PTEN and PIK3CA Mutant Human Cancer Cells.
Neoplasms
A kinase-independent function of AKT promotes cancer cell survival.
Neoplasms
A microscopic landscape of the invasive breast cancer genome.
Neoplasms
A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
Neoplasms
A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report.
Neoplasms
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Neoplasms
A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Neoplasms
A new evaluation method for quantifying PI3K activity by HTRF assay.
Neoplasms
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Neoplasms
A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance.
Neoplasms
A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.
Neoplasms
A novel approach to rescue immune escape in oral squamous cell carcinoma: Combined use of interferon-? and LY294002.
Neoplasms
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells.
Neoplasms
A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.
Neoplasms
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Neoplasms
A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation.
Neoplasms
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
Neoplasms
A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
Neoplasms
A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival.
Neoplasms
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death.
Neoplasms
A novel variant in GPAA1, encoding a GPI transamidase complex protein, causes inherited vascular anomalies with various phenotypes.
Neoplasms
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
Neoplasms
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Neoplasms
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Neoplasms
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.
Neoplasms
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Neoplasms
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer.
Neoplasms
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
Neoplasms
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Neoplasms
A Phase Ib Study of Alpelisib (BYL719), a PI3K?-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer.
Neoplasms
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Neoplasms
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
Neoplasms
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Neoplasms
A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.
Neoplasms
A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation.
Neoplasms
A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Neoplasms
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
Neoplasms
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
Neoplasms
A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy.
Neoplasms
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Neoplasms
A primary splenic angiosarcoma hepatic metastasis after splenectomy and its genomic alteration profile.
Neoplasms
A Prospective Cohort Study Shows Unique Epigenetic, Genetic, and Prognostic Features of Synchronous Colorectal Cancers.
Neoplasms
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Neoplasms
A robust screen for inhibitors and enhancers of phosphoinositide-3 kinase (PI3K) activities by ratiometric fluorescence superquenching.
Neoplasms
A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
Neoplasms
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Neoplasms
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene.
Neoplasms
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Neoplasms
A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.
Neoplasms
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Neoplasms
A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases.
Neoplasms
A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells.
Neoplasms
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
Neoplasms
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Neoplasms
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
Neoplasms
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.
Neoplasms
A unified nomenclature and amino acid numbering for human PTEN.
Neoplasms
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Neoplasms
Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer.
Neoplasms
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Neoplasms
Aberrant Rac pathway signalling in glioblastoma.
Neoplasms
Abnormal expression of PTEN and PIK3CA in pemetrexed-resistant human pancreatic cancer cell line Patu8988.
Neoplasms
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Neoplasms
Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
Neoplasms
Absence of the frequently reported PIK3CA, CASP8, and NOTCH1 mutations in South Indian oral cancers.
Neoplasms
Absolute quantification of four isoforms of the class I phosphoinositide-3-kinase catalytic subunit by real-time RT-PCR.
Neoplasms
Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells.
Neoplasms
Accumulated promoter methylation as a potential biomarker for esophageal cancer.
Neoplasms
ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia.
Neoplasms
Actionable mutations in canine hemangiosarcoma.
Neoplasms
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Neoplasms
Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
Neoplasms
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade.
Neoplasms
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Neoplasms
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.
Neoplasms
Activating Mutations in PIK3CA Lead to Widespread Modulation of the Tyrosine Phosphoproteome.
Neoplasms
Activating PIK3CA mutation promotes osteogenesis of bone marrow mesenchymal stem cells in macrodactyly.
Neoplasms
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Neoplasms
Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
Neoplasms
Activation of Akt predicts poor outcome in neuroblastoma.
Neoplasms
Activation of diverse signalling pathways by oncogenic PIK3CA mutations.
Neoplasms
Activation of endothelial ras signaling bypasses senescence and causes abnormal vascular morphogenesis.
Neoplasms
Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Neoplasms
Activation of IGF1R/p110?/AKT/mTOR confers resistance to ?-specific PI3K inhibition.
Neoplasms
Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth.
Neoplasms
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
Neoplasms
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Neoplasms
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Neoplasms
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Neoplasms
Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85? regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Neoplasms
Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Neoplasms
Activation of PI3K? by physiological effectors and by oncogenic mutations: structural and dynamic effects.
Neoplasms
Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
Neoplasms
Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1.
Neoplasms
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.
Neoplasms
Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Neoplasms
Activation of tumor suppressor protein PTEN and induction of apoptosis are involved in cAMP-mediated inhibition of cell number in B92 glial cells.
Neoplasms
Activation of WNT/?-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Neoplasms
Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Neoplasms
Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
Neoplasms
Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.
Neoplasms
Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors.
Neoplasms
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
Neoplasms
Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components.
Neoplasms
Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase.
Neoplasms
Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.
Neoplasms
Advanced glycation end products in diabetes, cancer and phytochemical therapy.
Neoplasms
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Neoplasms
Advances in subunits of PI3K class I in cancer.
Neoplasms
Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Neoplasms
Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT.
Neoplasms
AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
Neoplasms
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
Neoplasms
Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin.
Neoplasms
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.
Neoplasms
AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Neoplasms
AKT-independent PI3-K signaling in cancer - emerging role for SGK3.
Neoplasms
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Neoplasms
Akt/PKB signaling in cancer: a function in cell motility and invasion.
Neoplasms
Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Neoplasms
AKT1 E17K in Colorectal Carcinoma is Associated with BRAF V600E but not MSI-H status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Neoplasms
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
Neoplasms
AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.
Neoplasms
AKT3 is a key regulator of head and neck squamous cell carcinoma.
Neoplasms
Akt: a potential target for thyroid cancer therapy.
Neoplasms
ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
Neoplasms
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
Neoplasms
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Neoplasms
Alpelisib to treat breast cancer.
Neoplasms
Alpelisib-Induced Diabetic Ketoacidosis.
Neoplasms
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer.
Neoplasms
Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL).
Neoplasms
Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
Neoplasms
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Neoplasms
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
Neoplasms
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
Neoplasms
Altered Composition of Fatty Acids Exacerbates Hepatotumorigenesis during Activation of the Phosphatidylinositol 3-kinase Pathway.
Neoplasms
Altered gene expression in glycolysis-cholesterol synthesis axis correlates with outcome of triple-negative breast cancer.
Neoplasms
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Neoplasms
Alternative AKT2 splicing produces protein lacking the hydrophobic motif regulatory region.
Neoplasms
Amplicon profiles in ovarian serous carcinomas.
Neoplasms
An ?-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.
Neoplasms
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Neoplasms
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin.
Neoplasms
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Neoplasms
An essential role for protein synthesis in oncogenic cellular transformation.
Neoplasms
An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells.
Neoplasms
An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
Neoplasms
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Neoplasms
An insight into the molecular genetics of a uveal melanoma patient cohort.
Neoplasms
An insulin-like growth factor-mediated, phosphatidylinositol 3' kinase-independent survival signaling pathway in beta tumor cells.
Neoplasms
An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
Neoplasms
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Neoplasms
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
Neoplasms
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
Neoplasms
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Neoplasms
Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays.
Neoplasms
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Neoplasms
Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum.
Neoplasms
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Neoplasms
Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Neoplasms
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.
Neoplasms
Analysis of PI3K pathway components in human cancers.
Neoplasms
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Neoplasms
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Neoplasms
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Neoplasms
Analysis of PIK3CA mutations in breast cancer subtypes.
Neoplasms
Analysis of signaling pathways in 90 cancer cell lines by protein lysate array.
Neoplasms
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: Implications for cancer therapy.
Neoplasms
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Neoplasms
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
Neoplasms
Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
Neoplasms
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
Neoplasms
Anthricin Isolated from Anthriscus sylvestris (L.) Hoffm. Inhibits the Growth of Breast Cancer Cells by Inhibiting Akt/mTOR Signaling, and Its Apoptotic Effects Are Enhanced by Autophagy Inhibition.
Neoplasms
Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Neoplasms
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Neoplasms
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Neoplasms
Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B.
Neoplasms
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Neoplasms
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Neoplasms
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Neoplasms
Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?
Neoplasms
Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.
Neoplasms
APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
Neoplasms
APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Neoplasms
APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Neoplasms
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.
Neoplasms
Apoptosis and inactivation of the PI3-kinase pathway by tetrocarcin A in breast cancers.
Neoplasms
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.
Neoplasms
Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma.
Neoplasms
APRIL mediates follicular lymphoma B cell proliferation and cyclin D1 expression through PI3-kinase regulated mTOR activation.
Neoplasms
Aquaporin 9 is down-regulated in hepatocellular carcinoma and its over-expression suppresses hepatoma cell invasion through inhibiting epithelial-to-mesenchymal transition.
Neoplasms
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Neoplasms
ARID1A gene mutation in ovarian and endometrial cancers (Review).
Neoplasms
ARID2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
Neoplasms
Aspirin acts in esophageal cancer: a brief review.
Neoplasms
Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?
Neoplasms
Aspirin and colorectal cancer: back to the future.
Neoplasms
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Neoplasms
Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
Neoplasms
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Neoplasms
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Neoplasms
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Neoplasms
Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
Neoplasms
Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization.
Neoplasms
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
Neoplasms
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Neoplasms
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Neoplasms
Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Neoplasms
Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer.
Neoplasms
Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer.
Neoplasms
Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas.
Neoplasms
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
Neoplasms
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Neoplasms
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Neoplasms
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.
Neoplasms
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Neoplasms
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Neoplasms
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Neoplasms
Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
Neoplasms
Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Neoplasms
Associations of PI3KR1 and mTOR Polymorphisms with Esophageal Squamous Cell Carcinoma Risk and Gene-Environment Interactions in Eastern Chinese Populations.
Neoplasms
Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.
Neoplasms
Asymmetric real-time PCR and multiplex melting curve analysis with TaqMan probes for detecting PIK3CA mutations.
Neoplasms
AT-rich interactive domain 2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
Neoplasms
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
Neoplasms
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.
Neoplasms
Autophagy in the physiological endometrium and cancer.
Neoplasms
Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells.
Neoplasms
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Neoplasms
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Neoplasms
B cell receptor signaling in chronic lymphocytic leukemia.
Neoplasms
B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Neoplasms
Baculovirus production of fully-active phosphoinositide 3-kinase alpha as a p85alpha-p110alpha fusion for X-ray crystallographic analysis with ATP competitive enzyme inhibitors.
Neoplasms
Basic helix-loop-helix transcription factor DEC1 negatively regulates cyclin D1.
Neoplasms
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110? and p110? activities in tumor cell lines and xenograft models.
Neoplasms
BEAMing up personalized medicine: mutation detection in blood.
Neoplasms
Beta-testing of PI3-kinase inhibitors: is beta better?
Neoplasms
Better Understanding of Phosphoinositide 3-Kinase (PI3K) Pathways in Vasculature: Towards Precision Therapy Targeting Angiogenesis and Tumor Blood Supply.
Neoplasms
Beyond BRAF in Melanoma.
Neoplasms
Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Neoplasms
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Neoplasms
BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors.
Neoplasms
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
Neoplasms
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Neoplasms
Biological activities of sinularin: A literature-based review.
Neoplasms
Biological significance of c-erbB family oncogenes in head and neck cancer.
Neoplasms
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Neoplasms
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Neoplasms
Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
Neoplasms
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer.
Neoplasms
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Neoplasms
Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma.
Neoplasms
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
Neoplasms
BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-?B/MGMT signaling pathway.
Neoplasms
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Neoplasms
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
Neoplasms
BRAF and KRAS Mutations in Sporadic Glomus Tumors.
Neoplasms
BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
Neoplasms
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
Neoplasms
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Neoplasms
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
Neoplasms
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Neoplasms
Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.
Neoplasms
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Neoplasms
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Neoplasms
Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.
Neoplasms
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Neoplasms
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Neoplasms
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Neoplasms
C-terminal domain of p42 Ebp1 is essential for down regulation of p85 subunit of PI3K, inhibiting tumor growth.
Neoplasms
Caffeic acid phenethyl ester suppresses melanoma tumor growth by inhibiting PI3K/AKT/XIAP pathway.
Neoplasms
Caloric restriction augments radiation efficacy in breast cancer.
Neoplasms
Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.
Neoplasms
Cancer cell-derived clusterin modulates the phosphatidylinositol 3'-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation.
Neoplasms
Cancer-Associated Mutations in Endometriosis without Cancer.
Neoplasms
Cancer-associated mutations in the p85? N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Neoplasms
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.
Neoplasms
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Neoplasms
Cancer-specific mutations in PIK3CA are oncogenic in vivo.
Neoplasms
Cancers of the Upper Gastro-intestinal Tract: A Review of Somatic Mutation Distributions.
Neoplasms
Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds.
Neoplasms
Cannabinoid pharmacology in cancer research: A new hope for cancer patients?
Neoplasms
Carcinogenesis of PIK3CA.
Neoplasms
CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia.
Neoplasms
Caspase-activated phosphoinositide binding by CNT-1 promotes apoptosis by inhibiting the AKT pathway.
Neoplasms
Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis.
Neoplasms
Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
Neoplasms
CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
Neoplasms
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.
Neoplasms
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Neoplasms
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Neoplasms
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Neoplasms
Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity.
Neoplasms
Cellular and Genetic Determinants of the Sensitivity of Cancer to ?-Particle Irradiation.
Neoplasms
Cellular and molecular mechanisms of PIK3CA-related vascular anomalies.
Neoplasms
Cellular energy stress induces AMPK-mediated regulation of glioblastoma cell proliferation by PIKE-A phosphorylation.
Neoplasms
Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.
Neoplasms
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase 2 trial of FOLFOX plus cetuximab versus FOLFOX.
Neoplasms
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Neoplasms
Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts.
Neoplasms
Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics.
Neoplasms
Characterization of a tumor-associated activating mutation of the p110? PI 3-kinase.
Neoplasms
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Neoplasms
Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.
Neoplasms
Characterization of in vitro 3D cultures.
Neoplasms
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Neoplasms
Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
Neoplasms
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Neoplasms
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Neoplasms
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
Neoplasms
Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Neoplasms
Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab.
Neoplasms
Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence.
Neoplasms
Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy.
Neoplasms
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.
Neoplasms
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Neoplasms
Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K.
Neoplasms
Childhood tumors of the nervous system as disorders of normal development.
Neoplasms
Chromosomal and genomic changes in lung cancer.
Neoplasms
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer.
Neoplasms
Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer.
Neoplasms
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
Neoplasms
Circulating tumor cells and breast cancer-specific mutations in primary breast cancer.
Neoplasms
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
Neoplasms
CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4.
Neoplasms
Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.
Neoplasms
Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-?B-TNF?-PIK3CA loop.
Neoplasms
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Neoplasms
Class I phosphoinositide 3-kinases.
Neoplasms
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Neoplasms
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.
Neoplasms
Class I PI3K in oncogenic cellular transformation.
Neoplasms
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery.
Neoplasms
Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Neoplasms
Class III PI3K Vps34: essential roles in autophagy, endocytosis, and heart and liver function.
Neoplasms
Classes of phosphoinositide 3-kinases at a glance.
Neoplasms
Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis.
Neoplasms
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Neoplasms
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER project.
Neoplasms
Clinical Features and Genomic Characterization of Post-Colonoscopy Colorectal Cancer.
Neoplasms
Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Neoplasms
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
Neoplasms
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Neoplasms
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Neoplasms
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Neoplasms
Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Neoplasms
Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
Neoplasms
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
Neoplasms
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Neoplasms
Clinical relevance of oncogenic driver mutations identified in endometrial carcinoma.
Neoplasms
Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Neoplasms
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Neoplasms
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Neoplasms
Clinical significance of YAP1 activation in head and neck squamous cell carcinoma.
Neoplasms
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Neoplasms
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Neoplasms
Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer.
Neoplasms
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Neoplasms
Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Neoplasms
Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer.
Neoplasms
Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population.
Neoplasms
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Neoplasms
Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
Neoplasms
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Neoplasms
Clinicopathologic Significance of HNF-1?, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Neoplasms
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Neoplasms
Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
Neoplasms
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Neoplasms
Clinicopathological Characteristics of PIK3CA Mutation and Amplification in Korean Patients with Breast Cancers.
Neoplasms
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer.
Neoplasms
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Neoplasms
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Neoplasms
Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?
Neoplasms
Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma.
Neoplasms
Clonal analyses of refractory testicular germ cell tumors.
Neoplasms
Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
Neoplasms
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
Neoplasms
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
Neoplasms
CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.
Neoplasms
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Neoplasms
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Neoplasms
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Neoplasms
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Neoplasms
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.
Neoplasms
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Neoplasms
Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.
Neoplasms
Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.
Neoplasms
Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?
Neoplasms
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Neoplasms
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Neoplasms
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Neoplasms
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Neoplasms
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Neoplasms
Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
Neoplasms
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Neoplasms
Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
Neoplasms
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Neoplasms
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Neoplasms
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Neoplasms
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
Neoplasms
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Neoplasms
Commentary on Essential roles of PI(3)K-p110beta in cell growth, metabolism, and tumorigenesis Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Neoplasms
Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation.
Neoplasms
Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Neoplasms
Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.
Neoplasms
Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
Neoplasms
Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
Neoplasms
Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Neoplasms
Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.
Neoplasms
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Neoplasms
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
Neoplasms
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Neoplasms
Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.
Neoplasms
Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Neoplasms
Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.
Neoplasms
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
Neoplasms
Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors.
Neoplasms
Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells.
Neoplasms
Complete genomic landscape of a recurring sporadic parathyroid carcinoma.
Neoplasms
Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas.
Neoplasms
Comprehensive analysis of PTEN status in breast carcinomas.
Neoplasms
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Neoplasms
Comprehensive characteristics of somatic mutations in the normal tissues of patients with cancer and existence of somatic mutant clones linked to cancer development.
Neoplasms
Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.
Neoplasms
Comprehensive genomic characterization of head and neck squamous cell carcinomas.
Neoplasms
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Neoplasms
Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.
Neoplasms
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Neoplasms
Comprehensive genomic profile of cholangiocarcinomas in China.
Neoplasms
Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
Neoplasms
Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.
Neoplasms
Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
Neoplasms
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Neoplasms
Comprehensive molecular characterization of gastric adenocarcinoma.
Neoplasms
Comprehensive molecular portraits of human breast tumours.
Neoplasms
Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Neoplasms
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Neoplasms
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Neoplasms
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Neoplasms
Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.
Neoplasms
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Neoplasms
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Neoplasms
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Neoplasms
Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression.
Neoplasms
Connecting with an old partner in a new way.
Neoplasms
Constitutive activation of p70S6k in cancer cells.
Neoplasms
Constitutive cellular expression of PI 3-kinase is distinct from transient expression.
Neoplasms
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Neoplasms
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Neoplasms
Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.
Neoplasms
Convergent loss of PTEN leads to clinical resistance to a PI(3)K? inhibitor.
Neoplasms
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
Neoplasms
Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation.
Neoplasms
Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
Neoplasms
Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex.
Neoplasms
Copanlisib: First Global Approval.
Neoplasms
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Neoplasms
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Neoplasms
Copy number loss of variation_91720 in PIK3CA predicts risk of esophageal squamous cell carcinoma.
Neoplasms
Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer.
Neoplasms
Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Neoplasms
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Neoplasms
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Neoplasms
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2.
Neoplasms
Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Neoplasms
Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Neoplasms
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Neoplasms
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Neoplasms
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Neoplasms
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Neoplasms
Cowden Syndrome: Case Report, Update and Proposed Diagnostic and Surveillance Routines.
Neoplasms
Cracking the context-specific PI3K signaling code.
Neoplasms
Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation.
Neoplasms
Critical role for PI3-kinase in regulating the use of proteins as an amino acid source.
Neoplasms
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation.
Neoplasms
Cross regulation of signaling pathways in gastrointestinal stromal tumor.
Neoplasms
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Neoplasms
Cross-species oncogenic signatures of breast cancer in canine mammary tumors.
Neoplasms
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Neoplasms
Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium.
Neoplasms
CTNNB1 mutations in basal cell adenoma of the salivary gland.
Neoplasms
Current and future strategies for treatment of ovarian clear cell carcinoma.
Neoplasms
Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway.
Neoplasms
Custom Glycosylation of Cells and Proteins Using Cyclic Carbamate-Derivatized Oligosaccharides.
Neoplasms
Custom Pediatric Oncology Next-Generation Sequencing Panel Identifies Somatic Mosaicism in Archival Tissue and Enhances Targeted Clinical Care.
Neoplasms
Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.
Neoplasms
Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.
Neoplasms
Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
Neoplasms
Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
Neoplasms
Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells.
Neoplasms
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Neoplasms
Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Neoplasms
Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Neoplasms
Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.
Neoplasms
Defining the blueprint of the cancer genome.
Neoplasms
Deguelin targets multiple oncogenic signaling pathways to combat human malignancies.
Neoplasms
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Neoplasms
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Neoplasms
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.
Neoplasms
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.
Neoplasms
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Neoplasms
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.
Neoplasms
Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment.
Neoplasms
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Neoplasms
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Neoplasms
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Neoplasms
Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3K?/mTOR inhibitors.
Neoplasms
Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
Neoplasms
Design, synthesis, and anticancer properties of novel benzophenone-conjugated coumarin analogs.
Neoplasms
Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3K? inhibitors.
Neoplasms
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Neoplasms
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Neoplasms
Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Neoplasms
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma.
Neoplasms
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Neoplasms
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.
Neoplasms
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Neoplasms
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Neoplasms
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.
Neoplasms
Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Neoplasms
Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood.
Neoplasms
Development of a tandem affinity phosphoproteomic method with motif selectivity and its application in analysis of signal transduction networks.
Neoplasms
Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats.
Neoplasms
Development of Multi-Target Chemometric Models for the Inhibition of Class I PI3K Enzyme Isoforms: A Case Study Using QSAR-Co Tool.
Neoplasms
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Neoplasms
Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Neoplasms
Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.
Neoplasms
Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers.
Neoplasms
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
Neoplasms
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Neoplasms
Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature.
Neoplasms
Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.
Neoplasms
Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
Neoplasms
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Neoplasms
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Neoplasms
Different expression of apoptotic proteins between HBV-infected and non-HBV-infected hepatocellular carcinoma.
Neoplasms
Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.
Neoplasms
Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
Neoplasms
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Neoplasms
Differential Expression of IRS-1 and IRS-2 in Uterine Leiomyosarcomas with Distinct Oncogenic Phenotypes: Lack of Correlation with Downstream Signaling Events.
Neoplasms
Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.
Neoplasms
Differential involvement of RalA and RalB in colorectal cancer.
Neoplasms
Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228.
Neoplasms
Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration.
Neoplasms
Discovery and Features of an Alkylating Signature in Colorectal Cancer.
Neoplasms
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Neoplasms
Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3K? inhibitors.
Neoplasms
Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3K? inhibitors via docking-based virtual screening.
Neoplasms
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a ?-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
Neoplasms
Discovery of a novel class of AKT pleckstrin homology domain inhibitors.
Neoplasms
Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.
Neoplasms
Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.
Neoplasms
Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors.
Neoplasms
Discovery of a Phosphoinositide 3-Kinase (PI3K) ?/? Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3K? Potency in a PI3K?-Selective Template by Targeting Nonconserved Asp856.
Neoplasms
Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Neoplasms
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Neoplasms
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Neoplasms
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.
Neoplasms
Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy.
Neoplasms
Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Neoplasms
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3K? Inhibitors.
Neoplasms
Discovery of Potent and Selective PI3K? Inhibitors.
Neoplasms
Disease evolution and heterogeneity in bilateral breast cancer.
Neoplasms
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110?/PIK3CA but not by HER2 or mutant AKT1.
Neoplasms
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Neoplasms
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Neoplasms
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Neoplasms
Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Neoplasms
Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer.
Neoplasms
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes.
Neoplasms
Distinct epithelial-to-mesenchymal transitions induced by PIK3CA H1047R and PIK3CB.
Neoplasms
Distinct genomic profile in h. pylori-associated gastric cancer.
Neoplasms
Distinct molecular features of different macroscopic subtypes of colorectal neoplasms.
Neoplasms
Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
Neoplasms
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Neoplasms
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Neoplasms
Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B.
Neoplasms
Distinguishing the progression of an endometrioma: Benign or malignant?
Neoplasms
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations.
Neoplasms
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Neoplasms
DNA Methylation and Genetic Aberrations in Gastric Cancer.
Neoplasms
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Neoplasms
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Neoplasms
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation.
Neoplasms
Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers.
Neoplasms
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K? inhibitors.
Neoplasms
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
Neoplasms
Down Regulation of FOXO1 Promotes Cell Proliferation in Cervical Cancer.
Neoplasms
Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation.
Neoplasms
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Neoplasms
Downregulation of MACC1 inhibits the viability, invasion and migration and induces apoptosis in esophageal carcinoma cells through the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway.
Neoplasms
Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.
Neoplasms
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Neoplasms
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Neoplasms
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Neoplasms
Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo.
Neoplasms
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Dual Inhibition of PI3K/Akt/mTOR Pathway and Role of Autophagy in Non-Small Cell Lung Cancer Cells.
Neoplasms
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Neoplasms
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Neoplasms
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma.
Neoplasms
Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis.
Neoplasms
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Neoplasms
Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Neoplasms
Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Neoplasms
Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses.
Neoplasms
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR.
Neoplasms
Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells.
Neoplasms
Dynamic changes of driver genes' mutations across clinical stages in nine cancer types.
Neoplasms
Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer.
Neoplasms
Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor.
Neoplasms
Early-onset colorectal cancer: A distinct entity with unique genetic features.
Neoplasms
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Neoplasms
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Neoplasms
Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.
Neoplasms
Effects of dietary tryptophan levels on antioxidant status and immunity for juvenile blunt snout bream (Megalobrama amblycephala) involved in Nrf2 and TOR signaling pathway.
Neoplasms
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Neoplasms
Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
Neoplasms
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Neoplasms
Effects of PTEN inhibition on regulation of tau phosphorylation in an okadaic acid-induced neurodegeneration model.
Neoplasms
Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Neoplasms
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Neoplasms
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Neoplasms
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.
Neoplasms
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Neoplasms
EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.
Neoplasms
EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.
Neoplasms
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.
Neoplasms
EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy.
Neoplasms
Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer.
Neoplasms
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
Neoplasms
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.
Neoplasms
Emerging role of PTEN loss in evasion of the immune response to tumours.
Neoplasms
Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways.
Neoplasms
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.
Neoplasms
Emerging roles of microRNAs in regulating the mTOR signaling pathway during tumorigenesis.
Neoplasms
Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.
Neoplasms
Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
Neoplasms
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Neoplasms
Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MUTYH biallelic mutations.
Neoplasms
Endometrial cancer cells exhibit high expression of p110? and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Neoplasms
Endometrioid carcinoma of the endometrium: pathologic and molecular features.
Neoplasms
Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses.
Neoplasms
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.
Neoplasms
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Neoplasms
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Neoplasms
Environmental and sex-specific molecular signatures of glioma causation.
Neoplasms
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Neoplasms
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Neoplasms
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation.
Neoplasms
Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Neoplasms
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
Neoplasms
Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
Neoplasms
Epigenetic and genetic features of 24 colon cancer cell lines.
Neoplasms
Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation.
Neoplasms
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.
Neoplasms
Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.
Neoplasms
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Neoplasms
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Neoplasms
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Neoplasms
Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy.
Neoplasms
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Neoplasms
Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma.
Neoplasms
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
Neoplasms
Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Neoplasms
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Neoplasms
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
Neoplasms
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Neoplasms
ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA.
Neoplasms
Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer.
Neoplasms
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Neoplasms
Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.
Neoplasms
Evaluation of PTEN expression in cervical adenocarcinoma by tissue microarray.
Neoplasms
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Neoplasms
Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Neoplasms
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Neoplasms
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Neoplasms
Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Neoplasms
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Neoplasms
Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer.
Neoplasms
Evolutionary pathways in BRCA1-associated breast tumors.
Neoplasms
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.
Neoplasms
Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma.
Neoplasms
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.
Neoplasms
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Neoplasms
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.
Neoplasms
Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes.
Neoplasms
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
Neoplasms
Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
Neoplasms
Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.
Neoplasms
Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer.
Neoplasms
Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Neoplasms
Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3K? Kinase Using Computational Methods.
Neoplasms
Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code.
Neoplasms
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Neoplasms
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Neoplasms
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.
Neoplasms
Expression of HLA Class I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer.
Neoplasms
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
Neoplasms
Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.
Neoplasms
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.
Neoplasms
Expression of PTEN and Akt phosphorylation in lipopolysaccharide-treated NIH3T3 cells.
Neoplasms
Expression of TGF?3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway.
Neoplasms
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Neoplasms
Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML.
Neoplasms
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Neoplasms
FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
Neoplasms
Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
Neoplasms
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Neoplasms
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Neoplasms
FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features.
Neoplasms
First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.
Neoplasms
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Neoplasms
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Neoplasms
First-in-human trial of the PI3K?-selective inhibitor SAR260301 in patients with advanced solid tumors.
Neoplasms
First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Neoplasms
Fluoride Exposure Induces Inhibition of Sodium/Iodide Symporter (NIS) Contributing to Impaired Iodine Absorption and Iodine Deficiency: Molecular Mechanisms of Inhibition and Implications for Public Health.
Neoplasms
For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.
Neoplasms
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.
Neoplasms
FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients.
Neoplasms
FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K-AKT Pathway.
Neoplasms
Foxo3a drives proliferation in anaplastic thyroid carcinoma via transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic strategies.
Neoplasms
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.
Neoplasms
FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis.
Neoplasms
Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.
Neoplasms
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Neoplasms
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Neoplasms
Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.
Neoplasms
Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.
Neoplasms
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Neoplasms
Frequent activating PIK3CA mutations in sporadic angiolipoma.
Neoplasms
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Neoplasms
Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Neoplasms
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Neoplasms
Frequent FOXA1-Activating Mutations in Extramammary Paget's Disease.
Neoplasms
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Neoplasms
Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.
Neoplasms
Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Neoplasms
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Neoplasms
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Neoplasms
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
Neoplasms
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Neoplasms
Frequent PIK3CA activating mutations in nipple adenomas.
Neoplasms
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Neoplasms
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Neoplasms
Frequent PIK3CA mutations in radial scars.
Neoplasms
Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
Neoplasms
Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Neoplasms
FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration.
Neoplasms
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Neoplasms
Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.
Neoplasms
Function of G-Protein-Coupled Estrogen Receptor-1 in Reproductive System Tumors.
Neoplasms
Function of MiR-152 As a Tumor Suppressor in Human Breast Cancer By Targeting PIK3CA.
Neoplasms
Function of PTEN during the formation and maintenance of neuronal circuits in the brain.
Neoplasms
Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.
Neoplasms
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Neoplasms
Functional characterization of a novel somatic oncogenic mutation of
Neoplasms
Functional differences between two classes of oncogenic mutation in the PIK3CA gene.
Neoplasms
Functional differentiation of three phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) in response to Vibrio anguillarum infection in turbot (Scophthalmus maximus).
Neoplasms
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Neoplasms
Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.
Neoplasms
Functional integrity of nuclear factor kappaB, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor alpha-evoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxia-inducible factor 1alpha.
Neoplasms
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Neoplasms
Functional role of phosphatidylinositol 3-kinase in direct tumor lysis by human natural killer cells.
Neoplasms
Functional role of SGK3 in PI3K/Pten driven liver tumor development.
Neoplasms
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Neoplasms
Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA.
Neoplasms
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
Neoplasms
Gain of interaction with IRS1 by p110?-helical domain mutants is crucial for their oncogenic functions.
Neoplasms
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.
Neoplasms
Ganoderma lucidum targeting lung cancer signaling: A review.
Neoplasms
Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Neoplasms
GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Neoplasms
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Neoplasms
GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN.
Neoplasms
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Neoplasms
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Neoplasms
Gene amplifications associated with the development of hormone-resistant prostate cancer.
Neoplasms
Gene expression profiling analysis contributes to understanding the association between non-syndromic cleft lip and palate, and cancer.
Neoplasms
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Neoplasms
Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy.
Neoplasms
Gene of the month: PIK3CA.
Neoplasms
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.
Neoplasms
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Neoplasms
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Neoplasms
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.
Neoplasms
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Neoplasms
Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients.
Neoplasms
Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection.
Neoplasms
Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II.
Neoplasms
Genetic alterations in endometrial cancer by targeted next-generation sequencing.
Neoplasms
Genetic alterations in Japanese extrahepatic biliary tract cancer.
Neoplasms
Genetic Alterations in the PI3K Pathway in Prostate Cancer.
Neoplasms
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Neoplasms
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Neoplasms
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Neoplasms
Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers.
Neoplasms
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
Neoplasms
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.
Neoplasms
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Neoplasms
Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.
Neoplasms
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Neoplasms
Genetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease.
Neoplasms
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Neoplasms
Genetically engineered mouse models of PI3K signaling in breast cancer.
Neoplasms
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
Neoplasms
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Neoplasms
Genome-derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care.
Neoplasms
Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Neoplasms
Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
Neoplasms
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
Neoplasms
Genome-wide somatic copy number alteration analysis and database construction for cervical cancer.
Neoplasms
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Neoplasms
Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.
Neoplasms
Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva.
Neoplasms
Genomic Alterations in Gastrointestinal Stromal Tumors as Revealed by Conventional and Array-based Comparative Genomic Hybridization.
Neoplasms
Genomic alterations in neuroendocrine cancers of the ovary.
Neoplasms
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Neoplasms
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Neoplasms
Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma.
Neoplasms
Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.
Neoplasms
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
Neoplasms
Genomic analysis for the prediction of prognosis in small-bowel cancer.
Neoplasms
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Neoplasms
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.
Neoplasms
Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinoma.
Neoplasms
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Neoplasms
Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.
Neoplasms
Genomic Characterization of de novo Metastatic Breast Cancer.
Neoplasms
Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
Neoplasms
Genomic characterization of high-risk non-muscle invasive bladder cancer.
Neoplasms
Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Neoplasms
Genomic characterization of vulvar squamous cell carcinoma.
Neoplasms
Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway.
Neoplasms
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.
Neoplasms
Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy.
Neoplasms
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Neoplasms
Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart.
Neoplasms
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.
Neoplasms
Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
Neoplasms
Genomic landscape of adenoid cystic carcinoma of the breast.
Neoplasms
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Neoplasms
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Neoplasms
Genomic profile of advanced breast cancer in circulating tumour DNA.
Neoplasms
Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours.
Neoplasms
Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Neoplasms
Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer.
Neoplasms
Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread.
Neoplasms
Genomic profiling of large-cell neuroendocrine carcinoma of the lung.
Neoplasms
Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Neoplasms
Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Neoplasms
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
Neoplasms
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
Neoplasms
Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.
Neoplasms
Genomics and splicing events of type II endometrial cancers in the black population: racial disparity, socioeconomic and geographical differences.
Neoplasms
Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction.
Neoplasms
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.
Neoplasms
Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.
Neoplasms
Germline and Somatic mutations in postmenopausal breast cancer patients.
Neoplasms
Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.
Neoplasms
Glucose Metabolism Measured by [F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells.
Neoplasms
GSK-3?-mediated fatty acid synthesis enhances epithelial to mesenchymal transition of TLR4-activated colorectal cancer cells through regulation of TAp63.
Neoplasms
GSTO1*CC Genotype (rs4925) Predicts Shorter Survival in Clear Cell Renal Cell Carcinoma Male Patients.
Neoplasms
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
Neoplasms
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Neoplasms
HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
Neoplasms
Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
Neoplasms
Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.
Neoplasms
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
Neoplasms
Hepatic small vessel neoplasm, a rare infiltrative vascular neoplasm of uncertain malignant potential.
Neoplasms
Hepatoid adenocarcinoma of the stomach with PIK3Ca mutation during pregnancy: A case report with molecular profile.
Neoplasms
Hesperidin inhibits insulin-induced phosphoinositide 3-kinase/Akt activation in human pre-B cell line NALM-6.
Neoplasms
Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody.
Neoplasms
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Neoplasms
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Neoplasms
Heterogeneous mutational profile and prognosis conferred by TP53 mutations in Appendiceal mucinous neoplasms.
Neoplasms
Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.
Neoplasms
Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.
Neoplasms
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
Neoplasms
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.
Neoplasms
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Neoplasms
High frequency of mutations in the PIK3CA gene helical and kinase coding regions in a group of Iranian patients with high-grade glioblastomas: five novel mutations.
Neoplasms
High frequency of mutations of the PIK3CA gene in human cancers.
Neoplasms
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
Neoplasms
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
Neoplasms
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Neoplasms
High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy.
Neoplasms
High selectivity of PI3K? inhibitors in SETD2-mutated renal clear cell carcinoma.
Neoplasms
High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.
Neoplasms
High-resolution genomic and expression analyses of copy number alterations in breast tumors.
Neoplasms
High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing.
Neoplasms
High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Neoplasms
Highlights from the 38th SABCS annual meeting, 8th - 12th December 2015, San Antonio, USA.
Neoplasms
Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission.
Neoplasms
Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation.
Neoplasms
Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
Neoplasms
Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck.
Neoplasms
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Neoplasms
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Neoplasms
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Neoplasms
Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas.
Neoplasms
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Neoplasms
How autophagy controls the intestinal epithelial barrier.
Neoplasms
How moderate changes in Akt T-loop phosphorylation impact on tumorigenesis and insulin resistance.
Neoplasms
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Neoplasms
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Neoplasms
HPV: Molecular pathways and targets.
Neoplasms
HTLV-I Tax regulates the cellular proliferation through the down-regulation of PIP3-phosphatase expressions via the NF-?B pathway.
Neoplasms
Human mucosal CD4(+) T cells but not blood CD4(+) T cells respond vigorously towards CD28 engagement.
Neoplasms
Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells.
Neoplasms
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Neoplasms
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.
Neoplasms
Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes.
Neoplasms
Human tumor mutants in the p110alpha subunit of PI3K.
Neoplasms
Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.
Neoplasms
Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
Neoplasms
Hyperoside exerts potent anticancer activity in skin cancer.
Neoplasms
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Neoplasms
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Neoplasms
Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs.
Neoplasms
Identification of allosteric binding sites for PI3K? oncogenic mutant specific inhibitor design.
Neoplasms
Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments.
Neoplasms
Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing.
Neoplasms
Identification of differentially expressed genes in salivary adenoid cystic carcinoma cells associated with metastasis.
Neoplasms
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Neoplasms
Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.
Neoplasms
Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.
Neoplasms
Identification of novel effectors of invasive cell growth downstream of phosphoinositide 3-kinase.
Neoplasms
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
Neoplasms
Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Neoplasms
Identification of novel potential PI3K? inhibitors for cancer therapy.
Neoplasms
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.
Neoplasms
Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.
Neoplasms
Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing.
Neoplasms
Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
Neoplasms
Identification of potentially druggable molecular alterations in skin adnexal malignancies.
Neoplasms
Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations.
Neoplasms
Identification of somatic gene mutations in penile squamous cell carcinoma.
Neoplasms
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Neoplasms
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.
Neoplasms
Identification of ZASC1 encoding a Krüppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas.
Neoplasms
IGF-1 induces expression of zinc-finger protein 143 in colon cancer cells through phosphatidylinositide 3-kinase and reactive oxygen species.
Neoplasms
IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
Neoplasms
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Neoplasms
Imidazoquinolines: Recent Developments in Anticancer Activity.
Neoplasms
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Neoplasms
Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
Neoplasms
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Neoplasms
Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.
Neoplasms
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-?+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Neoplasms
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
Neoplasms
Impact of genetic alterations on mTOR-targeted cancer therapy.
Neoplasms
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Neoplasms
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Neoplasms
Impact of the obesity epidemic on cancer.
Neoplasms
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Neoplasms
Improving the genetic signature of prostate cancer, the somatic mutations.
Neoplasms
Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations.
Neoplasms
In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis.
Neoplasms
In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa.
Neoplasms
In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells.
Neoplasms
In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.
Neoplasms
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Neoplasms
In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.
Neoplasms
In-silico & In-vitro Identification of Structure-Activity Relationship Pattern of Serpentine & Gallic Acid Targeting PI3K? as Potential Anticancer Target.
Neoplasms
Inactivating CUX1 mutations promote tumorigenesis.
Neoplasms
Inactivation of endothelial cell phosphoinositide 3-kinase ? inhibits tumor angiogenesis and tumor growth.
Neoplasms
Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth.
Neoplasms
Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin.
Neoplasms
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Neoplasms
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Neoplasms
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Neoplasms
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Neoplasms
Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis.
Neoplasms
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Neoplasms
Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.
Neoplasms
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Neoplasms
Inflammation and prostate cancer: the role of interleukin-6.
Neoplasms
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Neoplasms
Influence of Pi3-K and PKC activity on 99mTc-(V)-DMSA uptake: correlation with tumour aggressiveness in an in vitro malignant glioblastoma cell line model.
Neoplasms
Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
Neoplasms
Inherited PTEN mutations and the prediction of phenotype.
Neoplasms
Inhibiting PI3K as a therapeutic strategy against cancer.
Neoplasms
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.
Neoplasms
Inhibition by platelet-activating factor of Src- and hepatocyte growth factor-dependent invasiveness of intestinal and kidney epithelial cells. Phosphatidylinositol 3'-kinase is a critical mediator of tumor invasion.
Neoplasms
Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair.
Neoplasms
Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.
Neoplasms
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Neoplasms
Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.
Neoplasms
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit.
Neoplasms
Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival.
Neoplasms
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Neoplasms
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Neoplasms
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Neoplasms
Inhibition of PI3K/AKT/mTOR Pathway Enhances Temozolomide-Induced Cytotoxicity in Pituitary Adenoma Cell Lines in Vitro and Xenografted Pituitary Adenoma in Female Nude Mice.
Neoplasms
Inhibition of the ?-subunit of phosphoinositide 3-kinase (PI3K) in heart increases late sodium current and is arrhythmogenic.
Neoplasms
Inhibition of the p110? isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.
Neoplasms
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Neoplasms
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.
Neoplasms
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Neoplasms
Inhibition of the PI3K Pathway: Hope We Can Believe in?
Neoplasms
Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45.
Neoplasms
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
Neoplasms
Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.
Neoplasms
Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN.
Neoplasms
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Neoplasms
Inhibitory activity of flavonoids against class I phosphatidylinositol 3-kinase isoforms.
Neoplasms
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Neoplasms
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Neoplasms
Initiation of a formalized precision medicine program in gynecologic oncology.
Neoplasms
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Neoplasms
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Neoplasms
Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling.
Neoplasms
INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.
Neoplasms
Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
Neoplasms
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Neoplasms
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Neoplasms
Insulin-Like Growth Factor-1 Increases the Expression of Inflammatory Biomarkers and Sebum Production in Cultured Sebocytes.
Neoplasms
Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence.
Neoplasms
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Neoplasms
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Neoplasms
Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Neoplasms
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Neoplasms
Integrated genomic characterization of endometrial carcinoma.
Neoplasms
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Neoplasms
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Neoplasms
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Neoplasms
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Neoplasms
Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
Neoplasms
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Neoplasms
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Neoplasms
Integrative clinical genomics of metastatic cancer.
Neoplasms
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Neoplasms
Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Neoplasms
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Neoplasms
Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin.
Neoplasms
Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.
Neoplasms
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Neoplasms
Intermittent high dose scheduling of AZD8835, a novel selective inhibitor of PI3K? and PI3K?, demonstrates treatment strategies for PIK3CA-dependent breast cancers.
Neoplasms
Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Neoplasms
Intraductal tubulopapillary neoplasm of the pancreas with somatic BRAF mutation.
Neoplasms
Intraductal Tubulopapillary Neoplasm of the Pancreas: An Overview.
Neoplasms
Intratumor heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification (MLPA). A DESCRIPTIVE STUDY.
Neoplasms
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial.
Neoplasms
Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3K?) inhibitors.
Neoplasms
Invasive ductal carcinoma arising in borderline phyllode tumor: A potential role of PIK3CA mutation.
Neoplasms
Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
Neoplasms
Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
Neoplasms
Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells.
Neoplasms
Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors
Neoplasms
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Neoplasms
Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: Therapeutic implications.
Neoplasms
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.
Neoplasms
Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice.
Neoplasms
Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.
Neoplasms
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Neoplasms
Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.
Neoplasms
Is the PIK3CA gene expression level in FNAB washouts equivalent to that in postoperative tissue specimens of papillary thyroid carcinoma?
Neoplasms
Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.
Neoplasms
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Neoplasms
JAK/STAT pathway interacts with intercellular cell adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) while prostate cancer stem cells form tumor spheroids.
Neoplasms
Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1? signaling pathway.
Neoplasms
KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer.
Neoplasms
Key autophagic targets and relevant small-molecule compounds in cancer therapy.
Neoplasms
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
Neoplasms
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
Neoplasms
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Neoplasms
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
Neoplasms
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
Neoplasms
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Neoplasms
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
Neoplasms
KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.
Neoplasms
KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Neoplasms
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
Neoplasms
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment.
Neoplasms
KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Neoplasms
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer.
Neoplasms
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
Neoplasms
Kras-driven heterotopic tumor development from hepatobiliary organoids.
Neoplasms
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management.
Neoplasms
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Neoplasms
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Neoplasms
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Neoplasms
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Neoplasms
Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
Neoplasms
Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors.
Neoplasms
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
Neoplasms
Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Neoplasms
Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.
Neoplasms
LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
Neoplasms
Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer.
Neoplasms
Lipid-dependent Akt-ivity: where, when, and how.
Neoplasms
Liquid biopsies for bladder cancer.
Neoplasms
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Neoplasms
Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer.
Neoplasms
Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
Neoplasms
Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
Neoplasms
LncRNA TSLC1-AS1 is a novel tumor suppressor in glioma.
Neoplasms
Lobular breast cancer: Clinical, molecular and morphological characteristics.
Neoplasms
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Neoplasms
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Neoplasms
Long noncoding RNA NEAT1 promotes the growth of gastric cancer cells by regulating miR-497-5p/PIK3R1 axis.
Neoplasms
Long-term p110? PI3K inactivation exerts a beneficial effect on metabolism.
Neoplasms
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Neoplasms
Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.
Neoplasms
Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Neoplasms
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Neoplasms
Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
Neoplasms
Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model.
Neoplasms
Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells.
Neoplasms
Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.
Neoplasms
Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
Neoplasms
Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin.
Neoplasms
Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling.
Neoplasms
Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.
Neoplasms
Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.
Neoplasms
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Neoplasms
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.
Neoplasms
LOXL1-AS1 Drives The Progression Of Gastric Cancer Via Regulating miR-142-5p/PIK3CA Axis.
Neoplasms
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Neoplasms
LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle.
Neoplasms
LRRC4 Suppresses E-Cadherin-Dependent Collective Cell Invasion and Metastasis in Epithelial Ovarian Cancer.
Neoplasms
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Neoplasms
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Neoplasms
Lung cancer in never smokers from the Princess Margaret Cancer Centre.
Neoplasms
Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy and Outcome.
Neoplasms
Luteolin, a flavonoid with potential for cancer prevention and therapy.
Neoplasms
LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
Neoplasms
LY294002, an inhibitor of PI-3K, enhances heat sensitivity independently of p53 status in human lung cancer cells.
Neoplasms
m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer.
Neoplasms
Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations.
Neoplasms
Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Neoplasms
Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
Neoplasms
Management of toxicity to isoform ?-specific PI3K inhibitors.
Neoplasms
MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.
Neoplasms
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Neoplasms
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma.
Neoplasms
Measurement of PIP3 levels reveals an unexpected role for p110? in early adaptive responses to p110?-specific inhibitors in luminal breast cancer.
Neoplasms
Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Neoplasms
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
Neoplasms
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model.
Neoplasms
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Neoplasms
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.
Neoplasms
MEK, P38 AND PI-3K MEDIATE CROSS TALK BETWEEN EGFR AND TNFR IN ENHANCING HEPATOCYTE GROWTH FACTOR PRODUCTION FROM HUMAN MESENCHYMAL STEM CELLS.
Neoplasms
Melatonin alleviates liver steatosis induced by prenatal dexamethasone exposure and postnatal high-fat diet.
Neoplasms
Membrane-binding and activation mechanism of PTEN.
Neoplasms
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases.
Neoplasms
MET in gastric cancer - discarding a 10% cutoff rule.
Neoplasms
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.
Neoplasms
Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line.
Neoplasms
Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Neoplasms
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.
Neoplasms
Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling.
Neoplasms
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
Neoplasms
MEX3A promotes development and progression of breast cancer through regulation of PIK3CA.
Neoplasms
Mgat5 and Pten interact to regulate cell growth and polarity.
Neoplasms
Mice expressing activated PI3K rapidly develop advanced colon cancer.
Neoplasms
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Neoplasms
MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer.
Neoplasms
MicroRNA MIR21 and T Cells in Colorectal Cancer.
Neoplasms
MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.
Neoplasms
MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.
Neoplasms
MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
Neoplasms
MicroRNA?363?3p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt/mTOR signaling pathway by targeting PIK3CA.
Neoplasms
Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Neoplasms
MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta.
Neoplasms
MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.
Neoplasms
miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition.
Neoplasms
miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA.
Neoplasms
miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer.
Neoplasms
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.
Neoplasms
MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
Neoplasms
MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.
Neoplasms
MiR-486-5p Serves as a Good Biomarker in Nonsmall Cell Lung Cancer and Suppresses Cell Growth With the Involvement of a Target PIK3R1.
Neoplasms
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
Neoplasms
miR-495 promotes apoptosis and inhibits proliferation in endometrial cells via targeting PIK3R1.
Neoplasms
miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma.
Neoplasms
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Neoplasms
miR?142?5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA.
Neoplasms
miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing.
Neoplasms
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.
Neoplasms
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Neoplasms
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Neoplasms
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Neoplasms
Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis.
Neoplasms
Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN).
Neoplasms
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.
Neoplasms
Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability.
Neoplasms
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.
Neoplasms
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Neoplasms
Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXR?.
Neoplasms
Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Neoplasms
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Neoplasms
Molecular alterations in uterine serous carcinoma.
Neoplasms
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Neoplasms
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Neoplasms
Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion.
Neoplasms
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Neoplasms
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation.
Neoplasms
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report.
Neoplasms
Molecular association of functioning stroma with carcinoma cells in the ovary: A preliminary study.
Neoplasms
Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study.
Neoplasms
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
Neoplasms
Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms.
Neoplasms
Molecular Characterization of an Endometrial Endometrioid Adenocarcinoma Metastatic to a Thyroid Hürthle Cell Adenoma Showing Cancerization of Follicles.
Neoplasms
Molecular characterization of colorectal cancer using whole-exome sequencing in a Taiwanese population.
Neoplasms
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.
Neoplasms
Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation.
Neoplasms
Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts.
Neoplasms
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.
Neoplasms
Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas.
Neoplasms
Molecular Dissection of AKT Activation in Lung Cancer Cell Lines.
Neoplasms
Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.
Neoplasms
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Neoplasms
Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma.
Neoplasms
Molecular imaging of Akt kinase activity.
Neoplasms
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Neoplasms
Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Neoplasms
Molecular pathological classification of colorectal cancer.
Neoplasms
Molecular pathways in head and neck cancer.
Neoplasms
Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia.
Neoplasms
Molecular patterns in salivary duct carcinoma identify prognostic subgroups.
Neoplasms
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
Neoplasms
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Neoplasms
Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.
Neoplasms
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Neoplasms
Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.
Neoplasms
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
Neoplasms
Molecular Profiling Reveals a Clonal Relationship Between Ovarian Mucinous Tumors and Corresponding Mural Carcinomatous Nodules.
Neoplasms
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach.
Neoplasms
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Neoplasms
Molecular spectrum of PIK3CA gene mutations in patients with nonsmall-cell lung cancer in Turkey.
Neoplasms
Molecular testing of NSCLC using a platform for rapid detection of multiple oncogenetic mutations.
Neoplasms
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer.
Neoplasms
Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
Neoplasms
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Neoplasms
Morin protects against acrylamide-induced neurotoxicity in rats: an investigation into different signal pathways.
Neoplasms
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Neoplasms
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Neoplasms
Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications.
Neoplasms
Mouse Models as a Tool for Understanding Progression in BrafV600E-Driven Thyroid Cancers.
Neoplasms
Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy.
Neoplasms
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
Neoplasms
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
Neoplasms
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Neoplasms
mTOR Signalling in Head and Neck Cancer: Heads Up.
Neoplasms
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
Neoplasms
mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Neoplasms
Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Neoplasms
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
Neoplasms
Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis.
Neoplasms
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Neoplasms
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).
Neoplasms
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
Neoplasms
Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study.
Neoplasms
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Neoplasms
Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.
Neoplasms
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.
Neoplasms
Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform.
Neoplasms
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
Neoplasms
Multiplexed assays for detection of mutations in PIK3CA.
Neoplasms
Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Neoplasms
Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin.
Neoplasms
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Neoplasms
Mutant PIK3CA Induces EMT in a Cell Type Specific Manner.
Neoplasms
Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation.
Neoplasms
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Neoplasms
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
Neoplasms
Mutant SF3B1 promotes AKT- and NF-?B-driven mammary tumorigenesis.
Neoplasms
Mutated PI 3-kinases: cancer targets on a silver platter.
Neoplasms
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Neoplasms
Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
Neoplasms
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
Neoplasms
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
Neoplasms
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Neoplasms
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Neoplasms
Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer.
Neoplasms
Mutation of the PIK3CA gene in ovarian and breast cancer.
Neoplasms
Mutation of the PIK3CA oncogene in human cancers.
Neoplasms
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
Neoplasms
Mutation profile of non-small cell lung cancer revealed by next generation sequencing.
Neoplasms
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Neoplasms
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Neoplasms
Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions.
Neoplasms
Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
Neoplasms
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
Neoplasms
Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
Neoplasms
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.
Neoplasms
Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours.
Neoplasms
Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Neoplasms
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Neoplasms
Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Neoplasms
Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.
Neoplasms
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Neoplasms
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
Neoplasms
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Neoplasms
Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Neoplasms
Mutational Hotspot in Exon 20 of PIK3CA in Breast Cancer Among Singapore Chinese.
Neoplasms
Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort.
Neoplasms
Mutational landscape of penile squamous cell carcinoma in a Chinese population.
Neoplasms
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Neoplasms
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Neoplasms
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Neoplasms
Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.
Neoplasms
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Neoplasms
Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
Neoplasms
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Neoplasms
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Neoplasms
Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance.
Neoplasms
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
Neoplasms
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
Neoplasms
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Neoplasms
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Neoplasms
Mutations in long-lived epithelial stem cells and their clonal progeny in pre-malignant lesions and in oral squamous cell carcinoma.
Neoplasms
Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Neoplasms
Mutations in PIK3CA are infrequent in neuroblastoma.
Neoplasms
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Neoplasms
Mutations in renal cell carcinoma.
Neoplasms
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Neoplasms
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Neoplasms
Mutations of PIK3CA are rare in cutaneous melanoma.
Neoplasms
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Neoplasms
Mutations of PIK3CA in gastric adenocarcinoma.
Neoplasms
Mutations of the human PTEN gene.
Neoplasms
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Neoplasms
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Neoplasms
MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase.
Neoplasms
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
Neoplasms
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Neoplasms
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Neoplasms
Myosin 1b Regulates Nuclear AKT Activation by Preventing Localization of PTEN in the Nucleus.
Neoplasms
Myristoylated p110? Causes Embryonic Death Due to Developmental and Vascular Defects.
Neoplasms
NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.
Neoplasms
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.
Neoplasms
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.
Neoplasms
Near-Comprehensive Resequencing of Cancer-Associated Genes in Surgically Resected Metastatic Liver Tumors of Gastric Cancer.
Neoplasms
NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling.
Neoplasms
Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis.
Neoplasms
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Neoplasms
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Neoplasms
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
Neoplasms
Neoadjuvant treatment of breast cancer--Clinical and research perspective.
Neoplasms
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Neoplasms
Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.
Neoplasms
Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism.
Neoplasms
Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease.
Neoplasms
Neuroblast niche position is controlled by Phosphoinositide 3-kinase-dependent DE-Cadherin adhesion.
Neoplasms
Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.
Neoplasms
New agents in follicular lymphoma.
Neoplasms
New and emerging factors in tumorigenesis: an overview.
Neoplasms
New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization.
Neoplasms
New generation breast cancer cell lines developed from patient-derived xenografts.
Neoplasms
New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
Neoplasms
New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs).
Neoplasms
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Neoplasms
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Neoplasms
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
Neoplasms
New miRNA expression abnormalities in laryngeal squamous cell carcinoma.
Neoplasms
New molecular prognostic factors of adult diffuse lower-grade gliomas in post-2016 molecular era: a retrospective analysis from single center.
Neoplasms
New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway--The Devil Is in the Details.
Neoplasms
Next generation sequencing of cervical high grade dysplasia and invasive squamous cell carcinoma: A case study.
Neoplasms
Next-generation sequencing identified somatic alterations that may underlie the etiology of Chinese papillary thyroid carcinoma.
Neoplasms
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Neoplasms
Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain.
Neoplasms
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Neoplasms
Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
Neoplasms
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Neoplasms
NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
Neoplasms
No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer.
Neoplasms
NODAL/TGF? signalling mediates the self-sustained stemness induced by PIK3CA
H1047R
homozygosity in pluripotent stem cells.
Neoplasms
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models.
Neoplasms
Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Neoplasms
Normal vitreous promotes angiogenesis via activation of Axl.
Neoplasms
Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway.
Neoplasms
Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K? inhibition.
Neoplasms
Novel approaches to inhibitor design for the p110? phosphoinositide 3-kinase.
Neoplasms
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Neoplasms
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Neoplasms
Novel molecular insights from routine genotyping of colorectal carcinomas.
Neoplasms
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Neoplasms
Novel Mutations in Neuroendocrine Carcinoma of the Breast: Possible Therapeutic Targets.
Neoplasms
Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
Neoplasms
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Neoplasms
Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells.
Neoplasms
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
Neoplasms
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Neoplasms
Nuclear upregulation of class I phosphoinositide 3-kinase p110? correlates with high 47S rRNA levels in cancer cells.
Neoplasms
NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.
Neoplasms
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Neoplasms
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Neoplasms
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Neoplasms
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects.
Neoplasms
Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA.
Neoplasms
Oncogene alterations in endometrial carcinosarcomas.
Neoplasms
Oncogene and therapeutic target analyses in Atypical fibroxanthomas and pleomorphic dermal sarcomas.
Neoplasms
Oncogene mutational profile in nasopharyngeal carcinoma.
Neoplasms
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
Neoplasms
Oncogenic ?-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids.
Neoplasms
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Neoplasms
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Neoplasms
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
Neoplasms
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Neoplasms
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Neoplasms
Oncogenic mutations of p110? isoform of PI 3-kinase upregulate its protein kinase activity.
Neoplasms
Oncogenic mutations of PIK3CA in human cancers.
Neoplasms
Oncogenic Mutations of PIK3CA in Human Cancers.
Neoplasms
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Neoplasms
Oncogenic PI3K and its role in cancer.
Neoplasms
Oncogenic PI3K mutations lead to NF-?B-dependent cytokine expression following growth factor deprivation.
Neoplasms
Oncogenic PI3K? promotes multipotency in breast epithelial cells.
Neoplasms
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
Neoplasms
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Neoplasms
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Neoplasms
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Neoplasms
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Neoplasms
Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner.
Neoplasms
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
Neoplasms
Oncogenic signaling of class I PI3K isoforms.
Neoplasms
Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway.
Neoplasms
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Neoplasms
OncomiRs: the discovery and progress of microRNAs in cancers.
Neoplasms
Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.
Neoplasms
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Neoplasms
Origin of mutations in genes associated with human glioblastoma multiform cancer: random polymerase errors versus deamination.
Neoplasms
Osthole shows the potential to overcome P-glycoprotein?mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway.
Neoplasms
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Neoplasms
Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.
Neoplasms
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
Neoplasms
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Neoplasms
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Neoplasms
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Neoplasms
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Neoplasms
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Neoplasms
Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics.
Neoplasms
p-AKT overexpression in primary renal cell carcinomas and their metastases.
Neoplasms
P-REX2a driving tumorigenesis by PTEN inhibition.
Neoplasms
P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin.
Neoplasms
p110? Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110? Kinase Activity.
Neoplasms
p110? PI 3-kinase inhibition perturbs APP and TNF? trafficking, reduces plaque burden, dampens neuroinflammation and prevents cognitive decline in an Alzheimer's disease mouse model.
Neoplasms
p110? PI3K as a therapeutic target of solid tumours.
Neoplasms
p110delta is required for innate immunity to transplantable lymphomas.
Neoplasms
p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease.
Neoplasms
p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities.
Neoplasms
P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma.
Neoplasms
p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.
Neoplasms
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
Neoplasms
p55PIK Transcriptionally Activated by MZF1 Promotes Colorectal Cancer Cell Proliferation.
Neoplasms
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Neoplasms
p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.
Neoplasms
p85? increases phosphoinositide 3-kinase activity and accelerates tumor progression.
Neoplasms
p85? neomorphic mutants: splitting away from the canonical path.
Neoplasms
p85? phosphoinositide 3-kinase subunit regulates tumor progression.
Neoplasms
Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis.
Neoplasms
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas.
Neoplasms
pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.
Neoplasms
Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Neoplasms
Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs.
Neoplasms
Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110?.
Neoplasms
Papillary thyroid cancer in a struma ovarii: a report of a rare case.
Neoplasms
Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.
Neoplasms
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase ? Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Neoplasms
Particular molecular and ultrastructural aspects in invasive mammary carcinoma.
Neoplasms
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Neoplasms
Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis.
Neoplasms
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
Neoplasms
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Neoplasms
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
Neoplasms
Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma.
Neoplasms
PD-1/PD-L1-associated immunoarchitectural patterns stratify pancreatic cancer patients into prognostic/predictive subgroups.
Neoplasms
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
Neoplasms
Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models.
Neoplasms
Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.
Neoplasms
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Neoplasms
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Neoplasms
Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Neoplasms
Perspective: Potential Impact and Therapeutic Implications of Oncogenic PI3K Activation on Chromosomal Instability.
Neoplasms
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Neoplasms
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer.
Neoplasms
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Neoplasms
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Neoplasms
Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells.
Neoplasms
Pharmacologically targeting the myristoylation of the scaffold protein FRS2? inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Neoplasms
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Neoplasms
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Neoplasms
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Neoplasms
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Neoplasms
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Neoplasms
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Neoplasms
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
Neoplasms
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Neoplasms
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma.
Neoplasms
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Neoplasms
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies.
Neoplasms
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
Neoplasms
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Neoplasms
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.
Neoplasms
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Neoplasms
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Neoplasms
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Neoplasms
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Neoplasms
Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.
Neoplasms
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Neoplasms
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Neoplasms
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Neoplasms
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
Neoplasms
Phase II trial of temsirolimus in patients with metastatic breast cancer.
Neoplasms
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Neoplasms
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Neoplasms
PHLPP2 gene L1016S (rs61733127) and PIK3R1 gene Met326Ile (rs3730089) polymorphisms are associated with the risk of colon and breast cancers.
Neoplasms
Phospatidylinositol 3-kinase expression in human breast cancer.
Neoplasms
Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins.
Neoplasms
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Neoplasms
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Neoplasms
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Neoplasms
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Neoplasms
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Neoplasms
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Neoplasms
Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages.
Neoplasms
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
Neoplasms
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.
Neoplasms
Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha.
Neoplasms
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Neoplasms
Phosphatidylinositol Phosphate 5-Kinase I? and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth.
Neoplasms
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Neoplasms
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Neoplasms
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Neoplasms
Phosphoinositide 3-kinase ? inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Neoplasms
Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy.
Neoplasms
Phosphoinositide 3-kinase beta controls replication factor C assembly and function.
Neoplasms
Phosphoinositide 3-kinase inhibition in cancer treatment.
Neoplasms
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Neoplasms
Phosphoinositide 3-kinase inhibitors in lymphoma.
Neoplasms
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Neoplasms
Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.
Neoplasms
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Neoplasms
Phosphoinositide 3-kinase signaling pathway mediated by p110? regulates invadopodia formation.
Neoplasms
Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.
Neoplasms
Phosphoinositide 3-kinase-related overgrowth: cellular phenotype and future therapeutic options.
Neoplasms
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer.
Neoplasms
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
Neoplasms
Phosphoinositide 3-kinases as drug targets in cancer.
Neoplasms
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Neoplasms
Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.
Neoplasms
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.
Neoplasms
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex.
Neoplasms
Phosphorylation of the PTEN tail regulates protein stability and function.
Neoplasms
Phylogenetic analysis of combined lobular and ductal carcinoma of the breast.
Neoplasms
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ER?-positive tumors.
Neoplasms
Phytochemicals and PI3K Inhibitors in Cancer-An Insight.
Neoplasms
PI 3-kinase and cancer: changing accents.
Neoplasms
PI 3-kinase, Akt and cell survival.
Neoplasms
PI 3-kinase, mTOR, protein synthesis and cancer.
Neoplasms
PI 3-kinases: hidden potentials revealed.
Neoplasms
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Neoplasms
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
Neoplasms
PI3-kinase ? promotes Rap1a-mediated activation of myeloid cell integrin ?4?1, leading to tumor inflammation and growth.
Neoplasms
PI3-kinase and the control of T cell growth and proliferation by FoxOs.
Neoplasms
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
Neoplasms
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
Neoplasms
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.
Neoplasms
PI3K and cancer: lessons, challenges and opportunities.
Neoplasms
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies.
Neoplasms
PI3K and RAC signalling in leukocyte and cancer cell migration.
Neoplasms
PI3K as a Target for Therapy in Haematological Malignancies.
Neoplasms
PI3K expression predicts overall survival in lung adenocarcinoma.
Neoplasms
PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment.
Neoplasms
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Neoplasms
PI3K inhibitors are finally coming of age.
Neoplasms
PI3K inhibitors for cancer therapy: what has been achieved so far?
Neoplasms
PI3K inhibitors: review and new strategies.
Neoplasms
PI3K mutations in breast cancer: prognostic and therapeutic implications.
Neoplasms
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Neoplasms
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers.
Neoplasms
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression free survival.
Neoplasms
PI3K pathway alterations in cancer: variations on a theme.
Neoplasms
PI3K Pathway in Gynecologic Malignancies.
Neoplasms
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Neoplasms
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.
Neoplasms
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Neoplasms
PI3K regulatory subunits lose control in cancer.
Neoplasms
PI3K signaling in cancer: beyond AKT.
Neoplasms
PI3K signaling in glioma--animal models and therapeutic challenges.
Neoplasms
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Neoplasms
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Neoplasms
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.
Neoplasms
PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Neoplasms
PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer.
Neoplasms
PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas.
Neoplasms
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations.
Neoplasms
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
Neoplasms
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
Neoplasms
PI3K? Is a Therapeutic Target in Hepatocellular Carcinoma.
Neoplasms
PI3K?? Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
Neoplasms
PI3KCA Mutations in Uterine Cervix Carcinoma.
Neoplasms
PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion.
Neoplasms
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
Neoplasms
PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.
Neoplasms
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
Neoplasms
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Neoplasms
PIK3CA alterations in Middle Eastern ovarian cancers.
Neoplasms
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Neoplasms
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Neoplasms
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Neoplasms
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.
Neoplasms
PIK3CA and AKT1 mutations in hidradenoma papilliferum.
Neoplasms
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Neoplasms
PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium.
Neoplasms
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
Neoplasms
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
Neoplasms
PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.
Neoplasms
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
Neoplasms
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.
Neoplasms
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.
Neoplasms
PIK3CA as an oncogene in cervical cancer.
Neoplasms
PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-? inhibition.
Neoplasms
PIK3CA cancer mutations display gender and tissue specificity patterns.
Neoplasms
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Neoplasms
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
Neoplasms
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Neoplasms
PIK3CA Double Mutations in Cis May Predict PI3K?-Inhibitor Response.
Neoplasms
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Neoplasms
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
Neoplasms
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Neoplasms
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.
Neoplasms
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Neoplasms
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
Neoplasms
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Neoplasms
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
Neoplasms
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
Neoplasms
PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
Neoplasms
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
Neoplasms
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Neoplasms
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma.
Neoplasms
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
Neoplasms
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis.
Neoplasms
PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies.
Neoplasms
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Neoplasms
PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.
Neoplasms
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
Neoplasms
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Neoplasms
PIK3CA in cancer: The past 30 years.
Neoplasms
PIK3CA in Colorectal Cancer.
Neoplasms
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
Neoplasms
PIK3CA is implicated as an oncogene in ovarian cancer.
Neoplasms
Pik3ca is required for mouse uterine gland development and pregnancy.
Neoplasms
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.
Neoplasms
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase.
Neoplasms
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
Neoplasms
PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis.
Neoplasms
PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Neoplasms
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Neoplasms
PIK3CA mutation associates with improved outcome in breast cancer.
Neoplasms
PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Neoplasms
PIK3CA mutation detected by liquid biopsy in patients with metastatic breast cancer.
Neoplasms
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
Neoplasms
PIK3CA mutation enrichment and quantitation from blood and tissue.
Neoplasms
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Neoplasms
PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups.
Neoplasms
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
Neoplasms
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
Neoplasms
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.
Neoplasms
PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.
Neoplasms
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Neoplasms
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Neoplasms
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Neoplasms
PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT).
Neoplasms
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
Neoplasms
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Neoplasms
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Neoplasms
PIK3CA mutation status in Japanese lung cancer patients.
Neoplasms
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Neoplasms
PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
Neoplasms
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Neoplasms
PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ER? serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.
Neoplasms
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Neoplasms
PIK3CA Mutational Analysis of Parathyroid Adenomas.
Neoplasms
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
Neoplasms
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Neoplasms
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
Neoplasms
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Neoplasms
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
Neoplasms
PIK3CA mutations and copy number gains in human lung cancers.
Neoplasms
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
Neoplasms
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Neoplasms
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.
Neoplasms
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
Neoplasms
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
Neoplasms
PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.
Neoplasms
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Neoplasms
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Neoplasms
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Neoplasms
PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations.
Neoplasms
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Neoplasms
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
Neoplasms
PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.
Neoplasms
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Neoplasms
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
Neoplasms
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Neoplasms
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Neoplasms
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers.
Neoplasms
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes.
Neoplasms
PIK3CA mutations in advanced ovarian carcinomas.
Neoplasms
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Neoplasms
PIK3CA mutations in breast cancer are associated with poor outcome.
Neoplasms
PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Neoplasms
PIK3CA mutations in hepatocellular carcinoma in Korea.
Neoplasms
PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients
Neoplasms
PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions.
Neoplasms
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Neoplasms
PIK3CA mutations in in situ and invasive breast carcinomas.
Neoplasms
PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.
Neoplasms
PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
Neoplasms
PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Neoplasms
PIK3CA mutations in oligodendroglial tumours.
Neoplasms
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
Neoplasms
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Neoplasms
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
Neoplasms
PIK3CA Mutations in Resected Small Cell Lung Cancer.
Neoplasms
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Neoplasms
PIK3CA mutations in small bowel adenocarcinoma.
Neoplasms
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Neoplasms
PIK3CA mutations in vascular malformations.
Neoplasms
PIK3CA mutations matter for cancer in dogs.
Neoplasms
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in Breast Cancer.
Neoplasms
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
Neoplasms
PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
Neoplasms
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Neoplasms
Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
Neoplasms
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Neoplasms
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
Neoplasms
PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
Neoplasms
PIK3CA somatic mutation in sinonasal teratocarcinosarcoma.
Neoplasms
PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.
Neoplasms
PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.
Neoplasms
PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Neoplasms
PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Neoplasms
PIK3CA, a hotspot for postzygotic mutations in nonhereditary overgrowth syndromes.
Neoplasms
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer.
Neoplasms
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Neoplasms
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Neoplasms
PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis.
Neoplasms
PIK3CD induces cell growth and invasion by activating AKT/GSK-3?/?-catenin signaling in colorectal cancer.
Neoplasms
PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.
Neoplasms
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
Neoplasms
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
Neoplasms
PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development.
Neoplasms
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Neoplasms
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
Neoplasms
Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.
Neoplasms
PipeIT: A Singularity Container for Molecular Diagnostic Somatic Variant Calling on the Ion Torrent Next-Generation Sequencing Platform.
Neoplasms
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Neoplasms
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation.
Neoplasms
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
Neoplasms
Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma.
Neoplasms
Plasma Fibronectin Promotes Tumor Cell Survival and Invasion through Regulation of Tie2.
Neoplasms
Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation.
Neoplasms
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer.
Neoplasms
Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.
Neoplasms
POLE somatic mutations in advanced colorectal cancer.
Neoplasms
Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer.
Neoplasms
Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.
Neoplasms
Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival.
Neoplasms
Posttranscriptional Control of PD-L1 Expression by 17?-Estradiol via PI3K/Akt Signaling Pathway in ER?-Positive Cancer Cell Lines.
Neoplasms
Potent anti-cancer activity of Alnus nitida against lung cancer cells; in vitro and in vivo studies.
Neoplasms
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Neoplasms
Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer.
Neoplasms
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Neoplasms
Power to see-Drivers of aerobic glycolysis in the mammalian retina: A review.
Neoplasms
PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Neoplasms
Pre-clinical validation of a next generation sequencing testing panel.
Neoplasms
Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.
Neoplasms
Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.
Neoplasms
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin.
Neoplasms
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Neoplasms
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Neoplasms
Preclinical Pharmacology of AZD5363, an Orally Bioavailable Inhibitor of AKT: Pharmacodynamics, Antitumor Activity and Correlation of Monotherapy Activity with Genetic Background.
Neoplasms
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.
Neoplasms
Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance).
Neoplasms
Prediction of PIK3CA mutations from cancer gene expression data.
Neoplasms
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Neoplasms
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Neoplasms
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Neoplasms
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Neoplasms
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Neoplasms
Predictors of Lymph Node Count in Colorectal Cancer Resections: Data From US Nationwide Prospective Cohort Studies.
Neoplasms
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Neoplasms
Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Neoplasms
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Neoplasms
Prevalence and architecture of posttranscriptionally impaired synonymous mutations in 8,320 genomes across 22 cancer types.
Neoplasms
Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer.
Neoplasms
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Neoplasms
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Neoplasms
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Neoplasms
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Neoplasms
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Neoplasms
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Neoplasms
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Neoplasms
Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3.
Neoplasms
PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.
Neoplasms
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Neoplasms
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer.
Neoplasms
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.
Neoplasms
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Neoplasms
Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells.
Neoplasms
Probable hereditary familial overlap syndrome with multiple synchronous lung tumors.
Neoplasms
Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA.
Neoplasms
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Neoplasms
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Neoplasms
Progestin-associated shift of meningioma mutational landscape.
Neoplasms
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Neoplasms
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Neoplasms
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Neoplasms
Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Neoplasms
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Neoplasms
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Neoplasms
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Neoplasms
Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Neoplasms
Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Neoplasms
Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.
Neoplasms
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Neoplasms
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Neoplasms
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
Neoplasms
Prognostic Significance and Molecular Associations of Tumor Growth Pattern in Colorectal Cancer.
Neoplasms
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Neoplasms
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
Neoplasms
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Neoplasms
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.
Neoplasms
Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma.
Neoplasms
Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity.
Neoplasms
Proliferative and antiapoptotic signaling stimulated by nuclear-localized PDK1 results in oncogenesis.
Neoplasms
Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3?/?-catenin signalling.
Neoplasms
Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.
Neoplasms
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Neoplasms
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer.
Neoplasms
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Neoplasms
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.
Neoplasms
Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.
Neoplasms
Prostate cancer, PI3K, PTEN and prognosis.
Neoplasms
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Neoplasms
Protein interactions of PTEN and its cancer-associated G20E mutant compared by stable isotope labeling by amino acids in cell culture -based parallel affinity purification.
Neoplasms
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.
Neoplasms
Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer.
Neoplasms
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion.
Neoplasms
Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting.
Neoplasms
Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Neoplasms
Proximity ligation assay to detect and localize the interactions of ER? with PI3-K and Src in breast cancer cells and tumor samples.
Neoplasms
PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer.
Neoplasms
PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
Neoplasms
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Neoplasms
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Neoplasms
PTEN and the PI3-Kinase Pathway in Cancer.
Neoplasms
PTEN deficiency contributes to the development and progression of head and neck cancer.
Neoplasms
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Neoplasms
PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression.
Neoplasms
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.
Neoplasms
PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway.
Neoplasms
PTEN is required for the migration and invasion of Ras-transformed MDCK cells.
Neoplasms
PTEN loss correlates with T cell exclusion across human cancers.
Neoplasms
PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5). Evidence for Ins(1,3,4,5,6)P5 as a proliferative signal.
Neoplasms
PTEN mutations are common in sporadic microsatellite stable colorectal cancer.
Neoplasms
PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.
Neoplasms
PTEN regulates cilia through Dishevelled.
Neoplasms
PTEN regulation of ERK1/2 signaling in cancer.
Neoplasms
PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Neoplasms
PTEN, more than the AKT pathway.
Neoplasms
PTEN-Associated Complexes: An Overview.
Neoplasms
PTEN-deficient cancers depend on PIK3CB.
Neoplasms
PTEN-mediated AKT activation contributes to the reduced apoptosis among Indian oral squamous cell carcinoma patients.
Neoplasms
Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction.
Neoplasms
PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.
Neoplasms
Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations.
Neoplasms
Pulmonary Adenocarcinoma With Signet Ring Cell Features: A Comprehensive Study From 3 Distinct Patient Cohorts.
Neoplasms
Putting the rap on Akt.
Neoplasms
Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.
Neoplasms
R-Ras promotes tumor growth of cervical epithelial cells.
Neoplasms
Racial Disparities in the Molecular Landscape of Cancer.
Neoplasms
Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.
Neoplasms
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Neoplasms
RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors.
Neoplasms
Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
Neoplasms
Ran GTPase in Nuclear Envelope Formation and Cancer Metastasis.
Neoplasms
Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Neoplasms
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
Neoplasms
Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
Neoplasms
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling.
Neoplasms
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Neoplasms
Rare genetic heterogeneity within single tumor discovered for the first time in colorectal liver metastases after liver resection.
Neoplasms
Rare Mutations in the PIK3CA Gene Contribute to Aggressive Endometrial Cancer.
Neoplasms
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Neoplasms
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Neoplasms
RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.
Neoplasms
Rational design of phosphoinositide 3-kinase ? inhibitors that exhibit selectivity over the phosphoinositide 3-kinase ? isoform.
Neoplasms
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Neoplasms
Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
Neoplasms
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology.
Neoplasms
Recent discovery of phosphoinositide 3-kinase ? inhibitors for the treatment of immune diseases and cancers.
Neoplasms
Recent Patents and Advances in Genomic Biomarker Discovery for Colorectal Cancers.
Neoplasms
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Neoplasms
Recent progess in phosphoinositide 3-kinases: oncogenic properties and prognostic and therapeutic implications.
Neoplasms
Recent therapeutic advances in the treatment of colorectal cancer.
Neoplasms
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k?, a single convergent point promoting tumor inflammation and progression.
Neoplasms
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
Neoplasms
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Neoplasms
Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Neoplasms
Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.
Neoplasms
Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor.
Neoplasms
Redox regulation of PI 3-kinase signalling via inactivation of PTEN.
Neoplasms
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.
Neoplasms
Regulation and repurposing of nutrient sensing and autophagy in innate immunity.
Neoplasms
Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells.
Neoplasms
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
Neoplasms
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Neoplasms
Regulation of dauer larva development in Caenorhabditis elegans by daf-18, a homologue of the tumour suppressor PTEN.
Neoplasms
Regulation of heart rate and the pacemaker current by phosphoinositide 3-kinase signaling.
Neoplasms
Regulation of human neutrophil-mediated cartilage proteoglycan degradation by phosphatidylinositol-3-kinase.
Neoplasms
Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Neoplasms
Regulation of mRNA Translation by Signaling Pathways.
Neoplasms
Regulation of multidrug resistance in cancer cells by hyaluronan.
Neoplasms
Regulation of phosphoinositide 3-kinase expression in health and disease.
Neoplasms
Regulation of PI 3-K, PTEN, p53, and mTOR in Malignant and Benign Tumors Deficient in Tuberin.
Neoplasms
Regulation of SCF(SKP2) ubiquitin E3 ligase assembly and p27(KIP1) proteolysis by the PTEN pathway and cyclin D1.
Neoplasms
Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
Neoplasms
Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells.
Neoplasms
Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Neoplasms
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Neoplasms
Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations.
Neoplasms
Relationship between mismatch repair protein, RAS, BRAF, PIK3CA gene expression and clinicopathological characteristics in elderly colorectal cancer patients.
Neoplasms
Relationship Between PIK3CA Amplification and P110? and CD34 Tissue Expression as Angiogenesis Markers in Iranian Women with Sporadic Breast Cancer.
Neoplasms
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Neoplasms
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
Neoplasms
Requirement for interaction of PI3-kinase p110? with RAS in lung tumor maintenance.
Neoplasms
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Neoplasms
Research Strategies for Low-Survival Cancers.
Neoplasms
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Neoplasms
Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report.
Neoplasms
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Neoplasms
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Neoplasms
Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.
Neoplasms
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Neoplasms
Revealing tumor heterogeneity of breast cancer by utilizing the linkage between somatic and germline mutations.
Neoplasms
Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer.
Neoplasms
Review of natural compounds for potential skin cancer treatment.
Neoplasms
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Neoplasms
Riedel's thyroiditis - a case report with genes' expression studies.
Neoplasms
Risk factors for brain metastases in patients with metastatic colorectal cancer.
Neoplasms
Rlip Depletion Suppresses Growth of Breast Cancer.
Neoplasms
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.
Neoplasms
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
Neoplasms
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Neoplasms
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Neoplasms
Role of c-Met in cancer: emphasis on lung cancer.
Neoplasms
Role of Cadherins in Cancer-A Review.
Neoplasms
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Neoplasms
Role of estrogen in lung cancer based on the estrogen receptor-epithelial mesenchymal transduction signaling pathways.
Neoplasms
Role of Forkhead Box Class O proteins in cancer progression and metastasis.
Neoplasms
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Neoplasms
Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737.
Neoplasms
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Neoplasms
Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant.
Neoplasms
Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells.
Neoplasms
Role of PTEN/PI3K pathway in endothelial cells.
Neoplasms
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Neoplasms
Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines.
Neoplasms
Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications.
Neoplasms
Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
Neoplasms
Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.
Neoplasms
Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Neoplasms
Rosette forming glioneuronal tumor in the optico-chiasmatic region-a novel entity in a new location.
Neoplasms
Rosette-Forming Glioneuronal Tumor in the Pineal Region: A Series of 6 Cases and Literature Review.
Neoplasms
Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1.
Neoplasms
Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Neoplasms
RTK-dependent inducible degradation of mutant PI3K? drives GDC-0077 (Inavolisib) efficacy.
Neoplasms
S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
Neoplasms
SABCS 2016: systemic therapy for metastatic breast cancer.
Neoplasms
Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway.
Neoplasms
Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Neoplasms
Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.
Neoplasms
SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice.
Neoplasms
Scaffolding Function of PI3Kgamma Emerges from Enzyme's Shadow.
Neoplasms
Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.
Neoplasms
Screening for PIK3CA mutations among Saudi women with ovarian cancer.
Neoplasms
Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
Neoplasms
Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.
Neoplasms
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Neoplasms
Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
Neoplasms
Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells.
Neoplasms
Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation.
Neoplasms
Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.
Neoplasms
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
Neoplasms
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.
Neoplasms
Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas.
Neoplasms
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Neoplasms
Sequence Mutations and Amplification of PIK3CA and AKT2 Genes in Purified Ovarian Serous Neoplasms.
Neoplasms
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.
Neoplasms
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
Neoplasms
SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3?/?-catenin signaling in HCC cells.
Neoplasms
SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).
Neoplasms
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Neoplasms
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Neoplasms
Should individual PI3 kinase isoforms be targeted in cancer?
Neoplasms
Sialadenoma Papilliferum of the Bronchus: An Unrecognized Bronchial Counterpart of the Salivary Gland Tumor With Frequent BRAF V600E Mutations.
Neoplasms
Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
Neoplasms
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin.
Neoplasms
Signaling pathways in HPV-associated cancers and therapeutic implications.
Neoplasms
Signalling specificity in the Akt pathway in breast cancer.
Neoplasms
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Neoplasms
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Neoplasms
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Neoplasms
Silencing TAK1 alters gene expression signatures in bladder cancer cells.
Neoplasms
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Neoplasms
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Neoplasms
Single Cell RNA-Seq Analysis Identifies Differentially Expressed Genes of Treg Cell in Early Treatment-Naive Rheumatoid Arthritis By Arsenic Trioxide.
Neoplasms
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Neoplasms
Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer.
Neoplasms
Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification.
Neoplasms
Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Neoplasms
Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in Small-Animal Model.
Neoplasms
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Neoplasms
Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Neoplasms
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
Neoplasms
Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27.
Neoplasms
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Neoplasms
SMARCB1 (INI1)-negative Rhabdoid Carcinomas of the Gastrointestinal Tract: Clinicopathologic and Molecular Study of a Highly Aggressive Variant With Literature Review.
Neoplasms
Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction.
Neoplasms
SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers.
Neoplasms
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Neoplasms
Somatic alterations in the human cancer genome.
Neoplasms
Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 were associated with chemosensitivity for breast cancers.
Neoplasms
Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.
Neoplasms
Somatic Host Cell Alterations in HPV Carcinogenesis.
Neoplasms
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Neoplasms
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Neoplasms
Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers.
Neoplasms
Somatic mutation of PIK3R1 gene is rare in common human cancers.
Neoplasms
Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.
Neoplasms
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Neoplasms
Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
Neoplasms
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Neoplasms
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
Neoplasms
Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas.
Neoplasms
Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Neoplasms
Somatic mutations in the notch, NF-KB, PIK3CA, and hedgehog pathways in human breast cancers.
Neoplasms
Somatic mutations of PIK3R1 promote gliomagenesis.
Neoplasms
Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.
Neoplasms
Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?
Neoplasms
Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.
Neoplasms
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Neoplasms
Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma.
Neoplasms
Spatiotemporal genomic architecture informs precision oncology in glioblastoma.
Neoplasms
Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
Neoplasms
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Neoplasms
Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
Neoplasms
Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells.
Neoplasms
Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.
Neoplasms
Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism.
Neoplasms
Starving PTEN-deficient prostate cancer cells thrive under nutrient stress by scavenging corpses for their supper.
Neoplasms
Stimulation of PI 3-kinase signaling via inhibition of the tumor suppressor phosphatase, PTEN.
Neoplasms
Stoichiometric quantification of Akt phosphorylation using LC-MS/MS.
Neoplasms
Stopping ras in its tracks.
Neoplasms
Stromal resistance of fibroblasts against oxidative damage: involvement of tumor cell-secreted platelet-derived growth factor (PDGF) and phosphoinositide 3-kinase (PI3K) activation.
Neoplasms
Stromal signatures in endometrioid endometrial carcinomas.
Neoplasms
Structural comparisons of class I phosphoinositide 3-kinases.
Neoplasms
Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein.
Neoplasms
Structure of the phosphoinositide 3-kinase (PI3K) p110?-p101 complex reveals molecular mechanism of GPCR activation.
Neoplasms
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
Neoplasms
Structure-Based Drug Design and Synthesis of PI3K?-Selective Inhibitor (PF-06843195).
Neoplasms
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Neoplasms
Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
Neoplasms
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Neoplasms
Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Neoplasms
Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.
Neoplasms
Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy.
Neoplasms
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
Neoplasms
Successful targeting of ErbB2 receptors-is PTEN the key?
Neoplasms
Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75.
Neoplasms
Suppression of epidermal growth factor receptor-mediated ?-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Neoplasms
Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Neoplasms
Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease.
Neoplasms
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
Neoplasms
Survival prediction model for non-small cell lung cancer based on somatic mutations.
Neoplasms
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Neoplasms
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
Neoplasms
Synchronous rosette-forming glioneuronal tumor and diffuse astrocytoma with molecular characterization: a case report.
Neoplasms
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Neoplasms
Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
Neoplasms
Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Neoplasms
Synergistic interactions with PI3K inhibition that induce apoptosis.
Neoplasms
Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.
Neoplasms
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Neoplasms
Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Neoplasms
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Neoplasms
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
Neoplasms
Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.
Neoplasms
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Neoplasms
Systemic therapy for gallbladder cancer.
Neoplasms
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
Neoplasms
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Neoplasms
T-Cell-Specific Loss of the PI-3-Kinase p110? Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Neoplasms
Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
Neoplasms
Target sequencing of cancer-related genes in early esophageal squamous neoplasia resected by endoscopic resection in Japanese patients.
Neoplasms
Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
Neoplasms
Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue.
Neoplasms
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Neoplasms
Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.
Neoplasms
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Neoplasms
Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.
Neoplasms
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Neoplasms
Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Neoplasms
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity.
Neoplasms
Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study.
Neoplasms
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Neoplasms
Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
Neoplasms
Targeted treatment and new agents in follicular lymphoma.
Neoplasms
Targeting ?-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
Neoplasms
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Neoplasms
Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.
Neoplasms
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
Neoplasms
Targeting disease through novel pathways of apoptosis and autophagy.
Neoplasms
Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.
Neoplasms
Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
Neoplasms
Targeting EGFR and PI3K pathways in ovarian cancer.
Neoplasms
Targeting HER2 heterogeneity in early-stage breast cancer.
Neoplasms
Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics.
Neoplasms
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Neoplasms
Targeting mTOR signaling in lung cancer.
Neoplasms
Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
Neoplasms
Targeting PDK1 in cancer.
Neoplasms
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
Neoplasms
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Neoplasms
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
Neoplasms
Targeting PI3K in neuroblastoma.
Neoplasms
Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Neoplasms
Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy.
Neoplasms
Targeting protein kinase inhibitors with Traditional Chinese Medicine.
Neoplasms
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Neoplasms
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Neoplasms
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Neoplasms
Targeting the genetic landscape of oral potentially malignant disorders has the potential as a preventative strategy in oral cancer.
Neoplasms
Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.
Neoplasms
Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Neoplasms
Targeting the Phosphatidyl Inositol 3-Kinase Signaling Pathway in Breast Cancer.
Neoplasms
Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Neoplasms
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Neoplasms
Targeting the phosphoinositide 3-kinase pathway in cancer.
Neoplasms
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Neoplasms
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Neoplasms
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Neoplasms
Targeting the PI3K signaling pathway in cancer.
Neoplasms
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Neoplasms
Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.
Neoplasms
Targeting truncated retinoid X receptor-? by CF31 induces TNF-?-dependent apoptosis.
Neoplasms
Targeting truncated RXR? for cancer therapy.
Neoplasms
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Neoplasms
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Neoplasms
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
Neoplasms
TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma.
Neoplasms
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Neoplasms
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
Neoplasms
The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
Neoplasms
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
Neoplasms
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
Neoplasms
The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway.
Neoplasms
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Neoplasms
The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.
Neoplasms
The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia.
Neoplasms
The cell biology behind the oncogenic PIP3 lipids.
Neoplasms
The chromosome 3q26 OncCassette: A multigenic driver of human cancer.
Neoplasms
The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer.
Neoplasms
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Neoplasms
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
Neoplasms
The conundrum of the Epstein-Barr virus-associated gastric carcinoma in the Americas.
Neoplasms
The CTLH Complex in Cancer Cell Plasticity.
Neoplasms
The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase ?
Neoplasms
The double life of p85.
Neoplasms
The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.
Neoplasms
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
Neoplasms
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Neoplasms
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
Neoplasms
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
Neoplasms
The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
Neoplasms
The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid.
Neoplasms
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Neoplasms
The evolving genomic landscape of urothelial carcinoma.
Neoplasms
The fate of BRCA1-related germline mutations in triple-negative breast tumors.
Neoplasms
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
Neoplasms
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.
Neoplasms
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Neoplasms
The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.
Neoplasms
The frequent co-expression of the oncogenes PIK3CA and PAK1 in oral carcinomas.
Neoplasms
The genetic landscape of 87 ovarian germ cell tumors.
Neoplasms
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Neoplasms
The Genomic Landscape of Lobular Breast Cancer.
Neoplasms
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.
Neoplasms
The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
Neoplasms
The genomics and epigenetics of olfactory neuroblastoma: A?systematic review.
Neoplasms
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin.
Neoplasms
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor {alpha}-mediated apoptosis by activation of phosphoinositol 3-kinase and {beta}-catenin.
Neoplasms
The Hidden Conundrum of Phosphoinositide Signaling in Cancer.
Neoplasms
The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
Neoplasms
The Hippo signal transduction pathway in soft tissue sarcomas.
Neoplasms
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
Neoplasms
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.
Neoplasms
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Neoplasms
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Neoplasms
The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
Neoplasms
The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.
Neoplasms
The INPP4B paradox: Like PTEN, but different.
Neoplasms
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Neoplasms
The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
Neoplasms
The KEAP1-NRF2 System in Cancer.
Neoplasms
The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136.
Neoplasms
The Landscape of PIK3CA Mutations in Colorectal Cancer.
Neoplasms
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
Neoplasms
The merlin interacting proteins reveal multiple targets for NF2 therapy.
Neoplasms
The Metabolic Mechanisms of Breast Cancer Metastasis.
Neoplasms
The metastasis suppressor protein NM23-H1 modulates the PI3K-AKT axis through interaction with the p110? catalytic subunit.
Neoplasms
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
Neoplasms
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
Neoplasms
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.
Neoplasms
The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers.
Neoplasms
The mutational landscape of head and neck squamous cell carcinoma.
Neoplasms
The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome.
Neoplasms
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
Neoplasms
The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
Neoplasms
The Occurrence of Genetic Alterations during the Progression of Breast Carcinoma.
Neoplasms
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Neoplasms
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
Neoplasms
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Neoplasms
The Opposing Roles of PIK3R1/p85? and PIK3R2/p85? in Cancer.
Neoplasms
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation.
Neoplasms
The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion.
Neoplasms
The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN.
Neoplasms
The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
Neoplasms
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Neoplasms
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes quiescent but not proliferating MG-63 human osteosarcoma cells to radiation.
Neoplasms
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Neoplasms
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Neoplasms
The phosphoinositide 3-kinase pathway and cancer.
Neoplasms
The phosphoinositide 3-kinase pathway and therapy resistance in cancer.
Neoplasms
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.
Neoplasms
The Phosphoinositide 3-Kinase Pathway Is Crucial for the Growth of Canine Mast Cell Tumors.
Neoplasms
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
Neoplasms
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
Neoplasms
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.
Neoplasms
The phosphoinositide 3-kinase/akt1/par-4 axis: a cancer-selective therapeutic target.
Neoplasms
The PI3K inhibitor arsenal: choose your weapon!
Neoplasms
The PI3K pathway at the crossroads of cancer and the immune system: strategies for next generation immunotherapy combinations.
Neoplasms
The PI3K Pathway in Human Disease.
Neoplasms
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Neoplasms
The PI3K/AKT Pathway as a Target for Cancer Treatment.
Neoplasms
The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
Neoplasms
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.
Neoplasms
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
Neoplasms
The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the ?-catenin/SIRT3 signaling pathway in cervical cancer.
Neoplasms
The PIK3CA gene as a mutated target for cancer therapy.
Neoplasms
The PIK3CA gene is mutated with high frequency in human breast cancers.
Neoplasms
The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells.
Neoplasms
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
Neoplasms
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
Neoplasms
The prevalence of PIK3CA mutations in gastric and colon cancer.
Neoplasms
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
Neoplasms
The promise of combining inhibition of PI3K and PARP as cancer therapy.
Neoplasms
The PTEN and Myotubularin Phosphoinositide 3-Phosphatases: Linking Lipid Signalling to Human Disease.
Neoplasms
The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.
Neoplasms
The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity.
Neoplasms
The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.
Neoplasms
The PTEN-PI3K pathway: of feedbacks and cross-talks.
Neoplasms
The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene.
Neoplasms
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Neoplasms
The Ras-association domain family (RASSF) members and their role in human tumourigenesis.
Neoplasms
The Rational Design of Selective Benzoxazepin Inhibitors of the ?-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Neoplasms
The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB.
Neoplasms
The relation between PI3K/AKT signalling pathway and cancer.
Neoplasms
The role of aspirin in colorectal cancer chemoprevention.
Neoplasms
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Neoplasms
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Neoplasms
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
Neoplasms
The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells.
Neoplasms
The Role of PI3K Inhibition in Lymphoid Malignancies.
Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Neoplasms
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
Neoplasms
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Neoplasms
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
Neoplasms
The Specificity of EGF-Stimulated IQGAP1 Scaffold Towards the PI3K-Akt Pathway is Defined by the IQ3 motif.
Neoplasms
The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer.
Neoplasms
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Neoplasms
The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells.
Neoplasms
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
Neoplasms
The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
Neoplasms
The transcriptional landscape and mutational profile of lung adenocarcinoma.
Neoplasms
The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion.
Neoplasms
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
Neoplasms
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
Neoplasms
Therapeutic benefit of selective inhibition of p110? PI3-kinase in pancreatic neuroendocrine tumors.
Neoplasms
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
Neoplasms
Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.
Neoplasms
Therapeutic potential of nvp-bkm120 in human osteosarcomas cells.
Neoplasms
Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Neoplasms
Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR.
Neoplasms
Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
Neoplasms
TIMP-3 and Phosphatidylinositol 3-kinase genes were found to be related to the progression of colon cancer in a comparison of pneumoperitoneum and laparotomy in a murine model.
Neoplasms
Tks5-dependent formation of circumferential podosomes/invadopodia mediates cell-cell fusion.
Neoplasms
Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
Neoplasms
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Neoplasms
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Neoplasms
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
Neoplasms
TPIP: a novel phosphoinositide 3-phosphatase.
Neoplasms
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Neoplasms
Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
Neoplasms
TRAF6 interacts with and ubiquitinates PIK3CA to enhance PI3K activation.
Neoplasms
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Neoplasms
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Neoplasms
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer.
Neoplasms
Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.
Neoplasms
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Neoplasms
Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis.
Neoplasms
Transient Inhibition of PI3K? Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Neoplasms
Translational control by oncogenic signaling pathways.
Neoplasms
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.
Neoplasms
Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.
Neoplasms
Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate.
Neoplasms
Triggering PIK3CA mutations in PI3K/AKT/mTOR axis: Exploration of newer inhibitors and rational preventive strategies.
Neoplasms
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Neoplasms
TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the Literature.
Neoplasms
Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours.
Neoplasms
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
Neoplasms
Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study.
Neoplasms
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Neoplasms
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Neoplasms
Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
Neoplasms
Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.
Neoplasms
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Neoplasms
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
Neoplasms
Tumor Necrosis Factor-? Promotes Phosphoinositide 3-Kinase Enhancer A and AMP-Activated Protein Kinase Interaction to Suppress Lipid Oxidation in Skeletal Muscle.
Neoplasms
Tumor necrosis factor-alpha inhibits differentiation of myogenic cells in human urethral rhabdosphincter.
Neoplasms
Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction.
Neoplasms
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Neoplasms
Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.
Neoplasms
Tumor suppression and promotion by autophagy.
Neoplasms
Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
Neoplasms
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.
Neoplasms
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
Neoplasms
Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function.
Neoplasms
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
Neoplasms
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Neoplasms
Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
Neoplasms
Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy.
Neoplasms
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.
Neoplasms
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.
Neoplasms
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Neoplasms
Understanding PTEN regulation: PIP2, polarity and protein stability.
Neoplasms
Understanding the relative affinity and specificity of the pleckstrin homology domain of protein kinase B for inositol phosphates.
Neoplasms
Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission.
Neoplasms
Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
Neoplasms
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Neoplasms
Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma (CRC) compared to age-related CRC: large cohort next generation sequence analysis.
Neoplasms
Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes.
Neoplasms
Up-regulation of ras-GAP genes is reversed by a MEK inhibitor and doxorubicin in v-Ki-ras-transformed NIH/3T3 fibroblasts.
Neoplasms
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
Neoplasms
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Neoplasms
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Neoplasms
Upregulation of microRNA-31 targeting integrin ?5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
Neoplasms
Upregulation of pAKT(Ser473) expression is involved in progression of HPV-positive oropharyngeal squamous cell carcinoma.
Neoplasms
Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
Neoplasms
Use of mutation profiles to refine the classification of endometrial carcinomas.
Neoplasms
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting a treatment outcomes of non-small cell lung cancer.
Neoplasms
Using isoform-specific inhibitors to target lipid kinases.
Neoplasms
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Neoplasms
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Neoplasms
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.
Neoplasms
Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo.
Neoplasms
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Neoplasms
VIP induces NF-?B1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
Neoplasms
Von Hippel-Lindau tumor suppressor (VHL) stimulates TOR signaling by interacting with phosphoinositide 3-kinase (PI3K).
Neoplasms
VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-?B activity in B cell precursor-acute lymphoblastic leukemia.
Neoplasms
Vulvar Pilomatrix Carcinoma: Morphologic and Molecular Features.
Neoplasms
Vulvar squamous cell carcinoma (VSCC) as two diseases: HPV status identifies distinct mutational profiles including oncogenic fibroblast growth factor receptor 3.
Neoplasms
Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets.
Neoplasms
Water extract from Pleurotus pulmonarius with antioxidant activity exerts in vivo chemoprophylaxis and chemosensitization for liver cancer.
Neoplasms
Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo.
Neoplasms
Weight Loss via exercise with controlled dietary intake may affect phospholipid profile for cancer prevention in murine skin tissues.
Neoplasms
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
Neoplasms
What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
Neoplasms
Whole exome sequencing of adenoid cystic carcinoma.
Neoplasms
Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.
Neoplasms
Whole-exome sequencing identified mutational profiles of high-grade colon adenomas.
Neoplasms
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Neoplasms
Will Kinase Inhibitors Make it as Glioblastoma Drugs?
Neoplasms
WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Neoplasms
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis.
Neoplasms
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
Neoplasms
XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
Neoplasms
Yeast-based methods to assess PTEN phosphoinositide phosphatase activity in vivo.
Neoplasms
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Neoplasms
YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
Neoplasms
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
Neoplasms
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
Neoplasms
[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumors to PI3-Kinase inhibition with the novel agent GDC-0941.
Neoplasms
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
Neoplasms
[Androgen receptor-positive triple negative breast cancer: From biology to therapy].
Neoplasms
[Aspirin and colorectal cancer].
Neoplasms
[BRAF-positive paucicellular variant of anaplastic carcinoma in the presence of tall cell variant papillary thyroid cancer].
Neoplasms
[Ca2+ is involved in tumor necrosis factor-alpha induced cardiomyocyte hypertrophy through PI3-kinase pathway in rats].
Neoplasms
[Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
Neoplasms
[Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
Neoplasms
[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].
Neoplasms
[Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
Neoplasms
[Effect of moxa-burning heat stimulating Liangmen (ST 21) and Zusanli (ST 36) on proliferation and apoptosis signaling proteins in rats with stress-induced gastric ulcer].
Neoplasms
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Neoplasms
[Molecular analysis of sporadic colon cancer].
Neoplasms
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Neoplasms
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Neoplasms
[PI3 kinases and the control of autophagia]
Neoplasms
[PIK3CA mutation analysis in isolated macrodactyly].
Neoplasms
[PIK3CA mutations in the most common types of cancer].
Neoplasms
[Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Neoplasms
[Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
Neoplasms
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
Neoplasms
[Signal transduction in urothelial cancer : How exactly do we know the targets for targeted therapy?]
Neoplasms
[The expression of PIK3CA in nasopharyngeal carcinoma].
Neoplasms, Basal Cell
CTNNB1 mutations in basal cell adenoma of the salivary gland.
Neoplasms, Germ Cell and Embryonal
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Neoplasms, Neuroepithelial
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
Neoplasms, Second Primary
PI3K/Akt/mTOR signalling pathway activation in patients with ER-positive, metachronous, contralateral breast cancer treated with hormone therapy.
Neoplasms, Squamous Cell
Associations of PI3KR1 and mTOR Polymorphisms with Esophageal Squamous Cell Carcinoma Risk and Gene-Environment Interactions in Eastern Chinese Populations.
Neoplasms, Squamous Cell
Carcinogenesis of PIK3CA.
Neoplasms, Squamous Cell
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
Neoplasms, Squamous Cell
Upregulation of pAKT(Ser473) expression is involved in progression of HPV-positive oropharyngeal squamous cell carcinoma.
Neoplastic Cells, Circulating
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Neoplastic Cells, Circulating
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Neoplastic Cells, Circulating
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Neoplastic Cells, Circulating
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Neoplastic Cells, Circulating
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Neoplastic Cells, Circulating
Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Neoplastic Cells, Circulating
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Neoplastic Cells, Circulating
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Neoplastic Cells, Circulating
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Neoplastic Cells, Circulating
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Neoplastic Processes
Riedel's thyroiditis - a case report with genes' expression studies.
Nephritis
Signal transduction involved in protective effects of 15(R/S)-methyl- lipoxin A(4) on mesangioproliferative nephritis in rats.
Nephritis
[Protective effects of 15-methyl-lipoxin A4 on mesangioproliferative nephritis in rats]
Nervous System Diseases
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Neuralgia
Celecoxib reverts oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion.
Neuralgia
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.
Neuralgia
Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1? pathway.
Neuralgia
Treatment With the Delta Opioid Agonist UFP-512 Alleviates Chronic Inflammatory and Neuropathic Pain: Mechanisms Implicated.
Neurilemmoma
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.
Neuritis
Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines.
Neuritis, Autoimmune, Experimental
Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines.
Neuroblastoma
Activation of Akt predicts poor outcome in neuroblastoma.
Neuroblastoma
Activation of phosphatidylinositol 3-kinase by cellular prion protein and its role in cell survival.
Neuroblastoma
Actovegin reduces the hydrogen peroxide-induced cell apoptosis of SK-N-SH neuroblastoma by means of p38MAPK and PI-3K inhibition.
Neuroblastoma
Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.
Neuroblastoma
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Neuroblastoma
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Neuroblastoma
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Neuroblastoma
Childhood tumors of the nervous system as disorders of normal development.
Neuroblastoma
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Neuroblastoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Neuroblastoma
Cofilin activity during insulin-like growth factor I-stimulated neuroblastoma cell motility.
Neuroblastoma
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Neuroblastoma
Cypermethrin Activates Autophagosome Formation Albeit Inhibits Autophagy Owing to Poor Lysosome Quality: Relevance to Parkinson's Disease.
Neuroblastoma
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Neuroblastoma
EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.
Neuroblastoma
Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C.
Neuroblastoma
FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma.
Neuroblastoma
GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN.
Neuroblastoma
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Neuroblastoma
Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody.
Neuroblastoma
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Neuroblastoma
Hydrogen Sulfide-Induced Processing of the Amyloid Precursor Protein in SH-SY5Y Human Neuroblastoma Cells Involves the PI3-K/Akt Signaling Pathway.
Neuroblastoma
Hypothalamic serotonin-insulin signaling cross-talk and alterations in a type 2 diabetic model.
Neuroblastoma
Inhibition of neuroblastoma cell phosphatidylinositol 3-kinase by CDP-diacylglycerol and phosphatidate.
Neuroblastoma
Inhibition of transforming growth factor-beta/Smad signaling by phosphatidylinositol 3-kinase pathway.
Neuroblastoma
Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway.
Neuroblastoma
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Neuroblastoma
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
Neuroblastoma
Mutations in PIK3CA are infrequent in neuroblastoma.
Neuroblastoma
Oestradiol regulates ?-catenin-mediated transcription in neurones.
Neuroblastoma
OncomiRs: the discovery and progress of microRNAs in cancers.
Neuroblastoma
Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus.
Neuroblastoma
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Neuroblastoma
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Neuroblastoma
PKC and Raf-1 inhibition-related apoptotic signalling in N2a cells.
Neuroblastoma
Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition.
Neuroblastoma
Silencing Intersectin 1 Slows Orthotopic Neuroblastoma Growth in Mice.
Neuroblastoma
Targeting PI3K in neuroblastoma.
Neuroblastoma
Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Neuroblastoma
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Neuroblastoma
VEGF-mediated survivin expression in neuroblastoma cells.
Neurocutaneous Syndromes
Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
Neurodegenerative Diseases
A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway.
Neurodegenerative Diseases
Driving neural regeneration through the mammalian target of rapamycin.
Neurodegenerative Diseases
Erythropoietin: new directions for the nervous system.
Neurodegenerative Diseases
Flavonoids Isolated from Flowers of Lonicera japonica Thunb. Inhibit Inflammatory Responses in BV2 Microglial Cells by Suppressing TNF-? and IL-? Through PI3K/Akt/NF-kb Signaling Pathways.
Neurodegenerative Diseases
Neuroprotective effects of estrogens: cross-talk between estrogen and intracellular insulin signalling.
Neurodegenerative Diseases
Novel compounds for the modulation of mTOR and autophagy to treat neurodegenerative diseases.
Neurodegenerative Diseases
Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade.
Neurodegenerative Diseases
Phosphatidylinositol 3-kinase: increased activity and protein level in amyotrophic lateral sclerosis.
Neurodegenerative Diseases
Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.
Neuroectodermal Tumors, Primitive
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Neuroendocrine Tumors
Therapeutic benefit of selective inhibition of p110? PI3-kinase in pancreatic neuroendocrine tumors.
Neuroendocrine Tumors
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Neuroendocrine Tumors
Updates and management algorithm for neuroendocrine tumors of the uterine cervix.
Neurofibroma
Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
Neurofibromatoses
"Wild type" GIST: Clinicopathological features and clinical practice.
Neurofibromatoses
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Neurofibromatosis 1
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Neurofibrosarcoma
CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Neurofibrosarcoma
Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors.
Neuroinflammatory Diseases
Impact of ambient temperature on inflammation-induced encephalopathy in endotoxemic mice-role of phosphoinositide 3-kinase gamma.
Neuroinflammatory Diseases
Induction of Neuronal PI3K? Contributes to Endoplasmic Reticulum Stress and Long-Term Functional Impairment in a Murine Model of Traumatic Brain Injury.
Neuroinflammatory Diseases
p110? PI 3-kinase inhibition perturbs APP and TNF? trafficking, reduces plaque burden, dampens neuroinflammation and prevents cognitive decline in an Alzheimer's disease mouse model.
Neuroinflammatory Diseases
Phosphoinositide 3-Kinase ? Restrains Neurotoxic Effects of Microglia After Focal Brain Ischemia.
Neuroinflammatory Diseases
PI3K? inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model.
Neuroma
Congenital infiltrating lipomatosis of the face with lingual mucosal neuromas associated with a PIK3CA mutation.
Neuroma
Somatic PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis.
Neuroma, Acoustic
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.
Nevus
Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus.
Nevus
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Nevus
Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.
Nevus
Cloves Syndrome: A Rare Disorder of Overgrowth with Unusual Features - An Uncommon Phenotype?
Nevus
Giant congenital melanocytic nevus with vascular malformation and epidermal cysts associated with a somatic activating mutation in BRAF.
Nevus
Keratinocytic epidermal nevus with ipsilateral breast hypoplasia.
Nevus
Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS.
Nevus
Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes.
Nevus
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Nevus
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Nevus
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Nevus
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Nevus
Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
Nevus
Sonographic screening for Wilms tumor in children with CLOVES syndrome.
Nevus
[PIK3CA-related overgrowth syndrome (PROS)].
Nevus, Pigmented
The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo.
Nevus, Sebaceous of Jadassohn
Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus.
Niemann-Pick Disease, Type C
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Niemann-Pick Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Non-alcoholic Fatty Liver Disease
Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Non-alcoholic Fatty Liver Disease
Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.
Noonan Syndrome
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Obesity
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Obesity
Changes in DNA Methylation and Gene Expression of Insulin and Obesity-Related Gene PIK3R1 after Roux-en-Y Gastric Bypass.
Obesity
Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.
Obesity
Dysfunction of human subcutaneous FAT arterioles in obesity associated or not with Type 2 diabetes.
Obesity
Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats.
Obesity
Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.
Obesity
Inhibition of phosphoinositide 3-kinase ? attenuates inflammation, obesity, and cardiovascular risk factors.
Obesity
Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus.
Obesity
Obesity, insulin resistance and hepatic perfusion.
Obesity
Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.
Obesity
Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits inositide trisphosphate accumulation in hypothalamus and regulates food intake and body weight.
Obesity
Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity.
Obesity
Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats.
Obesity
Specific knockout of p85? in brown adipose tissue induces resistance to high-fat diet-induced obesity and its metabolic complications in male mice.
Obesity
The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage.
Obesity
The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.
Obesity
The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages.
Obesity
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Obesity, Morbid
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Oculocerebrorenal Syndrome
The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease.
Oligodendroglioma
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Oligodendroglioma
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
Oncogene Addiction
Emerging therapeutic targets in endometrial cancer.
Oncogene Addiction
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Oropharyngeal Neoplasms
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.
Oropharyngeal Neoplasms
Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.
Oropharyngeal Neoplasms
Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer.
Osteoarthritis
Overexpression of microRNA-634 suppresses survival and matrix synthesis of human osteoarthritis chondrocytes by targeting PIK3R1.
Osteoarthritis
TNF-? increases the expression of inflammatory factors in synovial fibroblasts by inhibiting the PI3K/AKT pathway in a rat model of monosodium iodoacetate-induced osteoarthritis.
Osteoarthritis, Knee
A treatment combined prussian blue nanoparticles with low-intensity pulsed ultrasound alleviates cartilage damage in knee osteoarthritis by initiating PI3K/Akt/mTOR pathway.
Osteolysis
Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Osteolysis
The USP14-NLRC5 pathway inhibits titanium particle-induced osteolysis in mice by suppressing NF-?B and PI3K/AKT activities.
Osteosarcoma
Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway.
Osteosarcoma
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma.
Osteosarcoma
HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor efficacy of Tanshinone IIA in human osteosarcoma cells.
Osteosarcoma
Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha.
Osteosarcoma
Knockdown of autophagy-related protein 6, Beclin-1, decreases cell growth, invasion, and metastasis and has a positive effect on chemotherapy-induced cytotoxicity in osteosarcoma cells.
Osteosarcoma
MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.
Osteosarcoma
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.
Osteosarcoma
Phosphatidylinositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells.
Osteosarcoma
PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population.
Osteosarcoma
Probable hereditary familial overlap syndrome with multiple synchronous lung tumors.
Osteosarcoma
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Osteosarcoma
Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling.
Osteosarcoma
VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway.
Osteosarcoma
VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.
Ovarian Cysts
PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.
Ovarian Cysts
Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.
Ovarian Neoplasms
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.
Ovarian Neoplasms
Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Ovarian Neoplasms
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Ovarian Neoplasms
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Ovarian Neoplasms
Activation of the MEK-S6 Pathway in High-grade Ovarian Cancers.
Ovarian Neoplasms
Amplification of USP13 drives ovarian cancer metabolism.
Ovarian Neoplasms
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Ovarian Neoplasms
Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
Ovarian Neoplasms
beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.
Ovarian Neoplasms
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
Ovarian Neoplasms
Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-?B-TNF?-PIK3CA loop.
Ovarian Neoplasms
Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
Ovarian Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Ovarian Neoplasms
Comparative genomic hybridization for the analysis of unbalanced chromosomal abnormalities in ovarian tumors.
Ovarian Neoplasms
Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.
Ovarian Neoplasms
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Ovarian Neoplasms
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.
Ovarian Neoplasms
Detection of PIK3R1 (L449S) Mutation in a Patient with Ovarian Cancer: A Case Report.
Ovarian Neoplasms
Dihydroartemisinin selectively inhibits PDGFR?-positive ovarian cancer growth and metastasis through inducing degradation of PDGFR? protein.
Ovarian Neoplasms
Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene.
Ovarian Neoplasms
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ovarian Neoplasms
Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Ovarian Neoplasms
E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via ?-catenin-Egr1-mediated PTEN expression.
Ovarian Neoplasms
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Ovarian Neoplasms
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer.
Ovarian Neoplasms
Establishment of a New Ovarian Cancer Cell Line CA5171.
Ovarian Neoplasms
Eupatilin Promotes Cell Death by Calcium Influx through ER-Mitochondria Axis with SERPINB11 Inhibition in Epithelial Ovarian Cancer.
Ovarian Neoplasms
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ovarian Neoplasms
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.
Ovarian Neoplasms
Expression of Concern: Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Ovarian Neoplasms
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Ovarian Neoplasms
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Ovarian Neoplasms
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Ovarian Neoplasms
Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
Ovarian Neoplasms
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Ovarian Neoplasms
Gene expression and prognostic significance in ovarian cancer.
Ovarian Neoplasms
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Ovarian Neoplasms
Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene.
Ovarian Neoplasms
Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via ras mediated pathway.
Ovarian Neoplasms
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Ovarian Neoplasms
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.
Ovarian Neoplasms
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Ovarian Neoplasms
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Ovarian Neoplasms
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
Ovarian Neoplasms
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Ovarian Neoplasms
Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis.
Ovarian Neoplasms
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Ovarian Neoplasms
miR-214 targets the PTEN-mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer.
Ovarian Neoplasms
MiR?381 regulates cell motility, growth and colony formation through PIK3CA in endometriosis?associated clear cell and endometrioid ovarian cancer.
Ovarian Neoplasms
MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
Ovarian Neoplasms
Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer.
Ovarian Neoplasms
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Ovarian Neoplasms
Mutation of the PIK3CA gene in ovarian and breast cancer.
Ovarian Neoplasms
Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer.
Ovarian Neoplasms
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models.
Ovarian Neoplasms
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Ovarian Neoplasms
Ovarian cancer in endometriosis: an update on the clinical and molecular aspects.
Ovarian Neoplasms
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Ovarian Neoplasms
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Ovarian Neoplasms
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Ovarian Neoplasms
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations.
Ovarian Neoplasms
PIK3CA alterations in Middle Eastern ovarian cancers.
Ovarian Neoplasms
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Ovarian Neoplasms
PIK3CA is implicated as an oncogene in ovarian cancer.
Ovarian Neoplasms
PIK3CA mutations in ovarian cancer.
Ovarian Neoplasms
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
Ovarian Neoplasms
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Ovarian Neoplasms
PIK3CA: determining its role in cellular proliferation and ovarian cancer.
Ovarian Neoplasms
PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
Ovarian Neoplasms
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Ovarian Neoplasms
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Ovarian Neoplasms
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
Ovarian Neoplasms
RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo.
Ovarian Neoplasms
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Ovarian Neoplasms
Screening for PIK3CA mutations among Saudi women with ovarian cancer.
Ovarian Neoplasms
Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.
Ovarian Neoplasms
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Ovarian Neoplasms
Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer.
Ovarian Neoplasms
Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.
Ovarian Neoplasms
Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways.
Ovarian Neoplasms
Targeting a common collaborator in cancer development.
Ovarian Neoplasms
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Ovarian Neoplasms
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Ovarian Neoplasms
Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.
Ovarian Neoplasms
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Paget Disease, Extramammary
Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Paget Disease, Extramammary
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Pancreatic Cyst
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Pancreatic Neoplasms
A genetic variant in PIK3R1 is associated with pancreatic cancer survival in the Chinese population.
Pancreatic Neoplasms
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Pancreatic Neoplasms
Abnormal expression of PTEN and PIK3CA in pemetrexed-resistant human pancreatic cancer cell line Patu8988.
Pancreatic Neoplasms
Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
Pancreatic Neoplasms
Anticancer effect of HOTTIP regulates human pancreatic cancer via the metabotropic glutamate receptor 1 pathway.
Pancreatic Neoplasms
Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.
Pancreatic Neoplasms
Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Pancreatic Neoplasms
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
Pancreatic Neoplasms
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Pancreatic Neoplasms
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.
Pancreatic Neoplasms
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Pancreatic Neoplasms
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Pancreatic Neoplasms
Genetic progression of pancreatic cancer.
Pancreatic Neoplasms
Growth-inhibitory effect of phosphatidylinositol 3-kinase inhibitor on human pancreatic cancer cells and expression of Bcl-2 family.
Pancreatic Neoplasms
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Pancreatic Neoplasms
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Pancreatic Neoplasms
Induction of necrosis in human myeloma cells by kigamicin.
Pancreatic Neoplasms
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Pancreatic Neoplasms
Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.
Pancreatic Neoplasms
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
Pancreatic Neoplasms
KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
Pancreatic Neoplasms
miR?142?5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA.
Pancreatic Neoplasms
Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Pancreatic Neoplasms
Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
Pancreatic Neoplasms
Molecular landscape of pancreatic cancer: implications for current clinical trials.
Pancreatic Neoplasms
Molecular mechanism(s) of actinomycin-D induced sensitization of pancreatic cancer cells to CD95 mediated apoptosis.
Pancreatic Neoplasms
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
Pancreatic Neoplasms
OPENchip: an on-chip in situ molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells.
Pancreatic Neoplasms
Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling.
Pancreatic Neoplasms
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Pancreatic Neoplasms
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Pancreatic Neoplasms
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Pancreatic Neoplasms
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
Pancreatic Neoplasms
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Pancreatic Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Pancreatic Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Pancreatic Neoplasms
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.
Pancreatic Neoplasms
Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
Pancreatitis
Effect of hydrogen sulfide on PI3K-AKT pathway and on caerulein- induced cytokine production in isolated mouse pancreatic acinar cells.
Pancreatitis
Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis.
Papilloma
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Papilloma
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Papilloma
Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission.
Papilloma
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Papilloma
Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
Papilloma
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
Papilloma
Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
Papilloma
Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas.
Papilloma
Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.
Papilloma, Intraductal
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Papilloma, Intraductal
Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
Papilloma, Intraductal
PIK3CA and AKT1 mutations in hidradenoma papilliferum.
Papillomavirus Infections
APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Papillomavirus Infections
CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
Papillomavirus Infections
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Papillomavirus Infections
Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence.
Papillomavirus Infections
Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations.
Papillomavirus Infections
Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines.
Paraganglioma
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Paralysis
Measles virus induces expression of SIP110, a constitutively membrane clustered lipid phosphatase, which inhibits T cell proliferation.
Parathyroid Diseases
PIK3CA Mutational Analysis of Parathyroid Adenomas.
Parathyroid Neoplasms
PIK3CA Mutational Analysis of Parathyroid Adenomas.
Parkinson Disease
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Parkinson Disease
Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.
Parkinson Disease
Targeting disease through novel pathways of apoptosis and autophagy.
Penile Neoplasms
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
Penile Neoplasms
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer.
Penile Neoplasms
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
Perinatal Death
Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha.
Periodontitis
Large-scale investigation of genomic markers for severe periodontitis.
Peripheral Nerve Injuries
Control of Axonal Growth and Regeneration of Sensory Neurons by the p110delta PI 3-Kinase.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Peritoneal Neoplasms
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Peritonitis
Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma.
Pharyngeal Neoplasms
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Pharyngeal Neoplasms
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Pharyngeal Neoplasms
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Pheochromocytoma
Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells.
Pheochromocytoma
Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells.
Pheochromocytoma
Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70S6K activity.
Pheochromocytoma
HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells.
Pheochromocytoma
Insulin-like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: possible involvement of PI 3-kinase in IGF-1 signaling.
Pheochromocytoma
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
phosphatidylinositol-4,5-bisphosphate 3-kinase deficiency
Important roles of PI3Kgamma in osteoclastogenesis and bone homeostasis.
phosphatidylinositol-4,5-bisphosphate 3-kinase deficiency
Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo.
phosphatidylinositol-4,5-bisphosphate 3-kinase deficiency
Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.
phosphatidylinositol-4,5-bisphosphate 3-kinase deficiency
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
Pituitary ACTH Hypersecretion
Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Pituitary Neoplasms
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
Pituitary Neoplasms
Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
Pituitary Neoplasms
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Pityriasis
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Plasmacytoma
Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth.
Pleural Effusion
Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma.
Pneumococcal Infections
Panax ginseng aqueous extract prevents pneumococcal sepsis in vivo by potentiating cell survival and diminishing inflammation.
Pneumonia
Blockade of class IA phosphoinositide 3-kinase in neutrophils prevents NADPH oxidase activation- and adhesion-dependent inflammation.
Pneumonia
Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor.
Pneumonia
Effects of phosphoinositide 3-kinase in protease-induced acute and chronic lung inflammation, remodeling and emphysema in rats.
Pneumonia
Phosphoinositide 3-kinase {gamma} plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice.
Pneumonia
Phosphoinositide 3-kinase-? regulates fungus-induced allergic lung inflammation through endoplasmic reticulum stress.
Pneumonia
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Polycystic Kidney, Autosomal Dominant
Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia.
Polycystic Ovary Syndrome
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Polycystic Ovary Syndrome
Polymorphism in postinsulin receptor signaling pathway is not associated with polycystic ovary syndrome.
Polycythemia Vera
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3-Kinase pathway activation.
Polydactyly
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Polymicrogyria
Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway.
Polymicrogyria
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Pre-Eclampsia
Diagnostic Significance of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Complex 1 in Preeclampsia.
Pre-Eclampsia
Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1.
Pre-Eclampsia
Partial least squares-based gene expression analysis in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A novel germline variant in PIK3R1 results in SHORT syndrome associated with TAL/LMO T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bioinformatics analysis of gene expression profiles in childhood B-precursor acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Calming down T cell acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting nonclassical oncogenes for therapy in T-ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-?B activity in B cell precursor-acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
High accuracy mutation detection in leukemia on a selected panel of cancer genes.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PI3K?/? and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Targeting nonclassical oncogenes for therapy in T-ALL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
[Screening and verification of key genes in T-cell acute lymphoblastic leukemia].
Primary Immunodeficiency Diseases
An updated review on activated PI3 kinase delta syndrome (APDS).
Primary Immunodeficiency Diseases
Cracking the context-specific PI3K signaling code.
Primary Immunodeficiency Diseases
Phenotypic characterization of patients with activated PI3K? syndrome 1 presenting with features of systemic lupus erythematosus.
Primary Immunodeficiency Diseases
Primary immunodeficiency disorder caused by phosphoinositide 3-kinase ? deficiency.
Primary Immunodeficiency Diseases
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
Primary Myelofibrosis
Osteitis fibrosa is mediated by platelet-derived growth factor-a via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chronic hyperparathyroidism.
Prostatic Intraepithelial Neoplasia
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Prostatic Neoplasms
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Prostatic Neoplasms
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
Prostatic Neoplasms
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
Prostatic Neoplasms
Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B.
Prostatic Neoplasms
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Prostatic Neoplasms
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Prostatic Neoplasms
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
Prostatic Neoplasms
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Prostatic Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Prostatic Neoplasms
Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells.
Prostatic Neoplasms
Cytokine effects on cell viability and death of prostate carcinoma cells.
Prostatic Neoplasms
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Prostatic Neoplasms
Development of a peptide-drug conjugate for prostate cancer therapy.
Prostatic Neoplasms
Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
Prostatic Neoplasms
Differential role of PTEN in transforming growth factor ? (TGF-?) effects on proliferation and migration in prostate cancer cells.
Prostatic Neoplasms
Disruptive events in the life of prostate cancer.
Prostatic Neoplasms
Dual inhibition of autophagy and the AKT pathway in prostate cancer.
Prostatic Neoplasms
E17K substitution in AKT1 in prostate cancer.
Prostatic Neoplasms
Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades.
Prostatic Neoplasms
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Prostatic Neoplasms
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Prostatic Neoplasms
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Prostatic Neoplasms
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1? and sphingosine kinase 1.
Prostatic Neoplasms
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.
Prostatic Neoplasms
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.
Prostatic Neoplasms
Expression of TGF?3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway.
Prostatic Neoplasms
FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
Prostatic Neoplasms
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Prostatic Neoplasms
Genetic Alterations in the PI3K Pathway in Prostate Cancer.
Prostatic Neoplasms
Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.
Prostatic Neoplasms
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Prostatic Neoplasms
Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth.
Prostatic Neoplasms
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
Prostatic Neoplasms
Improving the genetic signature of prostate cancer, the somatic mutations.
Prostatic Neoplasms
Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
Prostatic Neoplasms
Inducible shRNA expression for application in a prostate cancer mouse model.
Prostatic Neoplasms
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Prostatic Neoplasms
Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.
Prostatic Neoplasms
Liquid Biopsy to Identify Actionable Genomic Alterations.
Prostatic Neoplasms
Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.
Prostatic Neoplasms
miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA.
Prostatic Neoplasms
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.
Prostatic Neoplasms
Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells.
Prostatic Neoplasms
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
Prostatic Neoplasms
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.
Prostatic Neoplasms
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.
Prostatic Neoplasms
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.
Prostatic Neoplasms
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors.
Prostatic Neoplasms
NF-kappaB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells.
Prostatic Neoplasms
Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Prostatic Neoplasms
P110? Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
Prostatic Neoplasms
Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer.
Prostatic Neoplasms
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Prostatic Neoplasms
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Prostatic Neoplasms
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Prostatic Neoplasms
PLZF mediates the PTEN/AKT/FOXO3a signaling in suppression of prostate tumorigenesis.
Prostatic Neoplasms
Prostate cancer, PI3K, PTEN and prognosis.
Prostatic Neoplasms
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Prostatic Neoplasms
Protein kinase inhibitors for the treatment of prostate cancer.
Prostatic Neoplasms
Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3).
Prostatic Neoplasms
Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Prostatic Neoplasms
REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.
Prostatic Neoplasms
Role of focal adhesion kinase and phosphatidylinositol 3'-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells.
Prostatic Neoplasms
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Prostatic Neoplasms
Starving PTEN-deficient prostate cancer cells thrive under nutrient stress by scavenging corpses for their supper.
Prostatic Neoplasms
Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
Prostatic Neoplasms
Targeting Fibroblast Growth Factor Pathways in Prostate Cancer.
Prostatic Neoplasms
The Androgen Receptor Induces Integrin {alpha}6{beta}1 to Promote Prostate Tumor Cell Survival via NF-{kappa}B and Bcl-xL Independently of PI3K Signaling.
Prostatic Neoplasms
The interaction of PKN3 with RhoC promotes malignant growth.
Prostatic Neoplasms
The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells.
Prostatic Neoplasms
The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells.
Prostatic Neoplasms
Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
Prostatic Neoplasms
TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
Prostatic Neoplasms
TRB3 is a PI 3-kinase dependent indicator for nutrient starvation.
Prostatic Neoplasms
Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice.
Prostatic Neoplasms
VIP induces NF-?B1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
Prostatic Neoplasms
[Obesity and prostate cancer : Role of adipocytokines and clinical implications].
Prostatic Neoplasms
[P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer]
Protein Deficiency
Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component.
Protein Deficiency
Early-onset colorectal cancer: A distinct entity with unique genetic features.
Proteinuria
Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis.
Proteinuria
Signal transduction involved in protective effects of 15(R/S)-methyl- lipoxin A(4) on mesangioproliferative nephritis in rats.
Proteinuria
[Protective effects of 15-methyl-lipoxin A4 on mesangioproliferative nephritis in rats]
Proteus Syndrome
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Proteus Syndrome
Fibroadipose Hyperplasia versus Proteus Syndrome: Segmental Overgrowth with a Mosaic Mutation in the PIK3CA Gene.
Proteus Syndrome
Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes.
Proteus Syndrome
Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
Proteus Syndrome
PIK3CA c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report.
Psoriasis
Differential regulation of IGF-II-induced IL-8 by extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinases in human keratinocytes.
Psoriasis
Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach.
Psoriasis
Up-regulation of phosphatidylinositol 3-kinase in psoriatic lesions.
Pulmonary Disease, Chronic Obstructive
A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.
Pulmonary Disease, Chronic Obstructive
A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
An Inhaled PI3K? Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial.
Pulmonary Disease, Chronic Obstructive
Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats.
Pulmonary Disease, Chronic Obstructive
Cigarette Smoke Exposure Alters mSin3a and Mi-2alpha/beta Expression; implications in the control of pro-inflammatory gene transcription and glucocorticoid function.
Pulmonary Disease, Chronic Obstructive
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Ectopic expressed miR-203 contributes to chronic obstructive pulmonary disease via targeting TAK1 and PIK3CA.
Pulmonary Disease, Chronic Obstructive
Exploring PI3K? Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials.
Pulmonary Disease, Chronic Obstructive
Histone deacetylase-2 and airway disease.
Pulmonary Disease, Chronic Obstructive
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Pulmonary Disease, Chronic Obstructive
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Pulmonary Disease, Chronic Obstructive
PI 3-kinase inhibition: a therapeutic target for respiratory disease.
Pulmonary Disease, Chronic Obstructive
PI3K signaling in chronic obstructive pulmonary disease: mechanisms, targets, and therapy.
Pulmonary Disease, Chronic Obstructive
PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy.
Pulmonary Disease, Chronic Obstructive
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Pulmonary Disease, Chronic Obstructive
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Pulmonary Disease, Chronic Obstructive
Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration.
Pulmonary Disease, Chronic Obstructive
Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.
Pulmonary Edema
Elucidation of the Mechanism of Action of Ginseng Against Acute Lung Injury/Acute Respiratory Distress Syndrome by a Network Pharmacology-Based Strategy.
Pulmonary Embolism
Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo.
Pulmonary Emphysema
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Pulmonary Fibrosis
A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats.
Pulmonary Fibrosis
LncRNA MEG3 Involved in NiO NPs-Induced Pulmonary Fibrosis via Regulating TGF-?1-Mediated PI3K/AKT Pathway.
Pulmonary Valve Stenosis
PIK3R1 mutations in two patients with SHORT syndrome and pulmonary stenosis.
Purpura, Thrombocytopenic, Idiopathic
Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase ?.
Rectal Neoplasms
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Rectal Neoplasms
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Rectal Neoplasms
Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences?
Rectal Neoplasms
Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses.
Rectal Neoplasms
Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.
Rectal Neoplasms
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Rectal Neoplasms
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Rectal Neoplasms
KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Rectal Neoplasms
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
Rectal Neoplasms
Monitoring colorectal cancer following surgery using plasma circulating tumor DNA.
Rectal Neoplasms
Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study.
Rectal Neoplasms
PIK3CA mutations predict local recurrences in rectal cancer patients.
Renal Insufficiency, Chronic
Investigation of the effects of indoxyl sulfate, a uremic toxin, on the intracellular oxidation level and phagocytic activity using an HL-60-differentiated human macrophage cell model.
Reperfusion Injury
Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.
Reperfusion Injury
JAK Redux - A Second Look at the Regulation and Role of JAKs in the Heart.
Reperfusion Injury
miR-10a overexpression aggravates renal ischemia-reperfusion injury associated with decreased PIK3CA expression.
Reperfusion Injury
PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway.
Reperfusion Injury
Reduction in Renal Ischemia-Reperfusion Injury in Mice by a Phosphoinositide 3-Kinase p110gamma-Specific Inhibitor.
Reperfusion Injury
Sevoflurane postconditioning protects chronically-infarcted rat hearts against ischemia-reperfusion injury by activation of pro-survival kinases and inhibition of mitochondrial permeability transition pore opening upon reperfusion.
Reperfusion Injury
T-588 inhibits astrocyte apoptosis via mitogen-activated protein kinase signal pathway.
Respiratory Distress Syndrome
ARDS Neutrophils Have a Distinct Phenotype and are Resistant to Phosphoinositide 3-kinase Inhibition.
Respiratory Hypersensitivity
Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.
Respiratory Syncytial Virus Infections
Adenovirus vectors activate survival pathways in lung epithelial cells.
Respiratory Tract Infections
Gain-of-function mutation in PIK3R1 in a patient with a narrow clinical phenotype of respiratory infections.
Respiratory Tract Infections
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
Reticuloendotheliosis, Avian
Advances and highlights in primary immunodeficiencies in 2017.
Retinoblastoma
Involvement of cyclin D1/CDK4 and pRb mediated by PI3K/AKT pathway activation in Pb2+ -induced neuronal death in cultured hippocampal neurons.
Retinoblastoma
Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
Retinoblastoma
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Retinoblastoma
MicroRNA?363?3p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt/mTOR signaling pathway by targeting PIK3CA.
Retinoblastoma
Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress.
Retinoblastoma
Molecular targeted therapy of glioblastoma.
Retinoblastoma
Mutational analysis of merkel cell carcinoma.
Retinoblastoma
p55PIK Transcriptionally Activated by MZF1 Promotes Colorectal Cancer Cell Proliferation.
Retinoblastoma
PI3K Stimulates DNA Synthesis and Cell-Cycle Progression via Its p55PIK Regulatory Subunit Interaction with PCNA.
Retinoblastoma
PI3K/Akt pathway mutations in Retinoblastoma.
Retinoblastoma
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Retinoblastoma
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Retinoblastoma
Retinoblastoma protein phosphorylation via PI 3-kinase and mTOR pathway regulates adipocyte differentiation.
Retinoblastoma
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Retinoblastoma
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity.
Retinoblastoma
TGF-? regulates the proliferation of lung adenocarcinoma cells by inhibiting PIK3R3 expression.
Retinoblastoma
Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1.
Rhabdomyosarcoma
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Rhabdomyosarcoma
Construction and characterization of a conditionally active construct of the insulin-regulated forkhead transcription factor FKHR.
Rhabdomyosarcoma
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma.
Rhabdomyosarcoma
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Rhabdomyosarcoma, Embryonal
Germline ATM mutation and somatic PIK3CA and BCOR mutations found in an infant with aggressive orbital embryonal rhabdomyosarcoma.
Rhabdomyosarcoma, Embryonal
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Rhabdomyosarcoma, Embryonal
Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.
Rhinitis, Allergic
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
Rhinitis, Allergic, Seasonal
Evaluation of the anti-allergic activity of Citrus unshiu using rat basophilic leukemia RBL-2H3 cells as well as basophils of patients with seasonal allergic rhinitis to pollen.
Salmonella Infections
Multiple Host Kinases Contribute to Akt Activation during Salmonella Infection.
Sarcoma
Acetylcholine-dependent upregulation of TASK-1 channels in thalamic interneurons by a smooth muscle-like signalling pathway.
Sarcoma
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Sarcoma
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Sarcoma
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Sarcoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Sarcoma
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Sarcoma
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Sarcoma
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Sarcoma
Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sarcoma
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.
Sarcoma
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Sarcoma
Genetic alterations in Japanese extrahepatic biliary tract cancer.
Sarcoma
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Sarcoma
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.
Sarcoma
High co-expression of PD-L1 and HIF-1? correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Sarcoma
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Sarcoma
Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia.
Sarcoma
Human sensory neuron-specific Mas-related G protein-coupled receptors-X1 sensitize and directly activate transient receptor potential cation channel V1 via distinct signaling pathways.
Sarcoma
Identification of protein kinase C as an intermediate in Na,K-ATPase Beta-subunit mediated lamellipodia formation and suppression of cell motility in carcinoma cells.
Sarcoma
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population.
Sarcoma
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Sarcoma
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Sarcoma
Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis.
Sarcoma
Molecular association of functioning stroma with carcinoma cells in the ovary: A preliminary study.
Sarcoma
Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.
Sarcoma
Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Sarcoma
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Sarcoma
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.
Sarcoma
Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: Report of 3 cases, with morphological and molecular analysis.
Sarcoma
Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.
Sarcoma
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
Sarcoma
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Sarcoma
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.
Sarcoma
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Sarcoma
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Sarcoma
RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
Sarcoma
Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells.
Sarcoma
Searching for molecular targets in sarcoma.
Sarcoma
Simultaneous Knockdown of Sprouty2 and PTEN Promotes Axon Elongation of Adult Sensory Neurons.
Sarcoma
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Sarcoma
Targeted therapies in development for non-small cell lung cancer.
Sarcoma
Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments.
Sarcoma
The Hippo signal transduction pathway in soft tissue sarcomas.
Sarcoma
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
Sarcoma
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Sarcoma
Triiodothyronine stimulates steroid and VEGF production in murine Leydig cells via cAMP-PKA pathway.
Sarcoma
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Sarcoma
[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
Sarcoma, Avian
The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity.
Sarcoma, Ewing
Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
Sarcoma, Kaposi
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Sarcopenia
Frailty and sarcopenia: The potential role of an aged immune system.
Scrapie
Tunneling-nanotube: A new way of cell-cell communication.
Seizures
4E-BP2-dependent translation in parvalbumin neurons controls epileptic seizure threshold.
Seizures
Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations.
Seizures
Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.
Seizures
Wortmannin reduces insulin signaling and death in seizure-prone Pcmt1-/- mice.
Sepsis
ARDS Neutrophils Have a Distinct Phenotype and are Resistant to Phosphoinositide 3-kinase Inhibition.
Sepsis
Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages.
Sepsis
Downregulation of PI3K-? in a mouse model of sepsis-induced myocardial dysfunction.
Sepsis
Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis.
Sepsis
Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury.
Sepsis
Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: reversal effect of fluvastatin therapy.
Sepsis
Stimulation of the ?7 Nicotinic Acetylcholine Receptor Protects Against Sepsis by Inhibiting Toll-like Receptor via Phosphoinositide 3-Kinase Activation.
Sepsis
Targeted delivery of a phosphoinositide 3-kinase ? inhibitor to restore organ function in sepsis.
Severe Combined Immunodeficiency
Advances and highlights in primary immunodeficiencies in 2017.
Shock, Septic
The role of SHIP1 in macrophage programming and activation.
Skin Diseases
FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.
Skin Neoplasms
A Potent Inhibitor of Phosphoinositide 3-Kinase (PI3K) and Mitogen Activated Protein (MAP) Kinase Signalling, Quercetin (3, 3', 4', 5, 7-Pentahydroxyflavone) Promotes Cell Death in Ultraviolet (UV)-B-Irradiated B16F10 Melanoma Cells.
Skin Neoplasms
Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Skin Neoplasms
Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Skin Neoplasms
Isorhamnetin Suppresses Skin Cancer through Direct Inhibition of MEK1 and PI3-K.
Skin Neoplasms
The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer.
Sleep Deprivation
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Small Cell Lung Carcinoma
Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling.
Small Cell Lung Carcinoma
Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
Small Cell Lung Carcinoma
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.
Small Cell Lung Carcinoma
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Small Cell Lung Carcinoma
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Small Cell Lung Carcinoma
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Small Cell Lung Carcinoma
PIK3CA mutations and copy number gains in human lung cancers.
Small Cell Lung Carcinoma
PIK3CA Mutations in Resected Small Cell Lung Cancer.
Small Cell Lung Carcinoma
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Small Cell Lung Carcinoma
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Small Cell Lung Carcinoma
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Small Cell Lung Carcinoma
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.
Spinal Cord Injuries
Clustering analysis to identify key genes associated with motor neuron excitability following spinal cord injury.
Spinal Cord Ischemia
Induction of phosphatidylinositol 3-kinase and serine-threonine kinase-like immunoreactivity in rabbit spinal cord after transient ischemia.
Squamous Cell Carcinoma of Head and Neck
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
Squamous Cell Carcinoma of Head and Neck
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Squamous Cell Carcinoma of Head and Neck
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
Squamous Cell Carcinoma of Head and Neck
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Squamous Cell Carcinoma of Head and Neck
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.
Squamous Cell Carcinoma of Head and Neck
Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population.
Squamous Cell Carcinoma of Head and Neck
AKT3 is a key regulator of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Squamous Cell Carcinoma of Head and Neck
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Squamous Cell Carcinoma of Head and Neck
Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Squamous Cell Carcinoma of Head and Neck
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Squamous Cell Carcinoma of Head and Neck
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Squamous Cell Carcinoma of Head and Neck
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Squamous Cell Carcinoma of Head and Neck
Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance.
Squamous Cell Carcinoma of Head and Neck
Epstein-Barr virus infection is strictly associated with the metastatic spread of sinonasal squamous-cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.
Squamous Cell Carcinoma of Head and Neck
Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Squamous Cell Carcinoma of Head and Neck
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Squamous Cell Carcinoma of Head and Neck
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.
Squamous Cell Carcinoma of Head and Neck
Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection.
Squamous Cell Carcinoma of Head and Neck
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Genomic insights into head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Genomic landscape of human papillomavirus-associated cancers.
Squamous Cell Carcinoma of Head and Neck
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck.
Squamous Cell Carcinoma of Head and Neck
Hypoxia-induced epithelial-mesenchymal transition is regulated by phosphorylation of GSK3-? via PI3 K/Akt signaling in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
Squamous Cell Carcinoma of Head and Neck
Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways.
Squamous Cell Carcinoma of Head and Neck
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.
Squamous Cell Carcinoma of Head and Neck
Molecular pathways in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.
Squamous Cell Carcinoma of Head and Neck
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Squamous Cell Carcinoma of Head and Neck
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
Squamous Cell Carcinoma of Head and Neck
Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.
Squamous Cell Carcinoma of Head and Neck
New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
Squamous Cell Carcinoma of Head and Neck
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Squamous Cell Carcinoma of Head and Neck
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Squamous Cell Carcinoma of Head and Neck
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Squamous Cell Carcinoma of Head and Neck
p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC.
Squamous Cell Carcinoma of Head and Neck
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Squamous Cell Carcinoma of Head and Neck
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
Squamous Cell Carcinoma of Head and Neck
PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation.
Squamous Cell Carcinoma of Head and Neck
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils.
Squamous Cell Carcinoma of Head and Neck
Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review.
Squamous Cell Carcinoma of Head and Neck
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.
Squamous Cell Carcinoma of Head and Neck
PTEN deficiency contributes to the development and progression of head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Squamous Cell Carcinoma of Head and Neck
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Squamous Cell Carcinoma of Head and Neck
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Squamous Cell Carcinoma of Head and Neck
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Sequencing the head and neck cancer genome: implications for therapy.
Squamous Cell Carcinoma of Head and Neck
Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Squamous Cell Carcinoma of Head and Neck
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Squamous Cell Carcinoma of Head and Neck
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
Squamous Cell Carcinoma of Head and Neck
The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
Squamous Cell Carcinoma of Head and Neck
The molecular pathogenesis of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The mutational landscape of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Squamous Cell Carcinoma of Head and Neck
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Starvation
Class III phosphoinositide 3-kinase--Beclin1 complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes.
Starvation
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway.
Starvation
Induction of Autophagy by Amino Acid Starvation in Fish Cells.
Starvation
LL5beta is a phosphatidylinositol (3,4,5)-trisphosphate sensor that can bind the cytoskeletal adaptor, gamma-filamin.
Starvation
Modulation of Src homology 3 proteins by the proline-rich adaptor protein Shb.
Starvation
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
Starvation
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Starvation
TRB3 is a PI 3-kinase dependent indicator for nutrient starvation.
Stomach Neoplasms
A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report.
Stomach Neoplasms
Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration.
Stomach Neoplasms
An ?-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.
Stomach Neoplasms
An increase in galectin-3 causes cellular unresponsiveness to IFN-?-induced signal transduction and growth inhibition in gastric cancer cells.
Stomach Neoplasms
Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Stomach Neoplasms
Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis.
Stomach Neoplasms
Association between telomere length and PIK3CA amplification in gastric cancer.
Stomach Neoplasms
Association of mast cell infiltration with gastric cancer progression.
Stomach Neoplasms
Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.
Stomach Neoplasms
Baculovirus production of fully-active phosphoinositide 3-kinase alpha as a p85alpha-p110alpha fusion for X-ray crystallographic analysis with ATP competitive enzyme inhibitors.
Stomach Neoplasms
Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1.
Stomach Neoplasms
C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Stomach Neoplasms
Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification.
Stomach Neoplasms
Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Stomach Neoplasms
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression.
Stomach Neoplasms
Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901.
Stomach Neoplasms
Clinical significance of PI3K/Akt/mTOR signaling in gastric carcinoma.
Stomach Neoplasms
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.
Stomach Neoplasms
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Stomach Neoplasms
Comprehensive molecular characterization of gastric adenocarcinoma.
Stomach Neoplasms
Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer.
Stomach Neoplasms
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.
Stomach Neoplasms
Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.
Stomach Neoplasms
Downregulation of miR203 induces overexpression of PIK3CA and predicts poor prognosis of gastric cancer patients.
Stomach Neoplasms
Effect of dexmedetomidine on the cognitive function of patients undergoing gastric cancer surgery by regulating the PI3K/AKT signaling pathway.
Stomach Neoplasms
Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Stomach Neoplasms
Effects of small interfering RNA inhibit Class I phosphoinositide 3-kinase on human gastric cancer cells.
Stomach Neoplasms
Epithelial-mesenchymal transition in gastric cancer (Review).
Stomach Neoplasms
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Stomach Neoplasms
Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
Stomach Neoplasms
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Stomach Neoplasms
Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake.
Stomach Neoplasms
Gastric Cancer: New Drugs - New Strategies.
Stomach Neoplasms
Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer.
Stomach Neoplasms
Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.
Stomach Neoplasms
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Stomach Neoplasms
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
Stomach Neoplasms
Identification and Validation of SNP-Containing Genes With Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis.
Stomach Neoplasms
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Stomach Neoplasms
Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil.
Stomach Neoplasms
Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
Stomach Neoplasms
LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.
Stomach Neoplasms
Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-?B pathway, and MMP-9 expression.
Stomach Neoplasms
MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.
Stomach Neoplasms
Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.
Stomach Neoplasms
Molecular Classification of Gastric Cancer among Alaska Native People.
Stomach Neoplasms
Molecular targets and biological modifiers in gastric cancer.
Stomach Neoplasms
Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Stomach Neoplasms
Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.
Stomach Neoplasms
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Stomach Neoplasms
Mutations of PIK3CA in gastric adenocarcinoma.
Stomach Neoplasms
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Stomach Neoplasms
Oncogenic mutations in gastric cancer with microsatellite instability.
Stomach Neoplasms
Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells.
Stomach Neoplasms
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Stomach Neoplasms
Phosphoinositide 3-kinase/Akt and nuclear factor ?B pathways are involved in tumor necrosis factor-related apoptosis-inducing ligand resistance in human gastric cancer cells.
Stomach Neoplasms
Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.
Stomach Neoplasms
PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Stomach Neoplasms
PIK3CA Mutation Analysis in Iranian Patients with Gastric Cancer
Stomach Neoplasms
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.
Stomach Neoplasms
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Stomach Neoplasms
Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway.
Stomach Neoplasms
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Stomach Neoplasms
RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.
Stomach Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Stomach Neoplasms
Signaling components involved in Bcl-w-induced migration of gastric cancer cells.
Stomach Neoplasms
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
Stomach Neoplasms
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Stomach Neoplasms
The AKT inhibitor AZD5363 is selectively active in PIK3CA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Stomach Neoplasms
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
Stomach Neoplasms
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Stomach Neoplasms
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer.
Stomach Neoplasms
The Wnt/?-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.
Stomach Neoplasms
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Stomach Neoplasms
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Stomach Neoplasms
Upregulation of microRNA-31 targeting integrin ?5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
Stomach Neoplasms
What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
Stomach Neoplasms
[Chitosan/PIK3CA siRNA nanoparticle-mediated PIK3CA gene interference decreases the invasive capacity of gastric cancer cells in vitro].
Stroke
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Stroke
Circulating mRNA and microRNA profiling analysis in patients with ischemic stroke.
Stroke
Electrical Stimulation of the Cerebral Cortex Exerts Antiapoptotic, Angiogenic, and Anti-Inflammatory Effects in Ischemic Stroke Rats Through Phosphoinositide 3-Kinase/Akt Signaling Pathway.
Stroke
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Stroke
Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor.
Stroke
Phosphoinositide 3-kinase promotes adult subventricular neuroblast migration after stroke.
Stroke
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Struma Ovarii
Papillary thyroid cancer in a struma ovarii: a report of a rare case.
Sturge-Weber Syndrome
Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
Subarachnoid Hemorrhage
Phosphatidylinositol 3-kinase inhibitor failed to reduce cerebral vasospasm in dog model of experimental subarachnoid hemorrhage.
Syndactyly
Somatic mosaicism of the PIK3CA gene identified in a Hungarian girl with macrodactyly and syndactyly.
Synovitis
Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis.
Tauopathies
DHCR24 Knock-Down Induced Tau Hyperphosphorylation at Thr181, Ser199, Thr231, Ser262, Ser396 Epitopes and Inhibition of Autophagy by Overactivation of GSK3?/mTOR Signaling.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasia, Hereditary Hemorrhagic
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120.
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120.
Telangiectasis
Roles of cyclin-dependent kinase 4 and p53 in neuronal cell death induced by doxorubicin on cerebellar granule neurons in mouse.
Teratoma
Ovarian clear cell carcinoma with an immature teratoma component showing ARID1A deficiency and an identical PIK3CA mutation.
Teratoma
P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma.
Teratoma
The genetic landscape of 87 ovarian germ cell tumors.
Testicular Neoplasms
Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility.
Thromboembolism
PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Thrombosis
Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Thrombosis
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
Thrombosis
Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis.
Thrombosis
Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization.
Thrombosis
Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo.
Thrombosis
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Thrombosis
Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3).
Thrombosis
In-depth PtdIns(3,4,5)P
Thrombosis
Inhibitory Effects of Ginsenoside Ro on Clot Retraction through Suppressing PI3K/Akt Signaling Pathway in Human Platelets.
Thrombosis
Naringenin Inhibits Platelet Activation and Arterial Thrombosis Through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling.
Thrombosis
Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation.
Thrombosis
Phosphoinositide 3-kinase p110? negatively regulates thrombopoietin-mediated platelet activation and thrombus formation.
Thrombosis
PI 3-kinase p110beta: a new target for antithrombotic therapy.
Thrombosis
Platelet PI3K? and GSK3 regulate thrombus stability at a high shear rate.
Thrombosis
Regulation of endogenous reactive oxygen species in platelets can reverse aggregation.
Thrombosis
Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing.
Thrombosis
Signalling through Class I PI3Ks in mammalian cells.
Thrombosis
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
Thrombosis
The Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) Binder Rasa3 Regulates Phosphoinositide 3-kinase (PI3K)-dependent Integrin ?IIb?3 Outside-in Signaling.
Thrombosis
The PI3K? Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
Thrombosis
Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Thrombosis
Type I phosphoinositide 3-kinases: potential antithrombotic targets?
Thrombotic Microangiopathies
Phosphoinositide 3-kinase ? mediates microvascular endothelial repair of thrombotic microangiopathy.
Thymoma
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Thymoma
A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1, and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
Thymoma
A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice.
Thymoma
AKT-independent PI3-K signaling in cancer - emerging role for SGK3.
Thymoma
Analysis of differentially expressed genes between endometrial carcinosarcomas and endometrioid endometrial carcinoma by bioinformatics.
Thymoma
Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates.
Thymoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Thymoma
Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.
Thymoma
Enhanced myeloid differentiation factor 88 promotes tumor metastasis via induction of epithelial-mesenchymal transition in human hepatocellular carcinoma.
Thymoma
Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
Thymoma
Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.
Thymoma
Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling.
Thymoma
MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway.
Thymoma
Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Thymoma
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Thymoma
New function of type I IFN: induction of autophagy.
Thymoma
Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization.
Thymoma
Oncogene alterations in endometrial carcinosarcomas.
Thymoma
p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
Thymoma
p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
Thymoma
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Thymoma
PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
Thymoma
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Thymoma
Protection of the Developing Brain with Anthocyanins Against Ethanol-Induced Oxidative Stress and Neurodegeneration.
Thymoma
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells.
Thymoma
Rare frequency of gene variation and survival analysis in thymic epithelial tumors.
Thymoma
Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal.
Thymoma
Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway.
Thymoma
Testosterone up-regulates seladin-1 expression by iAR and PI3-K/Akt signaling pathway in C6 cells.
Thymoma
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
Thymoma
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Thymoma
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Thyroid Cancer, Papillary
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Thyroid Cancer, Papillary
Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation.
Thyroid Cancer, Papillary
Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
Thyroid Cancer, Papillary
Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases.
Thyroid Cancer, Papillary
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Thyroid Cancer, Papillary
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
Thyroid Cancer, Papillary
MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.
Thyroid Cancer, Papillary
MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB1.
Thyroid Cancer, Papillary
MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.
Thyroid Cancer, Papillary
Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
Thyroid Cancer, Papillary
Next-generation sequencing identified somatic alterations that may underlie the etiology of Chinese papillary thyroid carcinoma.
Thyroid Cancer, Papillary
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Thyroid Cancer, Papillary
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Thyroid Cancer, Papillary
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Thyroid Carcinoma, Anaplastic
Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors.
Thyroid Carcinoma, Anaplastic
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Thyroid Carcinoma, Anaplastic
Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
Thyroid Carcinoma, Anaplastic
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Thyroid Carcinoma, Anaplastic
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Thyroid Carcinoma, Anaplastic
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Thyroid Diseases
A novel PIK3R1 mutation of SHORT syndrome in a Chinese female with diffuse thyroid disease: a case report and review of literature.
Thyroid Neoplasms
A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer.
Thyroid Neoplasms
Antineoplastic Activity of an Old Natural Antidiabetic Biguanoid on the Human Thyroid Carcinoma Cell Line.
Thyroid Neoplasms
Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways.
Thyroid Neoplasms
Carcinogenesis of PIK3CA.
Thyroid Neoplasms
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
Thyroid Neoplasms
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Thyroid Neoplasms
Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
Thyroid Neoplasms
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells.
Thyroid Neoplasms
Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.
Thyroid Neoplasms
ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA.
Thyroid Neoplasms
FOXO3a: a novel player in thyroid carcinogenesis?
Thyroid Neoplasms
GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1? (HIF-1?) pathways.
Thyroid Neoplasms
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
Thyroid Neoplasms
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Thyroid Neoplasms
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
Thyroid Neoplasms
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Thyroid Neoplasms
Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.
Thyroid Neoplasms
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
Thyroid Neoplasms
Mouse Models as a Tool for Understanding Progression in BrafV600E-Driven Thyroid Cancers.
Thyroid Neoplasms
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Thyroid Neoplasms
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Thyroid Neoplasms
Overexpression and overactivation of Akt in thyroid carcinoma.
Thyroid Neoplasms
Papillary thyroid cancer in a struma ovarii: a report of a rare case.
Thyroid Neoplasms
Periostin silencing suppresses the aggressive phenotype of thyroid carcinoma cells by suppressing the Akt/thyroid stimulating hormone receptor axis.
Thyroid Neoplasms
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Thyroid Neoplasms
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Thyroid Neoplasms
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Thyroid Neoplasms
Roles of XB130, a novel adaptor protein, in cancer.
Thyroid Neoplasms
Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
Thyroid Neoplasms
Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification.
Thyroid Neoplasms
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Thyroid Neoplasms
TGF-?1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion.
Thyroid Neoplasms
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway.
Thyroid Neoplasms
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.
Thyroid Neoplasms
Thyroid Carcinoma in a Child with Activated Phosphoinositide 3-Kinase ? Syndrome: Somatic Effect of a Germline Mutation.
Thyroid Neoplasms
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.
Thyroid Neoplasms
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Thyroid Neoplasms
Whole-genome sequencing of follicular thyroid carcinomas reveal recurrent mutations in microRNA processing subunit DGCR8.
Thyroid Neoplasms
XB130 Mediates Cancer Cell Proliferation and Survival through Multiple Signaling Events Downstream of Akt.
Thyroid Nodule
Relationship between TSHR, BRAF and PIK3CA gene copy number variations and thyroid nodules.
Thyroiditis
Riedel's thyroiditis - a case report with genes' expression studies.
Thyroiditis
The role of phosphoinositide 3-kinase subunits in chronic thyroiditis.
Tics
BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
Tongue Neoplasms
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach.
Tongue Neoplasms
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
Toxoplasmosis
Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase ? Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Toxoplasmosis, Congenital
Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase ? Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Triple Negative Breast Neoplasms
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Triple Negative Breast Neoplasms
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Triple Negative Breast Neoplasms
Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
Triple Negative Breast Neoplasms
Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
Triple Negative Breast Neoplasms
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Triple Negative Breast Neoplasms
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.
Triple Negative Breast Neoplasms
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
Triple Negative Breast Neoplasms
MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
Triple Negative Breast Neoplasms
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Triple Negative Breast Neoplasms
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Triple Negative Breast Neoplasms
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Triple Negative Breast Neoplasms
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Triple Negative Breast Neoplasms
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Triple Negative Breast Neoplasms
PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Triple Negative Breast Neoplasms
PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report.
Triple Negative Breast Neoplasms
PIK3CA mutations and downstream effector p-mTOR expression: implication for prognostic factors and therapeutic targets in triple negative breast cancer.
Triple Negative Breast Neoplasms
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Triple Negative Breast Neoplasms
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Triple Negative Breast Neoplasms
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Triple Negative Breast Neoplasms
Targeted Treatment of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Targeting the PI3-kinase pathway in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Triple Negative Breast Neoplasms
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Tuberculosis
1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase.
Tuberculosis
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Tuberculosis
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
Tuberculosis
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
Tuberculosis
PI3-Kinase ?? Catalytic Isoforms Regulate the Th-17 Response in Tuberculosis.
Tuberculosis
Susceptibility to Tuberculosis Is Associated With PI3K-Dependent Increased Mobilization of Neutrophils.
Tuberous Sclerosis
14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s).
Tuberous Sclerosis
A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Tuberous Sclerosis
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Tuberous Sclerosis
Macropinocytosis, mTORC1 and cellular growth control.
Tuberous Sclerosis
mTOR mutations in Smith-Kingsmore syndrome: four additional patients and a review.
Tuberous Sclerosis
Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin.
Tuberous Sclerosis
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
Tuberous Sclerosis
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.
Tuberous Sclerosis
Targeting phosphoinositide 3-kinase: moving towards therapy.
Tuberous Sclerosis
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.
Tubular Sweat Gland Adenomas
PIK3CA and AKT1 mutations in hidradenoma papilliferum.
Tubular Sweat Gland Adenomas
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Urinary Bladder Neoplasms
Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells.
Urinary Bladder Neoplasms
Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Urinary Bladder Neoplasms
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Urinary Bladder Neoplasms
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Urinary Bladder Neoplasms
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Urinary Bladder Neoplasms
High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy.
Urinary Bladder Neoplasms
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Urinary Bladder Neoplasms
Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells.
Urinary Bladder Neoplasms
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Integrated gene network analysis and text mining revealing PIK3R1 regulated by miR-127 in human bladder cancer.
Urinary Bladder Neoplasms
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Urinary Bladder Neoplasms
Knockdown of KNTC1 Inhibits the Proliferation, Migration and Tumorigenesis of Human Bladder Cancer Cells and Induces Apoptosis.
Urinary Bladder Neoplasms
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Urinary Bladder Neoplasms
Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.
Urinary Bladder Neoplasms
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
Urinary Bladder Neoplasms
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Urinary Bladder Neoplasms
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.
Urinary Bladder Neoplasms
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Urinary Bladder Neoplasms
Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
Urinary Bladder Neoplasms
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Urinary Bladder Neoplasms
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Urinary Bladder Neoplasms
PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer.
Urinary Bladder Neoplasms
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Urinary Bladder Neoplasms
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Urinary Bladder Neoplasms
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
Urinary Bladder Neoplasms
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Urinary Bladder Neoplasms
Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.
Urinary Bladder Neoplasms
Retraction note: Integrated gene network analysis and text mining revealing PIK3R1 regulated by miR-127 in human bladder cancer.
Urinary Bladder Neoplasms
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.
Urinary Bladder Neoplasms
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
Urinary Bladder Neoplasms
Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.
Urinary Bladder Neoplasms
The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Urinary Bladder Neoplasms
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Urinary Bladder Neoplasms
[Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Urticaria
Critical Signaling Events in the Mechanoactivation of Human Mast Cells through p.C492Y-ADGRE2.
Uterine Cervical Neoplasms
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Uterine Cervical Neoplasms
Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: A comprehensive review.
Uterine Cervical Neoplasms
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Uterine Cervical Neoplasms
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Uterine Cervical Neoplasms
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Uterine Cervical Neoplasms
Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome'.
Uterine Cervical Neoplasms
Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
Uterine Cervical Neoplasms
FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration.
Uterine Cervical Neoplasms
Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
Uterine Cervical Neoplasms
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Uterine Cervical Neoplasms
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Uterine Cervical Neoplasms
INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
Uterine Cervical Neoplasms
Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
Uterine Cervical Neoplasms
MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma.
Uterine Cervical Neoplasms
MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta.
Uterine Cervical Neoplasms
miR-92a promotes cervical cancer cell proliferation, invasion, and migration by directly targeting PIK3R1.
Uterine Cervical Neoplasms
Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients.
Uterine Cervical Neoplasms
Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Uterine Cervical Neoplasms
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Uterine Cervical Neoplasms
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Uterine Cervical Neoplasms
PIK3CA as an oncogene in cervical cancer.
Uterine Cervical Neoplasms
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
Uterine Cervical Neoplasms
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
Uterine Cervical Neoplasms
PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Uterine Cervical Neoplasms
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
Uterine Cervical Neoplasms
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
Uterine Cervical Neoplasms
PIK3CA pathway mutations predictive of poor response following Standard radio chemotherapy +/- Cetuximab in cervical cancer patients.
Uterine Cervical Neoplasms
PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro.
Uterine Cervical Neoplasms
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Uterine Cervical Neoplasms
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Uterine Cervical Neoplasms
S100A6 promotes the proliferation and migration of cervical cancer cells via the PI3K/Akt signaling pathway.
Uterine Cervical Neoplasms
Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines.
Uterine Cervical Neoplasms
Targeting of ?-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA-E545K Mutation.
Uterine Cervical Neoplasms
Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Uterine Cervical Neoplasms
The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the ?-catenin/SIRT3 signaling pathway in cervical cancer.
Uterine Cervical Neoplasms
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Uterine Cervical Neoplasms
Translating Imaging Results into Tumor Biology: FDG-PET and The Response to Chemoradiation in Human Cervical Carcinoma.
Uterine Cervical Neoplasms
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Uterine Neoplasms
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Uterine Neoplasms
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
Vascular Malformations
CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
Vascular Malformations
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Vascular Malformations
Cloves Syndrome: A Rare Disorder of Overgrowth with Unusual Features - An Uncommon Phenotype?
Vascular Malformations
CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
Vascular Malformations
Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations.
Vascular Malformations
Managing Vascular Anomalies in the Era of Genetics and Precision Medicine: An Opportunity or a Challenge?
Vascular Malformations
Menstrual disorders associated with sirolimus treatment.
Vascular Malformations
Molecular analysis of a uterine broad ligament leiomyoma in a patient with CLOVES syndrome.
Vascular Malformations
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.
Vascular Malformations
New and Emerging Targeted Therapies for Vascular Malformations.
Vascular Malformations
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
Vascular Malformations
PIK3CA mutations in vascular malformations.
Vascular Malformations
PIK3CA vascular overgrowth syndromes: an update.
Vascular Malformations
PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.
Vascular Malformations
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Vascular Malformations
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Vascular Malformations
Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Vascular Malformations
Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
Vascular Malformations
Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth.
Vascular Malformations
Sonographic screening for Wilms tumor in children with CLOVES syndrome.
Vascular Malformations
Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
Vascular Malformations
Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Vascular Malformations
Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum.
Vascular Malformations
[PIK3CA-related overgrowth syndrome (PROS)].
Vascular System Injuries
Matrine attenuates high-fat diet-induced in vivo and ox-LDL-induced in vitro vascular injury by regulating the PKC?/eNOS and PI3K/Akt/eNOS pathways.
Vascular System Injuries
The role of Rac1 in glycoprotein Ib-IX-mediated signal transduction and integrin activation.
Vasculitis
Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report.
Vasculitis
L-selectin: an emerging player in chemokine function.
Ventilator-Induced Lung Injury
Lack of phosphoinositide 3-kinase-gamma attenuates ventilator-induced lung injury.
Vesicular Stomatitis
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Vesicular Stomatitis
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Vesicular Stomatitis
Stable lentiviral vector-mediated gene silencing in human monocytic cell lines.
Viremia
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Virus Diseases
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Virus Diseases
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
Virus Diseases
Adenovirus vectors activate survival pathways in lung epithelial cells.
Virus Diseases
Exhaustion of the CD8
Virus Diseases
GSK-3-associated signaling is crucial to virus infection of cells.
Virus Diseases
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.
Virus Diseases
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Virus Diseases
Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter.
Virus Diseases
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Virus Diseases
Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.
Virus Diseases
Use of a tandem affinity purification assay to detect interactions between West Nile and dengue viral proteins and proteins of the mosquito vector.
Waldenstrom Macroglobulinemia
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
West Nile Fever
Use of a tandem affinity purification assay to detect interactions between West Nile and dengue viral proteins and proteins of the mosquito vector.
Whooping Cough
A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation.
Whooping Cough
Acetylcholine leads to free radical production dependent on K(ATP) channels, G(i) proteins, phosphatidylinositol 3-kinase and tyrosine kinase.
Whooping Cough
Activation of HIF-1? by ?-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells.
Whooping Cough
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Whooping Cough
Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation.
Whooping Cough
Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis.
Whooping Cough
Activation of PI 3-kinase by G protein betagamma subunits.
Whooping Cough
ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils.
Whooping Cough
Aldosterone inhibits apical NHE3 and HCO3- absorption via a nongenomic ERK-dependent pathway in medullary thick ascending limb.
Whooping Cough
Alpha1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis.
Whooping Cough
Angiotensin AT(1) receptor phosphorylation and desensitization in a hepatic cell line. Roles of protein kinase c and phosphoinositide 3-kinase.
Whooping Cough
Bradykinin B2 receptors activate Na+/H+ exchange in mIMCD-3 cells via Janus kinase 2 and Ca2+/calmodulin.
Whooping Cough
C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro.
Whooping Cough
C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase.
Whooping Cough
Characterization of the migration of lung and blood T cells in response CXCL12 in a three-dimensional matrix.
Whooping Cough
Chemotactic peptide fMetLeuPhe induces translocation of the TRPV2 channel in macrophages.
Whooping Cough
Contrasting signaling pathways of alpha1A- and alpha1B-adrenergic receptor subtype activation of phosphatidylinositol 3-kinase and Ras in transfected NIH3T3 cells.
Whooping Cough
Critical Signaling Events in the Mechanoactivation of Human Mast Cells through p.C492Y-ADGRE2.
Whooping Cough
CysLT1 receptor-induced human airway smooth muscle cells proliferation requires ROS generation, EGF receptor transactivation and ERK1/2 phosphorylation.
Whooping Cough
Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of beta-Adrenergic Receptors to Phosphoinositide 3-Kinase.
Whooping Cough
Differences in CXCR4-mediated signaling in B cells.
Whooping Cough
Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells.
Whooping Cough
Erk1/2- and p38 MAP kinase-dependent phosphorylation and activation of cPLA2 by m3 and m2 receptors.
Whooping Cough
Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30.
Whooping Cough
Expression and functional role of formyl peptide receptor in human bone marrow-derived mesenchymal stem cells.
Whooping Cough
Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway.
Whooping Cough
G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms.
Whooping Cough
Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy.
Whooping Cough
Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways.
Whooping Cough
Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors.
Whooping Cough
Human catestatin enhances migration and proliferation of normal human epidermal keratinocytes.
Whooping Cough
Identification of a structural element in phospholipase C beta2 that interacts with G protein betagamma subunits.
Whooping Cough
Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors.
Whooping Cough
Independent activation of endogenous p21-activated protein kinase-3 (PAK3) and JNK by thrombin in CCL39 fibroblasts.
Whooping Cough
Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells.
Whooping Cough
Interleukin-1 inhibits angiotensin II-stimulated protein kinase B pathway in renal mesangial cells via the inducible nitric oxide synthase.
Whooping Cough
Involvement of MAP kinase signal transduction pathway in UVB-induced activation of macrophages in vitro.
Whooping Cough
Involvement of phosphatidylinositol 3-kinase in stromal cell-derived factor-1 alpha-induced lymphocyte polarization and chemotaxis.
Whooping Cough
Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors.
Whooping Cough
Lithium activates mammalian Na+/H+ exchangers: isoform specificity and inhibition by genistein.
Whooping Cough
Lysophosphatidic acid and receptor-mediated activation of endothelial nitric-oxide synthase.
Whooping Cough
Lysophosphatidic acid induces alpha1B-adrenergic receptor phosphorylation through G beta gamma, phosphoinositide 3-kinase, protein kinase C and epidermal growth factor receptor transactivation.
Whooping Cough
Lysophosphatidylserine Stimulates L2071 Mouse Fibroblast Chemotactic Migration via a Process Involving Pertussis Toxin-Sensitive Trimeric G-Proteins.
Whooping Cough
Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.
Whooping Cough
MIP-3alpha induces human eosinophil migration and activation of the mitogen-activated protein kinases (p42/p44 MAPK).
Whooping Cough
Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration.
Whooping Cough
Novel role of Gi?2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells.
Whooping Cough
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Whooping Cough
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I.
Whooping Cough
PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1).
Whooping Cough
Platelet microparticles induce angiogenesis in vitro.
Whooping Cough
Potentiation of chemotactic peptide-induced superoxide generation by CD38 ligation in human myeloid cell lines.
Whooping Cough
Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein.
Whooping Cough
Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1.
Whooping Cough
Recruitment of pleckstrin and phosphoinositide 3-kinase gamma into the cell membranes, and their association with G beta gamma after activation of NK cells with chemokines.
Whooping Cough
Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms.
Whooping Cough
Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B4-induced enzyme release.
Whooping Cough
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Whooping Cough
Resistin: a newly identified chemokine for human CD4-positive lymphocytes.
Whooping Cough
Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes.
Whooping Cough
Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells.
Whooping Cough
Sphingosine 1-phosphate and control of vascular tone.
Whooping Cough
Stimulation of extracellular signal-regulated kinases and proliferation in the human gastric cancer cells KATO-III by obestatin.
Whooping Cough
Stromal cell-derived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase.
Whooping Cough
Synergistic activation of phospholipases Cgamma and Cbeta: A novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release.
Whooping Cough
The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3-L1 adipocytes.
Whooping Cough
The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase.
Whooping Cough
The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes.
Whooping Cough
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B.
Whooping Cough
The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
Whooping Cough
Thrombin-promoted release of UDP-glucose from human astrocytoma cells.
Whooping Cough
Thromboxane A(2) receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells.
Whooping Cough
Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis.
Whooping Cough
Wortmannin-sensitive activation of p70s6k by endogenous and heterologously expressed Gi-coupled receptors.
Wilms Tumor
Correspondence to Gripp et al. nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Wilms Tumor
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Wiskott-Aldrich Syndrome
A phosphatidylinositol 3-kinase-independent insulin signaling pathway to N-WASP/Arp2/3/F-actin required for GLUT4 glucose transporter recycling.
Wiskott-Aldrich Syndrome
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.